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CHAPTER 1. AMINOGLYCOSIDE ANTIBIOTICS (AGAs). 
1.1. General Introduction: 
          Bacteria constitute a large domain of prokaryotic microorganisms and were one of the first 
life forms to appear on earth. The Dutch microbiologist Antonie Van Leeuvenhoek first observed 
bacteria in 1776.1 In 1884 Danish bacteriologist Hans Christian Gram developed a method for 
staining bacteria, to make them more visible under a microscope and this became very useful in 
classifying bacteria. A Gram stain is made using a primary stain of crystal-violet and a counterstain 
of safranin. Bacteria that turn purple when stained are called “Gram-positive” while those that turn 
red when counterstained are called “Gram-negative”.2 The basic difference between Gram-positive 
and Gram-negative bacteria is the structure of their cell wall. In Gram-positive bacteria, the cell 
wall consists of a thick peptidoglycan layer and a plasma membrane. On the other hand, in Gram-
negative bacteria, the cell wall composed of a thinner peptidoglycan layer sandwiched between an 
inner plasm membrane and an outer membrane (Figure 1).3 When the bacteria form a parasitic 
association with other organisms, they are classified as pathogens. Pathogenic bacteria are the 
major cause of human diseases and many lethal diseases like tetanus, typhoid, diphtheria, syphilis, 
cholera, leprosy, tuberculosis, pneumonia etc., are caused by bacterial infection. Diseases resulting 
from pathogenic bacteria are one of the leading causes of human mortality and tuberculosis is top 
of the list. According to “Global Tuberculosis Report 2016” published by WHO,4 there were an 
estimated 10.4 million new cases of TB and 1.8 million deaths worldwide in the year 2015 alone. 
TB is the leading killer of HIV-positive people and in 2015, 35% of HIV deaths were due to TB. 
Globally in 2015, an estimated 580,000 people developed multidrug-resistant tuberculosis (MDR-
TB) and TB remained one of the top 10 causes of human death. 
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Figure 1. Cell wall structure of Gram-positive and Gram-negative bacteria. 
          Antibiotics are the weapons discovered by humans to fight against bacteria. An antibiotic is 
a substance which either kills or inhibits the growth of bacteria. Bactericidal antibiotics kill the 
bacteria whereas bacteriostatic antibiotics inhibit the rapid growth of the bacteria leaving it to the 
host’s immune system to clear the bacteria. It wasn’t until the late 19th century that scientists started 
observing the antimicrobial action of chemicals. Initially the German physician Paul Erhlich noted 
that certain chemical dyes colored some bacterial cells but not others; a precursor technique to 
gram staining and proposed that it might be possible to create substances that can kill certain 
bacteria without affecting other cells. In 1907 his laboratory synthesized a chemical salvarsan now 
called arsphenamine (Figure 2) that was an effective treatment for syphilis.5-7 This organoarsenic 
compound was the first modern chemotherapeutic agent. The Ukrainian-American biochemist and 
microbiologist Selman Waksman first used the term antibiotic in 1942.8  
 
Figure 2. Dimeric and pentameric structure of salvarsan (arsphenamine).9 
3 
 
 
 
          Penicillin-G was the first antibiotic discovered by Scottish biologist Sir Alexander Fleming 
in 1928.10 It was isolated from Penicillium fungi and used for the treatment of a number of bacterial 
infections. The discovery of Penicillin-G started the antibiotic era and opened the door for the 
development of several structurally similar derivatives to treat many other bacterial infections. 
Since the discovery of penicillin, various other types of antibiotics emerged including other β-
lactams, aminoglycosides, tetracyclines, quinolones etc. Antibiotics can be divided into four 
categories based on their mode of action:3  
1. Cell wall biosynthesis inhibitors (e.g. penicillins, cephalosporins). 
2. Protein biosynthesis inhibitors (e.g. aminoglycosides, tetracyclines, oxazolidinones, 
macrolides). 
3. DNA replication and repair inhibitors (e.g. quinolones, fluoroquinolones). 
4. Folate coenzyme biosynthesis inhibitors (e.g. sulfonamides). 
          AGAs belong to the category of antibiotics that inhibit bacterial protein synthesis. AGAs 
are highly potent broad spectrum antibiotics and have much desired bactericidal activity. 
Streptomycin, the first AGA, was discovered by Selman Waksman in 1944. Its discovery was a 
landmark in antibiotic history and it was used for decades for the treatment of TB caused by 
Mycobacterium tuberculosis.11 Streptomycin is a bactericidal antibiotic and was isolated from the 
Actinobacterium Streptomyces griseus. Most of the AGAs are produced by Actinomycetes of either 
genus Streptomyces (AGAs named as “mycin”) or Micromonospora (AGAs named as “micin”). 
AGAs are particularly effective against Gram-negative bacteria.  
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Figure 3. Penicillin-G and Streptomycin: starting points of the antibiotic era. 
          AGAs are listed by the WHO as one of the critically important antimicrobials and have long 
been used as highly potent broad-spectrum antibiotics against Gram-negative pathogens, 
methicillin-resistant Staphylococcus aureus (MRSA), and multidrug-resistant tuberculosis (MDR-
TB) as well as to treat many other complex infectious diseases. The AGAs form a large family of 
water soluble, polycationic amino sugars that inhibit the protein synthesis by direct interaction 
with ribosomal RNA which leads to the bacterial cell death. AGAs are given intravenously because 
of their poor absorbance from the gastrointestinal tract. Due to their significant toxic effects, in 
particular irreversible hearing loss (ototoxicity) and kidney damage (nephrotoxicity), and with the 
development of new orally administered antibiotics, interest in development of AGAs declined in 
1970s. In recent years, there is much interest in the development of new generation of AGAs for 
multiple reasons.12-14 First, the increase in antibiotic resistant diseases has limited the use of 
available antibiotics and AGAs remain very crucial for the treatment of those diseases.15-17 Second, 
the mechanism of AGA antibacterial action and the mechanisms of resistance are well-studied, 
which provides a strong basis for rational design of a new generation of resistance proof and less 
toxic AGAs.18-31 Third, there are significant challenges in discovering a new class of antibiotics 
and bacterial metabolism offers only a limited number of targets suitable for antibiotic 
development. Because of these significant hurdles in the antibiotics discovery, only two new 
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classes of antibiotics have been developed since the 1970s (Figure 4).32 Finally, the low cost of 
naturally occurring AGAs and the well-developed AGA chemistry enables the easy synthesis of 
novel AGAs.25,33,34 Numerous strategies have been applied in recent years to circumvent AGA 
resistance35 and the ongoing renewal of AGA research has yielded plazomicin, a semisynthetic 
derivative of the natural AGA sisomicin, which is currently in phase III clinical trials for 
complicated urinary tract infections (Figure 5).36,37  
 
 
Figure 4. Timelines for the discovery of new classes of antibiotics. 
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Figure 5. Plazomicin, a new generation of AGA derived from sisomicin. 
1.2. Chemical Structure of AGAs: 
          Structurally AGAs are amino modified sugars linked through glycosidic bonds. Most of the 
AGAs have a backbone structure consisting of an aminocyclitol linked to other amino sugars 
through glycosidic bonds. In most of the clinically useful AGAs, the aminocyclitol is disubstituted 
2-deoxystreptamine (DOS). Streptomycin has a monosubstituted streptamine core where amino 
groups are modified to guanidino groups. Beside streptomycin, neomycin and kanamycin are the 
two most studied AGAs. Neomycin belongs to a group of AGAs containing a 4,5-disubstitued 2-
deoxystreptamine core (ring-II), while kanamycin contains a 4,6-disubstitued 2-deoxystreptamine 
core (Figure 6).25 However, other AGAs have been discovered whose unusual structures do not fit 
the classification (Figure 7). Aparamycin is one such unusual monosubstituted 2-deoxystreptamine 
AGA that is produced by Streptomyces tenebrarius.38 It causes little or no ototoxicity in animal 
models39,40 and avoid modifications by most aminoglycoside modifying enzymes, thereby 
retaining activity against multidrug resistant pathogens. Hygromycin B, produced by a bacterium 
Streptomyces hygroscopicus and isolated in 1953 from a soil sample, has an unusual 5-substituted 
2-deoxystreptamine structure.41 It is added to swine and chicken feed as an anthelmintic or anti-
worming agent. Another example is spectinomycin, which consists of three fused rings and whose 
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aminocyclotol ring is called spectinamine.27,42 Spectinomycin was discovered in 1961 and is 
industrially produced by the fermentation of the bacterium Streptomyces spectabilis. 
Spectinomycin is a very useful antibiotic for the treatment of gonorrhea, especially in patients who 
are allergic to penicillin or cephalosporin.43 
  
                                                                                                 
 
 R1 R2 R3 R4 
Neomycin B NH2 OH H DAG 
Paromomycin I OH OH H DAG 
Lividomycin B OH H H DAG 
Butirosin B NH2 OH AHB H 
Ribostamycin NH2 OH H H 
        DAG: 2,6-diamino-2,6-dideoxy-α-L-idoopyranosyl 
                     4,5-AGA Series (Neomycin Class)    
 R1 R2 R3 R4 
Kanamycin A OH OH OH H 
Kanamycin B NH2 OH OH H 
Dibekacin NH2 H H H 
Tobramycin NH2 H OH H 
Amikacin OH OH OH AHB 
Arbekacin NH2 H H AHB 
                   AHB:(S)-4-amino-2-hydroxylbutyryl 
                4,6-AGA Series (Kanamycin Class)
Figure 6. Neomycin and Kanamycin classes of aminoglycosides. 
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Figure 7. Some AGAs with unusual structures. 
1.3. Mode of action of AGAs: 
          Nucleotides have various roles in cellular mechanisms and are the constituents of 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Nucleotides have three basic 
components: (i) a nitrogenous base (pyrimidine and purine base), (ii) a pentose sugar (deoxyribose 
in DNA and ribose in RNA), and (iii) a phosphate. Nucleic acids are the polymeric structures of 
the nucleotides joined in specific sequences through a covalent phosphodiester linkage and called 
polynucleotides. DNA and RNA both have two purine bases, adenine (A) and guanine (G). In both 
DNA and RNA one of the pyrimidine bases is cytosine (C); while the other is thymine (T) in DNA 
and uracil (U) in RNA. The ring exo and endocyclic amines and carbonyl groups present on the 
nitrogenous bases are such that specific pairs of bases form very crucial hydrogen-bonding 
interactions with each other. These important hydrogen bonding interactions were discovered by 
Watson and Crick in 1953, thus A pairs specifically with T or U and G pairs specifically with C. 
These two types of base pairing are responsible for the double stranded structure of DNA and parts 
of RNA and underlie the duplication of genetic information (Figure 8).44  
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Figure 8. Purine and pyrimidines bases present in nucleic acids and Watson-Crick base pairs. 
          Protein synthesis is a complex process and ribosomes are the molecular machines that serve 
as the sites for protein synthesis by a process called translation. Ribosomes connect the amino 
acids together by peptide bonds in a defined sequence specified by m-RNA. A specific m-RNA 
bearing the codons for the polypeptide to be made is synthesized in the nucleus from DNA by a 
process called transcription. Then m-RNA binds to the smaller ribosomal subunit and to the 
aminoacyl transfer-RNA that carries the amino acid to be incorporated. Finally, the large ribosomal 
subunit binds to form an initiation complex. Then the polypeptide chain is elongated by covalent 
attachment of successive amino acids. Each amino acid is carried and correctly positioned by t-
RNA. t-RNA contains a complimentary anticodon on one end and amino acid on the other. Based 
on correct codon-anticodon matching a specific amino acid is transferred to the peptide chain by 
t-RNA and this process is repeated to form a polypeptide chain. The ribosome contains three RNA 
binding sites: (i) A-site; aminoacyl t-RNA binding site, (ii) P-site; peptidyl t-RNA (t-RNA bound 
to the peptide chain being synthesized) binding site, and (iii) E-site; empty t-RNA (before it leaves 
the ribosomes) binding site (Figure 9).44 
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Figure 9. Schematic representation of protein synthesis. 
          AGAs are water-soluble polycationic amino sugars and the amino groups are protonated 
under physiological conditions. In this way, they have strong electrostatic interactions with the 
negatively charged nucleotides. AGAs inhibit protein synthesis in bacteria by direct interaction 
with r-RNA. The binding site is within a conserved loop of the 16S r-RNA helix 44 present in the 
A-site of 30S ribosomal subunit. Protein synthesis is inhibited in three ways: (i) by interference 
with the binding of aminoacyl t-RNA to the ribosome and consequent prevention of the correct 
initiation of protein synthesis, (ii) by inducing the misreading of m-RNA, which causes 
incorporation of incorrect amino acids in-to peptides, resulting in a non-functional or abnormal 
proteins, (iii) by inhibition of ribosomal translocation (i.e., movement of peptidyl t-RNA from the 
A-site to the P-site). Ultimately, interference with protein synthesis in this way yields conditions 
of oxidative stress and the formation of reactive oxygen species, which results in cell death (Figure 
10).18,20,28,45-48 
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Figure 10. Schematic representation of AGA interfering with the protein synthesis. 
          The neamine core (rings I and II) of both the 4,5- and 4,6-classes of AGAs is mainly 
responsible for binding. The 6’-substituent and the ring oxygen of the neamine core (e.g., NH2 in 
neomycin and OH in paromomycin) interact through hydrogen bonding with N-1 and N-6 of A-
1408 and making a pseudo base-pair type interaction. Binding of the neamine core is also 
characterized by CH-π interaction of the β-face of ring-I with G-1491. The 2-Deoxystreptamine 
ring (ring-II) of the neamine core forms hydrogen bonds with G-1494 and U-1495. Rings III and 
IV of the 4,5-series of AGAs reaches to the base pairs 1409-1491 and 1410-1490, which gives 
additional hydrogen bonding interactions between the 5”-hydroxyl group and N-7 of G-1491 
(Figure 12). In the case of the 4,6-series of AGAs, ring-III is located in a different position and 
forms hydrogen bond to G-1405.49,50 This mode of AGA binding causes residues A-1492 and A-
1493 to adopt a flipped out conformation in which they interact with minor groove of the codon-
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anticodon helix (Figure 13).18,51-53 This flipped out conformation stabilizes the t-RNA-A-site 
complex, facilitates misreading, and increases the energy barrier for translocation.22 
 
Figure 11. Pseudo base-pair type interaction between ring-I of paromomycin  
and residue A-1408. 
 
Figure 12. Schematic representation of paromomycin (4,5-series AGA) interactions with 
bacterial 16S r-RNA. 
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Figure 13. Schematic representation “flipped-in” and “flipped-out” conformation of adenines in 
bacterial A-site. 
1.4. Toxicity and selectivity of AGAs: 
          The therapeutic use of AGAs and their development is inhibited by their toxicity. The main 
toxic responses are nephrotoxicity (kidney damage) and ototoxicity (hearing damage).25,54-56  
1.4.1. Nephrotoxicity: 
          Nephrotoxicity is one of the well-known side-effects associated with AGAs and it is a drug-
induced kidney damage that leads to their inability to eliminate urine and other wastes from the 
body. The reported incidence of AGA-induced nephrotoxicity fluctuates between 5 and 26 %, 
depending on various factors. AGAs are largely eliminated from the body through glomerular 
filtration by kidneys and excretion in the urine. After glomerular filtration, a significant 
accumulation (~5 % of the administered dose) of AGAs in the epithelial cells lining S1 and S2 
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segments of the proximal tubules is the main cause of nephrotoxicity. Because of their polycationic 
nature at physiological pH, AGAs show a high affinity for phospholipid receptors on the brush 
border cell of the proximal convoluted tubule and pars recta. Subsequently, the AGAs are 
reabsorbed by a process called pinocytosis and accumulate in lysosomes and other subcellular 
compartments of the proximal tubular cell. Ultimately proximal tubular cell damage occurs and 
leads to nephrotoxicity. 
          Nephrotoxicity is reversible and rarely leads to a fatal outcome, nevertheless it is desirable 
to minimize it. In the clinic, this is achieved by injection of a single large daily dose rather than 
several small doses. This method of injection was developed on the basis of the fact that the AGA 
uptake by kidney tubular cells is saturable, meaning the uptake of AGAs by the kidneys is limited 
even when large doses are given.57,58 Additionally, hydration treatments can alleviate the 
symptoms of AGA-induced nephrotoxicity.28 Also, co-administration of polyaspartic acid with 
AGAs has been shown to prevent their binding to phospholipids, thereby reducing the AGA-
induced nephrotoxicity.59 
1.4.2. Ototoxicity: 
          Streptomycin and other AGAs target sensory hair cells of the inner ear and can lead to hair 
cell degeneration and permanent loss.  This ototoxicity is the most important and severe toxic 
response of AGAs. Ototoxicity is irreversible and is reported to affect up to 20% of the patient 
population on extended treatment.25   There are two types of ototoxicity: (i) vestibular toxicity, and 
(ii) cochlear toxicity. AGAs destroy the vestibular and cochlear cells by inhibiting the 
mitochondrial protein synthesis which ultimately leads to hearing loss. The permanence of AGA-
induced toxicity is the result of degeneration of hair cells in the cochlea, which cells don’t 
regenerate once damaged.28,60-62 The magnitude of ototoxicity is variable and influenced by several 
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factors. One factor is the type of AGA used since different AGAs have different toxic potentials. 
For instance, neomycin is more ototoxic than gentamicin or tobramycin, which in turn more 
ototoxic than netilmicin. Another factor is the dose and duration of treatment. Longer usage of 
AGAs, as in the treatment of tuberculosis, leads to a higher incidence of ototoxicity. Impaired 
kidney functions and nutritional or physiological conditions of the patient may also affect the 
magnitude of ototoxicity.63  
          AGAs enter the inner ear quickly within few minutes of administration. The half-life of most 
AGAs in serum is 3-5 h, but their half-life in the inner ear may exceed 30 days.64 The primary 
targets of AGAs are the sensory hair cells of the inner ear, which are essential for the transduction 
of auditory stimuli (inner and outer hair cells) and balance sensation (type-I and type-II vestibular 
hair cells).65,66 The AGAs carry a positive charge on protonated amino group under physiological 
pH, which causes a number of actions and enable them to bind with negatively charged cell 
components or displace cations from binding sites. Recent studies suggest that ototoxicity is due 
to the inhibition of human mitochondrial protein synthesis or the promotion of abnormal 
mitochondrial protein synthesis leading to ROS formation and ultimately cell death, arising from 
binding between AGAs and the human mitochondrial A-site.  The mechanism of ototoxicity is 
therefore related to the mechanism of bactericidal activity.48,67-69 Ototoxicity occurs in two ways: 
(i) a sporadic dose-dependent manner in general patients; (ii) an aggravated manner in genetically 
susceptible people. This susceptibility is linked to a mutation in mitochondrial r-RNA. In 
particular, when the A1555 residue is mutated to G in the A-site of mitoribosomal small subunit 
(Figure 10).70  
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          Many efforts have been made to attenuate ototoxicity in animals, for example, by co-
administration of various vitamins, amino acids, hormones, antibiotics, sulfhydryl compounds, 
etc., but none have been developed into a successful clinical treatment for the prevention of AGA-
induced ototoxicity. However, antioxidant therapy to overcome the effects of ROS formation is 
considered a promising lead for the mitigation of ototoxicity. Antioxidants have been found 
effective against both the vestibular and cochlear ototoxicity.71,72 For example, salicylate, the 
active ingredient of aspirin, which act as both an antioxidant and iron-chelator has been shown to 
reduce gentamicin-induced ototoxicity.73  
1.4.3. Selectivity of AGAs: 
          The small differences between eukaryotic and prokaryotic ribosomes can be exploited for 
the development of new generation of AGAs. AGAs bind more tightly to the bacterial ribosomal 
A-site than the human ribosomal A-site. The human cytosolic A-site differs from bacterial A-site 
in three ways. The first difference is in position 1408 which is an A residue in the bacterial A-site 
but is a G in the cytosolic A-site. This change disrupts the key hydrogen bonding interaction to the 
6’-substituent in the neamine core. The second difference is in the 1409-1491 base pair (C-G in 
bacteria, but C-A in human cytosolic A-site), and the third is in the 1410-1490 base pair (G-C in 
bacteria, but U-A in human cytosolic A-site).50,69 These changes are sufficient to cause selective 
binding of the AGAs to the bacterial ribosome over the human cytosolic ribosome, meaning that 
systemic toxicity is not a major consideration. The human mitochondrial A-site on the other hand 
retains the critical A-1408 residue of the bacterial A-site, but differs in the positions 1409-1491 
(C-G in bacteria, but C-C in human mitochondrial A-site) and 1410-1490 (G-C in bacteria, but C-
A in human mitochondrial A-site) (Figure 14). Consequently, AGAs show lower selectivity for 
the bacteria A-site over the mitochondrial A-site, resulting in ototoxicity.69,74 The single nucleotide 
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mutation A1555G in the mitochondrial A-site is increases the similarity to the bacterial A-site, 
resulting in tighter AGA binding, and causing susceptibility to AGA-induced ototoxicity in 
affected people (Figure 15).69,74,75 
 
Figure 14. Origin dependent differences in the r-RNA decoding A-Site (AGA binding site is 
shown in the box). 
          A central hypothesis of this thesis is that the differences between the bacterial and 
mitochondrial A-sites can be exploited in the design of improved and more selective AGAs 
presenting reduced ototoxicity. Prof. Erick Böttger’s lab in the University of Zurich screen the 
newly synthesized AGA derivatives for their antibacterial properties and selectivity. The 
ribosomal drug susceptibility was analyzed on a single r-RNA allelic derivative of the eubacterium 
Mycobacterium smegmatis48,76 and it was determined by establishing the Minimal Inhibitory 
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Concentration values (MIC values) for the growth of M. smegmatis. The MIC value is the lowest 
concentration of the AGAs, which completely inhibit the growth of bacteria. Prof. Böttger and his 
coworkers developed cell free translation assays with purified 70S bacterial ribosome of both wild 
type and recombinant hybrid 45,77 carrying the complete decoding A-site cassettes of human 
mitochondrial (Mit 13), the A1555G mutant of the human mitochondrial (A1555G), and the human 
cytosolic (Cyt 14) ribosomes (Figure 14). By the help of these translation assays, IC50 values were 
determined for each synthesized AGA. The IC50 value is the concentration of AGA required to 
inhibit the protein synthesis by 50 percent.  
 
Figure 15. Origin dependent differences in the r-RNA decoding A-Site (Bacterial numbering is 
used throughout for clarity and A1555 in the mitochondrial numbering corresponds to A1490 in 
the bacterial numbering). 
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1.5. Bacterial resistance to AGAs: 
          Circumventing antibiotic resistance is an important factor in the development of novel 
AGAs as therapeutic agents. Aminoglycoside resistance occurs through several mechanisms but 
the four are: (i) decreased uptake of the AGAs in bacteria; (ii) AGA efflux; (iii) target modification; 
and (iv) aminoglycoside modifying enzymes.  
1.5.1. Decreased uptake of AGAs: 
          Reduced drug uptake is due to membrane impermeabilization or diminished inner membrane 
transport. The bacterial cell wall is the natural barrier for small molecules such as AGAs and for 
their action they must transverse the cell wall.  AGAs carry a positive charge at physiological pH 
and have a very hydrophilic nature. Accordingly, it is hypothesized that they cross the bacterial 
cell wall through porin channels rather than by direct diffusion through the phospholipid 
bilayer.78,79 The sugar-modified phospholipids (LPSs) present on the outer membrane bear a net 
negative charge and attract the cationic AGAs. The most common LPS modification is the 
incorporation of 4-amino-4-deoxy-L-arabinose, which reduces the net negative charge of the LPS 
layer and causes the decreased AGA-uptake.80-82 Additionally, phosphoethanolamine was also 
reported to be incorporated in response to the presence of cationic molecules.83 The lipid 
composition of innermost layer of the inner membrane in Mycobacterium smegmatis has been 
reported to consist of an unusual lipid, diacylphosphatidylinositol dimannoside.84 This lipid has 
four hydrocarbon chains and is proposed to lead to poor drug permeability. In some bacteria like 
E. coli, S. aureus, and P. aeruginosa, mutations in ATP-synthase also resulted in their decreased 
susceptibility to AGAs.85  
          The porin proteins considered to be the point of entry of the AGAs are water filled channels 
allowing passive diffusion of hydrophilic small molecules. Ompf is the classical porin in E. coli 
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which transports small molecules, but there is no conclusive evidence available to support its role 
in AGA transport.86 Two type of porins have been reported in mycobacteria: MspA-like from M. 
Smegmatis and OmpA-like from M. tuberculosis. Many studies on MspA-like porins have shown 
that deletion of porins results in reduced drug uptake.87 However, for kanamycin the Msp deletion 
did not cause a significant increase in MIC values, suggesting that these porins are not directly 
involved in AGA-transportation.88 The crystal structure of MspA also suggest that it is not directly 
involved in AGA resistance.89 These observations indicate the need for better understanding of 
AGA-uptake mechanism.  
1.5.2. AGA efflux: 
          AGA efflux is another mechanism of AGA-resistance which involve active transport of 
AGAs out of the cells by efflux pumps. There are five known classes of efflux pumps, of which 
the resistance nodulation division (RND) is the most widespread family in Gram-negative 
bacteria.90 These RND efflux pumps consist of three main components: the RND pump, a 
periplasmic membrane fusion protein (MFP), and an outer-membrane factor (OMF). Together 
these three proteins effectively pump a variety of antibiotics, dyes, and ions out of the cells. AGAs 
are known to be poor substrates for some other efflux pumps. For example, the small multidrug 
resistance (SMR) transporter in P. aeruginosa,91 the multidrug ABC transporter in L. lactis,92 and 
the major facilitator superfamily (MFS) in E. coli.90 The multidrug and toxic compound extrusion 
(MATE) family of efflux pumps have also been shown to transport AGAs in V. cholerea.93 These 
energy-dependent bacterial efflux pumps lower the AGA concentration in the bacterial cell and 
now identified as one of the major cause of antibiotic resistance.  
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1.5.3. Target modification: 
          AGA target the 16S r-RNA present in the A-site of bacterial ribosome and in this way, they 
inhibit the bacterial protein synthesis leading to the cell death. Therefore, any modification in the 
binding site will significantly affect the antibacterial activity of AGAs. There are two most 
common target modification mechanism known to cause AGA-resistance in several bacteria: 
mutation in ribosomal A-site and enzymatic modification of ribosomal A-site.  
1.5.3.1. Mutations in the ribosomal A-site: 
          AGA resistance may arise from mutations in the rrs gene, which codes for 16S r-RNA and 
causes decreased binding of AGAs to 16S r-RNA.94 The most common example is a A1408G 
mutation, which causes a high level of resistance for gentamicin, tobramycin, kanamycin, 
amikacin, arbekacin, isepamicin and neomycin.95,96 The non-DOS AGA streptomycin which 
interacts with the ribosomal protein S12 in addition to 16S r-RNA, is also rendered ineffective by 
this mechanism. Thus, mutations in either the 16S r-RNA or the S12 protein, result in high levels 
of resistance to streptomycin in M. tuberculosis.97,98 Similarly, N. gonorrhoeae has been shown to 
contain a mutation in ribosomal protein S5, which causes resistance to spectinomycin.99 
1.5.3.2. Enzymatic modification of the ribosomal A-site: 
          A significant amount of resistance is caused by enzymatic methylation of certain bases in 
the ribosomal A-site. These methylations are catalyzed by the enzymes commonly referred as 
RNA methyltransferases.100 These methyltransferases naturally occur in AGA-producing bacteria 
(Streptomyces and Micromonospora) where they protect the parent organism from the AGAs they 
produce by methylation of 16S r-RNA.101,102 For example, M. purpurea (gentamicin producer) and 
S. tenebrarius (tobramycin producer) encode Sadenosylmethionine-dependent methyltransferases, 
which modify G1405 or A1408 to the 7-methyl derivatives.103 Previously these methyltransferases 
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were confined to the non-pathogenic actinomycetes and have only recently been reported to cause 
resistance to AGAs in various pathogenic bacteria. The common examples are, RmtA in P. 
aeruginosa;104 RmtB in S. marcescens, A. baumannii, P. aeruginosa, E. coli, and K. 
pneumoniae;105 RmtC in K. pneumoniae;106 and Arm in S. marcescens, E. coli, and K. 
pneumoniae.101,107,108 The modifications caused by methyltransferases pose a serious threat to the 
4,6-series of AGAs including plazomicin, as they mostly interfere with the G1405 residue that 
contacts ring-III of that series.109-112 
1.5.4. Aminoglycoside modifying enzymes (AMEs): 
          AMEs are the most widespread and clinically relevant mechanism of AGA-resistance. 
AMEs are bacterially expressed enzymes which modify the antibiotics and thereby inactivate 
them.23-27 These enzymes catalyze the covalent modification of amino or hydroxyl groups in AGAs 
thereby disrupting AGA binding to the ribosome and leading to compounds devoid of antibiotic 
activity. AMEs can be classified into three major categories: (i) Aminoglycoside N-
acetyltransferases (AACs), (ii) Aminoglycoside O-phosphotransferases (APHs), and (iii) 
Aminoglycoside O-nucleotidyltransferases (ANTs). AACs use acetyl coenzyme-A as a donor and 
modify the amino groups. Both ANTs and APHs use ATP as a donor and affect the hydroxyl 
functions. Figure 15 depicts the potential modification sites of some representative AGAs. 
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Figure 16. Potential modification sites of streptomycin, kanamycin B, neomycin B, 
 and apramycin. 
1.5.4.1. Aminoglycoside N-acetyltransferases (AACs): 
          These enzyme act by acetylating one or amino groups in the AGAs.  AACs use acetyl-CoA 
to transfer the acetyl functionality. By acetylating the amino groups, they (i) reduce the positive 
charge on AGAs and (ii) result in a steric block to interaction with residues in the binding site. 
There are four major categories of AACs based on their regiospecificity for acetyl transfer: AAC 
(6’), AAC (2’), AAC (1), and AAC (3).  In this notation, the number in parentheses indicates the 
specific positions the enzyme acetylates AGAs. Four AAC enzymes have been crystallized and 
their 3D structures determined; these are AAC (3)-Ia from Serratia marcesans,113 AAC (6’)-Ii 
from Enterococcus faecium,114 AAC (6’)-Iy from Salmonella enterica,115 and AAC (2’)-Ic from 
Mycobacterium tuberculosis.116 Their structures revealed that they are closely related with the 
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GCN5-related N-acetyltransferases (GNAT) protein superfamily.117 Now more than 50 different 
AAC enzymes have been identified and subcategorized based on their regiospecificity.28 These 
enzymes are present in both Gram-positive and Gram-negative and confer a broad aminoglycoside 
resistance profile. Recently there are reports of the emergence of a bifunctional enzyme AAC (6’)-
APH (2’’), which can catalyze both acetylation and phosphorylation in the substrate AGAs. This 
enzyme can modify almost all the DOS based AGAs and is of serious concern.118,119 
1.5.4.2. Aminoglycoside O-phosphotransferases (APHs): 
          These enzymes phosphorylate the key hydroxyl functionalities on AGAs using ATP as a 
donor. The phosphorylation of hydroxy groups blocks their hydrogen bond donor ability and 
therefore disrupts key hydrogen bond interactions of AGAs with the bacterial A-site. In addition, 
phosphorylation introduces a negative charge on AGAs, which reduces their affinity to the 
bacterial A-site.120,121 Seven classes of APH enzyme have been identified at present; APH-(3’), 
APH-(2’’), APH-(3’’), APH-(4), APH-(7’’), APH-(6), and APH-(9) have been identified till now. 
APH-(3’) is the most widespread and well-studied enzyme; it is generally found in gram-positive 
bacteria.13 There are eight main types of enzymes, from APH-(3’)-I to APH-(3’)-VIII have been 
identified in APH-(3’) sub-class. The APH-(III)a is the most extensively studied enzyme and 
known to catalyze phosphorylation of a wide range of AGAs.122 Several extensive studies have 
been performed on regioselectivity of phosphorylation by APH-(3’)-IIIa and it was proposed that 
the 4,5-disustuituted AGAs lacking a 3’-hydroxy group (e.g. lividomycin A), could also be 
phosphorylated at 5’’-position.123 The APH-(3’)-IIIa bound conformations of amikacin, a 4,6-
disubstituted AGA, and butirosin A, a 4,5-disubstituted AGA, were probed and it was found that 
their binding pattern is different. In case of amikacin, only 3’-hydroxy group approaches the γ-
phosphate of ATP, whereas in case of butirosin A, both the 3’- and 5’’-hydroxyl groups approach 
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the γ-phosphate of ATP.124 These results were further confirmed by showing the exclusive 
monophosphorylation in 4,6-series of AGAs and mono as well as bisphosphorylation in the case 
of 4,5-series of AGAs.125 Another member which has the structural information is APH-(2’’) and 
it favors 4,6-AGAs over  4,5-AGAs.126  
1.5.4.3. Aminoglycoside O-nucleotidyltransferases (ANTs): 
          The third mechanism of AGA modification is the ATP-based transfer of AMP group on 
hydroxyl functionalities by the enzymes called ANTs. There are five classes of ANT enzymes 
based on their regiospecificity, ANT-(2’’), ANT-(4’), ANT-(3”), ANT-(6’), and ANT-(9). These 
are the smallest family of AMEs with only ten enzymes identified till now.28 ANT-(2”) is the most 
clinically significant class and widespread among gram-negative bacteria. ANT-(2’’) caused a 
significant amount of resistance to gentamicin, tobramycin, and amikacin (Figure 17). 
         
Figure 17. Structures of gentamicin, tobramycin, and amikacin. 
1.5.5. Strategies to overcome aminoglycoside resistance: 
          AGAs are the highly potent broad-spectrum antibiotics and they have much desired 
bactericidal activity. Their clinical use is somewhat limited by the emergence of resistant bacterial 
strains. As a result, there is no new AGA introduced in the clinics for a number of years. But with 
the emergence of resistance to other class of antibiotics, the availability of detailed atomic level 
understanding of AGA binding to the bacterial A-site and well-studied mechanism of their 
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resistance have offered an opportunity to revisit the AGAs and design the new more efficient 
antibiotics of this class. Commonly two approaches have been employed to avoid the resistance: 
inhibition of resistance and resistance-proof AGAs. 
          A small molecule inhibitor of AMEs could be a good strategy to avoid the resistance and 
this strategy has been successful for β-lactam antibiotics.127 7-Hydroxytropolone 13, was reported 
to have inhibitory activity on ANT-(2’’).128 Similarly, the compounds with the structure like 14, 
have been reported to have inhibitory activity on AAC-(6’).129 Based on the fact that AMEs have 
a negatively charged binding pocket to accommodate cationic AGA, many cationic peptides were 
screened against several AMEs, and their inhibitory activity against several enzymes were 
identified.130 
 
Figure 18. Some of the AME inhibitors. 
          The other and better approach is to rationally design the resistance-proof AGAs those can 
avoid the modifications by AMEs. Tobramycin and gentamicin don’t have the 3’-hydroxyl group 
and are not susceptible to APH-(3’). Amikacin, a semisynthetic derivative of kanamycin has a 
better activity against many AGA resistant strains. Neamine dimers having a structure like 15, are 
reported not to be affected by AAC-(6’), APH-(3’), and APH-(2’’).131 Semisynthetic derivatives 
of neamine, termed as pyranmycin 16 and pyrankacin 17 retain their activity against resistant strain 
of E. Coli, K. pneumoniae, and S. aureus.132,133 The semisynthetic neamine derivative 18 was 
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designed to mimic amikacin and was found to be a poor substrate for modification by APH-(3’), 
AAC-(6’) and APH-(2”).20,134 Conformationally rigid neomycin B derivative 19 was designed to 
resemble the confirmation of neomycin B bound to bacterial A-site, but to differ from the 
confirmation of neomycin bound to ANT-(4’) active site. As desired this compound is a poor 
substrate for modification by ANT-(4’) and AAC-(2’).135 Additionally, AGA hybrids having a 
structure like 20, which contain features of neomycin B or paromomycin with sisomicin were 
shown to display good antibacterial and to evade APH-(3’) and ANT-(4’) resistance 
mechanisms.136 These results are very promising and show that it is possible to build new 
generation of resistance-proof AGAs (Figure 19). 
 
Figure 19. Some of the rationally designed semisynthetic AGAs. 
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1.6. Goals: 
          The overall goal of this research project is to rationally design and synthesize novel 
aminoglycoside antibiotics which will cause little to no ototoxicity and completely evade the 
modifications by common AMEs. The differences between the bacterial and mitochondrial A-sites 
can be exploited in the design of improved and more selective AGAs presenting reduced 
ototoxicity. At the same time, well understood mechanism of resistance to AGA can be used to 
design new AGAs which are active against resistant strains of various bacteria. For this purpose, 
Neomycin B and paromomycin from 4,5-series of AGAs were selected.  Neomycin B and 
paromomycin are highly potent broad spectrum antibiotics and discovered almost six decades ago. 
Their clinical use was limited due to their toxic responses and evolution of resistant bacteria. They 
are one of the most extensively studied aminoglycoside antibiotics. Their binding pattern to 
bacterial and mitochondrial A-sites is well known and mechanism of resistance is also well studied. 
These earlier observations reported in the literature on neomycin B and paromomycin made them 
ideal substrates for further modifications and to determine the influence of these modifications on 
antibacterial activity, ribosomal selectivity, and activity against resistant strains of bacteria to 
determine their susceptibility against common AMEs. In neomycin B series, the 2’, 4’, 6’, and 
6’’’-positions will be targeted for modifications. Similarly, in paromomycin will be modified at 2’ 
and 5’’-positions. Based on the information obtained from these single modifications, advanced 
compound will be made with multiple modifications. 
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CHAPTER 2. MODIFICATIONS TO NEOMYCIN B.  
2.1. N6’-, N6’’’-, and O4’-modifications to neomycin B.137 
2.1.1. Introduction: 
          Neomycin B is a 4,6-series AGA that was discovered by Selman Waksman in 1949. It is 
naturally produced by the bacterium Streptomyces fradiae. Neomycin B is a very potent broad 
spectrum antibiotic and its binding pattern to bacterial ribosome is similar to paromomycin shown 
in Figure 11. The only difference between neomycin B and paromomycin is the 6’-substituent; an 
amino group in neomycin B but a hydroxyl group in paromomycin. This 6’-amino present in 
neomycin B increases its affinity to bacterial ribosome and responsible for its higher antibacterial 
activity as compared to the paromomycin.   This 6-amino group also results in higher affinity of 
neomycin B for human mitochondrial ribosome and its A1555G mutant and makes it more ototoxic 
as compared to the paromomycin.55,56,70,74,75,138  This can be explained based on the fact that 
hydrogen bond involving an ammonium ion as a donor in the case of neomycin B is estimated to 
be ≥ 3 kcla.mol-1 stronger then the hydrogen bond involving a hydroxy group as a donor in the 
case of paromomycin.67 Additionally, 6-amino group makes neomycin B susceptible to 
inactivation by the AAC-(6’) class of AMEs.110,139 In recent years, many reports have been 
published on the synthesis of improved neomycin B derivatives, including 6’- N -alkyl derivatives 
with reduced susceptibility to AAC-(6’).140-148 It has also been reported that 4’-O-ethylation of 
paromomycin  increases its selectivity for the bacterial over the human cytosolic and mitochondrial 
ribosomes and decreases the susceptibility to inactivation by AMEs.149 Based on these 
observations reported in the past, neomycin B was modified either at 6’-position alone and in 
combination with 4’-O-ethylation. The 2-hydroxyethyl group was selected for 6’-N-alkylation. It 
was first introduced in the sisomicin series 150,151 and also present in plazomicin (Figure 20).36 
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These 1,2- and 1,3-amino alcohol modifications do not cause reduction in antibacterial activity of 
AGAs and suggested to enhance binding to phosphate backbone and nucleic acid bases.152,153 
Moreover, the presence of 2-hydroxyethyl group would decrease the basicity of the amino group154 
and would reduce the affinity of neomycin B for the human mitochondrial ribosome and its 
A1555G mutant. The synthetic routes also provided easy access to the other neomycin derivatives 
modified at 5”- and 6’’’-positions and they were also screened for their antiribosomal and 
antibacterial activities. 
 
Figure 20. Structures of neomycin B, paromomycin, 4’-O-ethyl paromomycin, sisomicin, 
 and plazomicin. 
2.1.2. Synthesis: 
          The synthesis of 4’-O-Ethyl neomycin B 27 started from the 4’, 6'-diol intermediate 23, 
which was readily prepared from paromomycin 21 by following the procedure described in the 
literature.155 Selective sulfonylation of 23 with 2,4,6-triisopropylbenzenesulfonyl chloride gave 24 
in 53% yield and then displacement with azide afforded intermediate 25 in 73% yield. Ethylation 
of 25 with sodium hydride and ethyl idodide in N,N-dimethylformamide gave intermediate 26 in 
73% yield. Global deprotection by hydrogenolysis, followed by purification on Sephadex and 
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lyophilization from aqueous acetic acid gave 27 as the peracetate salt with a 41% yield (Scheme 
1). 
          The synthesis of 6’-N-(2-hydroxyethyl) neomycin B 37 started with the selective protection 
of 6’-NH2 group with benzyl carbamate by following a procedure described in the literature,156 in 
which treatment of neomycin B sulfate with N-(benzyloxycarbonyloxy) succinimide and sodium 
carbonate in aqueous dioxane gave an inseparable 1:1 mixture of the N6’- and N6’’’-benzyl 
carbamates 28 and 29 in 32% yield, along with 29% of the N6’, N6”’-bis (benzyl carbamate) 30. 
This 28/29 mixture on subjecting to the diazo transfer reaction  using imidazolesulfonyl azide157,158 
in the presence of potassium carbonate and catalytic copper sulfate in aqueous methanol afforded 
the regioisomeric mixture of pentaazides 31 and 32 in 53% yield. Saponification of benzyl 
carbamate in hot aqueous dioxane gave a 1:1 mixture of regioisomeric amines 33 and 34 in 57% 
yield. Reductive amination of the 33/34 mixture with benzyloxyacetaldehyde using 
sodiumcyanoborohydride159 as a reducing agent in methanol gave a 1:1 mixture of the N6’- and 
N6’’’-(2-benzyloxyethyl) derivatives 35 and 36 in a combined 47% yield. This 35/36 mixture was 
separated by preparative HPLC to obtain pure samples of 35 and 36. Finally, application of 
Staudinger reaction to reduce azides with trimethylphosphine and sodium hydroxide in hot 
aqueous THF,155 followed by hydrogenolysis to deprotect benzyl ether, and then purification on 
sephadex and lyophilization from aqueous acetic acid  gave the N6’- and N6’’’-(2-hydroxyethyl) 
derivatives 37 and 38 as their peracetate salts with 23 and 26% yield respectively (Scheme 2). 
Application of the same sequence of reactions to the N6’, N6’’’-biscarbamate intermediate 30 
afforded the N6’, N6’’’-bis (2-hydroxyethyl) derivative 42 as the peracetate salt, via the 
intermediates 39-41 (Scheme 2). 
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Scheme 1. Synthesis of 4’-O-ethyl neomycin B 27. 
          Slow and careful separation of the 33/34 mixture in silica gel using a mixture of three 
solvents (chloroform, methanol, and ammonium hydroxide) was able to give pure samples of the 
regioisomeric amines 33 and 34.  Treatment of 33 with acetic anhydride in methanol gave the 
intermediate 43, which upon reduction of azides by hydrogenolysis, purification on sephedex, and 
lyophilization from aqueous acetic acid afforded a sample of known 6’-N-acetyl neomycin B 
44160,161 as peracetate salt in 44% yield (Scheme 3). Diazotization of 34 with sodium nitrite in 
aqueous acetic acid156,162,163 gave the pentazide intermediate 45164 in 39% yield. Deprotection of 
the azides by Staudinger reaction with trimethylphosphine, purification on Sephadex, and 
lyophilization from aqueous acetic acid afforded the sample of known 6’’’-deamino-6’’’-hydroxy 
neomycin B 46156 as the peracetate salt in 35% yield (Scheme 3). 
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Scheme 2. Synthesis of neomycin B derivatives 37, 38 and 42. 
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Scheme 3. Synthesis of neomycin B derivatives 44 and 46. 
          The synthesis of doubly modified neomycin B derivative 53 started from 4’-O-ethyl 
paromomycin 22.149 Application of the same diazo transfer reaction conditions to  4’-O-ethyl 
paromomycin 22 using imidazolesulfonyl azide in the presence of potassium carbonate and 
catalytic copper sulfate in aquous methanol gave the pentaazide intermediate 47 in 57% yield. 
Treatment of pentaazide 47 with p-toluenesulfonyl chloride in pyridine at room temperature gave 
an approximately 1:0.7 mixture of regioisomeric monotosylates 48 and 49 in a combined 30% 
yield, along with 10% of the ditosylate 50. Treatment of 48/49 mixture with ethanolamine at room 
temperature gave a mixture of 2-hydroxyethyl derivatives 51 and 52 in a combined yield of 52%. 
This 51/52 mixture was separated by preparative HPLC to obtain pure samples of 51 and 52. 
Reduction of the azides by Staudinger reaction with trimethylphosphine, purification on Sephadex, 
and lyophilization from aqueous acetic acid afforded the neomycin B derivative 53 and 
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paromomycin derivative 54 as their peracetate salts in 42 and 44% yields respectively (Scheme 4). 
Application of the same sequence of tosylate displacement by ethanolamine and reduction of 
azides by Staudinger reaction to the ditosylate intermediate 50 afforded the neomycin B derivative 
56 as the peracetate salt via the intermediate 55 (Scheme 4).  
2.1.3. Biological evaluations: 
          All the synthesized neomycin B derivatives 27, 37, 38, 42, 44, 46, 53, 54 and 56 were 
screened to establish their ability to inhibit the protein synthesis. The antiribosomal activities were 
determined in cell free translational assays employing wild type bacterial ribosomes and 
recombinant hybrid bacterial ribosomes. Their antiribosomal activities were also compared with 
the parent neomycin B 9, paromomycin 21 and 4’-O-ethyl paromomycin 22 (Table 1). 4’-O-
ethylation (27) and 6’-N-(2-hydroxyethylation) (37) do not cause any reduction in antiribosomal 
activity of neomycin B against the bacterial ribosome. The modifications at 6’’’-postion also do 
not have any effect on antiribosomal activity against the bacterial ribosome (38 and 46, Table 1). 
6’’’-N-(2-hydroxyethyl) neomycin B 38 and 6’’’-deamino-6’’’-hydroxy neomycin 46 are as active 
as the parent neomycin B, which is consistent with the earlier reports on the antibacterial activity 
of 46.156,165 In contrast, the 4-O-ethylation (22) in paromomycin show a 4-fold decrease in 
antiribosomal activity against bacterial ribosome and similarly the 6’’’-deamino-6’’’-hydroxy 
modification also known to cause a significant decrease in antibacterial activity of 
paromomycin.156,165 This difference between the neomycin series and paromomycin series can be 
explained on the basis of the strength of hydrogen bond between the 6’-substituent and N1 of 
A1408 residue. The hydrogen bond involving an ammonium ion as a donor in neomycin series is 
estimated to be ≥3 kcal/mol stronger than the hydrogen bond involving a hydroxy group as a donor 
in paromomycin series.67 The 6’-N-acetylation (44) causes a significant reduction in antiribosomal 
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activity against bacterial ribosome and it is consistent with the AAC-(6’) mechanism of AGA 
resistance.13,14,25,28,30 Double and triple modifications in one single molecule cause a significant 
reduction in antiribosomal activity against the bacterial ribosome (42, 53, 54 and 56, Table 1). 
Therefore, it can be concluded that each of these single modifications have a small detrimental 
effect on binding, although this small change is not sufficient to be reflected in the IC50 values in 
antiribisomal assay.  
          To compare the influence of each modification on ribosomal selectivity, the data presented 
in Table 1 have been converted into selectivity quotients (SelQ) with respect to the parent 
neomycin B (Table 2). Paromomycin is 10- to 15-fold more selective for the bacterial over 
mitochondrial and mutant mitochondrial ribosomes, but less selective over cytosolic ribosome 
(Entry 1, Table 2). The decrease in selectivity of paromomycin for the bacterial over cytosolic 
ribosome is due to the fact that the 6’-hydroxyl group of paromomycin can still accept the hydrogen 
bonds from 1408G reside in cytosolic ribosome in contrast to the repulsive interaction between 
protonated 6’-amino group of neomycin B and G1408.166,167 The 6’-N-(2-hydroxyethyl) 
modification of neomycin B increases selectivity for the bacterial over mutant mitochondrial 
ribosome to a greater extent than over the wild type mitochondrial ribosome (37, Entry 2, Table 
2). Similarly, the 6’-N-acetyl neomycin B also show a larger increase in selectivity for the bacterial 
over mutant mitochondrial ribosome as compared to the wild type mitochondrial ribosome (44, 
Entry 5, Table 2). Most probably, the looser wild type mitochondrial A-site accommodates the 6’-
N-(2-hydroxyethyl) and 6’-N-acetyl group better than the more rigid mutant mitochondrial A-site. 
The slight increase in selectivity of 37 for the bacterial over the cytosolic ribosome can be 
explained by the increased repulsive interaction with the 1408G residue due to the increased steric 
hindrance at 6’-position. The 6’’’-N-(2-hydroxyethyl) and 6’’’-deamino-6’’’-hydroxy 
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modifications of neomycin B cause relatively minor increase in ribosomal selectivities (38 and 46, 
Entries 3 and 4, Table 2). This is consistent with the fact that ring-IV of the 4,5-AGAs mainly 
contributes to binding through electrostatic interaction rather than through any specific 
interactions.168-170 The 4’-O-ethyl neomycin B show reduction in selectivity for the bacterial over 
the mitochondrial ribosome but an increase in selectivity over the mutant mitochondrial ribosome 
(27, Entry 6, Table 2). Whereas 4’-O-ethyl paromomycin 22 show a greater increase in selectivities 
for both the bacterial over mitochondrial and the mutant mitochondrial ribosomes (22, Entry 7, 
Table 2). In contrast, the combination of 6’-N-(2-hydroxyethyl) and 6’’’-N-(2-hydroxyethyl) 
modification in a single molecule, 42, does not cause an improvement in SelQ (Entry 8, Table 2), 
nor does the combination of 6’-N-(2-hydroxyethyl) and 4’-O-ethyl modifications in 53 (Entry 9, 
Table 2). The compounds 54 and 56 are the byproducts of synthetic and in both the compounds 
the 5’’-hydroxy group is replaced by an ethanolamine linked via nitrogen. The key feature of these 
two compounds is the marked decrease in the selectivity for the bacterial over cytosolic ribosomes 
(Entries 10 and 11, Table 2). This is due to an increase in affinity for the cytosolic ribosome and 
earlier observed in 5’’-deoxy-5’’-amino derivative of 4,5-AGA ribostamycin.171-173 
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Scheme 4. Synthesis of neomycin B derivatives 53, 54, and 56. 
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Table 1. Antiribosomal activities (IC50, µg/mL) and selectivities of modified neomycin B 
derivatives (selectivities are obtained by dividing the eukaryotic values by the bacterial values). 
  
Compound 
In vitro M. smegmatis (IC50, µg/mL) 
Bacterial 
Mit13 
(Selectivity) 
A1555G 
(Selectivity) 
Cyt14 
(Selectivity) 
Paromomycin 21 0.02 50.2 (2506) 5.39 (267) 9.4 (471) 
22 0.08 99.3 (1240) 114.7 (1434) 102.9 (1286) 
Neomycin B 9 0.01 1.62 (162) 0.22 (22) 17.12 (1712) 
27 0.01 0.94 (94) 2.76 (276) 32.3 (3232) 
37 0.01 13.11 (1311) 5.51 (551) 38.31 (3831) 
38 0.01 9.72 (972) 0.74 (74) 21.51 (2151) 
42 0.04 44.56 (1114) 11.96 (299) 76.33 (1908) 
44 0.16 122 (776) 606 (3860) 295 (1879) 
46 0.01 12.16 (1216) 1.13 (113) 54.71 (5471) 
53 0.07 2.91 (41) 20.26 (289) 60.54 (865) 
54 1.90 74.81 (39) 95.79 (50) 83.85 (44) 
56 0.64 43.15 (67) 47.54 (74) 53.39 (83) 
 
          All the compounds were screened for their antibacterial activities against clinical isolates of 
methicillin-resistant Gram-positive bacterium Staphylococcus aureus (MRSA) and Gram-negative 
bacterium Escherichia coli and Pseudomonas aeruginosa obtained from the Diagnostic Division 
of the Institute of Medical Microbiology, University of Zurich. The MIC data against the clinical 
isolates of MRSA and E. coli is given in Table 3 and no significant activity was observed against 
clinical isolates of P. aeruginosa. Some compounds were also screened for their activity against 
the ESKAPE pathogens Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter 
baumannii (Table 4). Most of the singly modified neomycin B derivatives showed antibacterial 
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activities comparable to that of the parent neomycin B against MRSA and E. coli (Table 3), and 
against the ESKAPE pathogens (Table 4). Doubly and triply modified neomycin B derivatives are 
relatively less active than the singly modified derivatives. It is important to note that compounds 
27 and 53 carrying a 4’-O-ethyl modification retain good antibacterial activity against neomycin 
resistant strains of MRSA (Table 3). 
Table 2. Change in antiribosomal selectivity (selectivity quotient = selectivity of 
derivative/selectivity of parent) of neomycin B derivatives with respect to parent neomycin B. 
Entry Compounds 
Selectivity Quotient (SelQ) 
Mit13 A1555G Cyt14 
1 Paromomycin 21 15.47 12.14 0.28 
2 37 8.09 25.05 2.24 
3 38 6.00 3.37 1.26 
4 46 7.51 5.14 3.20 
5 44 4.5 176 1.1 
6 27 0.58 12.55 1.89 
7 22 7.66 65.18 0.75 
8 42 6.88 13.28 1.12 
9 53 0.26 13.14 0.51 
10 54 0.24 2.27 0.03 
11 56 0.42 3.37 0.05 
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Table 3. Antibacterial activities of modified neomycin B derivatives (MIC, µg/mL). 
 Compound 
MRSA E. coli 
AG038 AG039 AG042 AG044 AG001 AG055 AG003 
Paromomycin 21 4 >256 >256 4-8 4 2-4 2-4 
22 8-16 16 8-16 8-16 64 32-64 32 
Neomycin 9 1-2 128 128 1 2 1-2 1 
27 4 2 2 1-2 4 2-4 2-4 
37 4 >128 >128 2 4 2-4 4 
38 2 >128 >128 2 2-4 4 4 
42 8 >128 >128 4 16-32 16 16 
44 8 >64 >64 8-16 8 8 8 
46 4 >128 >128 2 4 4 4 
53 8-16 8 4-8 4-8 16 8-16 8-16 
54 32-64 32-64 32 64 64-128 64-428 32-64 
56 16 16-32 16 16 32 16-32 16-32 
 
 
Table 4. Antibacterial activities (MIC, µg/mL) of modified neomycin B derivatives against 
ESKAPE pathogens. 
 Compound 
K. pneumoniae E. cloacae A. baumannii 
AG261 AG262 AG263 AG290 AG291 AG292 AG225 AG226 AG286 
Paromomycin 21 1 1 1 2 1-2 2 4 2-4 1-2 
22 4 8 8 8-16 8-16 8 16 16 32 
Neomycin B 9 0.5 0.5 1 1 1 1 4 4 0.5-1 
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27 0.5 1 1 1 1 1 4 4 1-2 
37 0.5-1 1 0.5 1 1 1 2 2 1 
38 0.5 0.5 1 1 0.5 0.5 2 2 0.5 
46 0.5 0.5 1 1 0.5-1 2 2 2 1 
53 2-4 4 4 8 4 4 8-16 4-8 8 
 
          In order to determine the effectiveness of each modification in circumventing the 
modifications by common AMEs, all the synthesized Compounds were screened against wild type 
and recombinant Escherichia coli strains carrying defined resistance determinants39 (Table 5). The 
4’-O-ethylation as in the case of 27 and 53 is effective in evading the modifications caused by 
ANT-(4’, 4’’) class of AMEs and retains good antibacterial activity against resistant strains. This 
is consistent with the earlier reports in the paromomycin and other series.149,168,174,175 Most of the 
derivatives were not inactivated by the presence of either the AAC-(3) or AAC-(2’) resistance 
determinants and this is consistent with the general lower susceptibility of the 4,5-AGAs than the 
4,6-AGAs to AACs.111 None of the modifications were helpful in circumventing the APH-(3’, 5”) 
mechanism of resistance and compounds are completely inactive against these resistant strains. 
The ACC (6’) resistance determinants cause about eight-fold decrease in antibacterial activity of 
neomycin B (Table 5) and this is in accordance with the literature reports that 6’-N-acetylation 
doesn’t completely inactivate neomycin B, and also proved here by 6’-N-acetyl neomycin B 
(44).160,161,176 Compounds 27, 38 and 46 display greater loss of activity in the presence of AAC-
(6’) class of AMEs. The introduction of 6’-N-(2-hydroxyethyl) modification (37, 42, 53 and 56) 
was able to effectively protect against AAC-(6’) resistance mechanism.  
    
 
43 
 
 
 
Table 5. Antibacterial data of modified neomycin B derivatives against wild type and engineered 
strains of E. coli carrying specific resistance determinants (MIC, µg/ml). 
Strain: AG006 AG007 AG105 AG009 AG036 AG037 
Resistance 
Mechanism: Wild Type AAC (3) AAC (2’) AAC (6’) 
ANT 
(4’, 4”) 
APH 
(3’, 5”) 
Neomycin B 9 1 4 2 8 32 >256 
27 0.5 2 2 32-64 0.5 >256 
37 1 2 2 2 64 >256 
38 1 2 2 16 32 >256 
42 2 8 - 8-16 >64 >256 
44 4-8 16 4 16 >64 >256 
46 1 2 2-4 64 128 >256 
53 2-4 8-16 8 16 4 >256 
56 4 8 - 16-32 8 >256 
 
2.1.4. Conclusion: 
The 6’-N-(2-hydrxyethyl) modification of neomycin B doesn’t cause any significant reduction in 
antibacterial activity and leads to enhanced selectivity for the bacterial ribosome over 
mitochondrial and mutant mitochondrial ribosomes. It also effectively suppresses the action of the 
AAC-(6’) resistance mechanism. The 4’-O-ethyl modification of neomycin B also causes an 
increase in selectivity for prokaryotic over eukaryotic ribosomes and does not cause any reduction 
in antibacterial activity. This 4’-O-ethylation also block the activity of the ANT-(4’, 4’’) class of 
AMEs. Double and triple modifications of neomycin B are less advantageous as they generally 
show a greater loss in antibacterial activity and antiribosomal selectivity.  
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2.2. N2’-modifications to neomycin B. 
2.2.1. Introduction: 
          After modifications of the 4’, 6’, and 6’’’-positions in neomycin B, the 2’-position was 
targeted. The 2’-amino group present in most of the 4,5- and 4,6-series of AGAs, does not make 
any specific interaction with the bacterial A-site and mainly contributes to binding through 
electrostatic interactions.18,27,49,50,177 In neomycin B and other members of the 4,5-series of AGAs 
the protonated 2’-amino group has been considered to makes an intramolecular hydrogen bond 
with the 5’’-hydroxy group that is hypothesized to enforce the correct conformation for the optimal 
interaction of rings-I and II with the  bacterial A-site (Figure 21).135,177 Conversely, the 2’-amino 
group makes neomycin B and other members of the 4,5- and 4,6-series of AGAs susceptible to 
inactivation by the AAC-(2’) class of AMEs.116,166,178-182 There are only limited examples in the 
literature of 2’-modifications to AGAs and their influence on antibacterial activity. 2’-N-Alkylated 
derivatives of sisomicin retain their antibacterial activities and 2’-N-ethyl netilimicin has a 
comparable antibacterial activity to netilimicin itself, neither are susceptible to modifications by 
the AAC-(2’) class of AMEs.183-188 Similarly, 2’-N-ethyl paromomycin has also been shown to 
possess comparable activity to paromomycin.189 Kanamycin A, with a 2’-hydroxy substituent has 
a similar antibacterial profile as kanamycin B, with its 2’-amino substituent, and is not affected by 
most of the AAC-(2’) class of AMEs.27,117,166,168,190 However, it has been reported that AAC-(2’)-
Ic from M. tuberculosis can catalyze the acetyl-CoA dependent acetylation of kanamycin A and 
amikacin, both of which feature a 2’-hydroxyl substituent, suggesting that this AME can catalyze 
O-acetylation.182 It has also been reported that the 2’-deamino-2’-hydroxy modification of 
neomycin B is not detrimental to antibacterial activity.162 In contrast to the above limited but 
generally encouraging literature precedent on the modification of neomycin B at the 2’-position 
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with regard to activity, nothing is known of the effect of this type of modification on ribosomal 
selectivity and hence toxicity. Modification of the neomycin B 2’-position was therefore 
considered a reasonable avenue of exploration in the search of novel AGAs with an improved 
pharmacological profile. Accordingly, several 2’-N-alkylated, 2’-deamino, and 2’-amido 
derivatives were synthesized, and their antiribosomal and antibacterial activities were screened.  
 
 
Figure 21. Schematic representation of intramolecular 2’-5’’-hydrogen bond in neomycin B and 
its interactions with bacterial 16S r-RNA. 
2.2.2. Synthesis: 
          The 2’-N-methyl and 2’-N-ethyl neomycin B derivatives 59 and 61 were readily prepared 
from neomycin B. Following a literature procedure,162,189 treatment of neomycin B free base with 
acetic anhydride in the presence of equimolar 1N HCl in aqueous methanol gave penta-N-acetyl 
neomycin B derivative 57 as the major product in 39% yield. The observed regioselectivity can be 
attributed to the difference in the basicity of the amino groups and the steric environments. Double 
one pot reductive amination of 57, first with benzaldehyde and then with formaldehyde using 
sodium cyanoborohydride as reducing agent159 gave a crude preparation of the corresponding 2’-
N-benzyl-N-methyl derivative, which was per-acetylated using acetic anhydride in pyridine to give 
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the fully protected intermediate 58 with an overall 62% yield for the three steps. Finally, 
application of a two-step deprotection procedure, involving hydrogenolysis to remove benzyl 
group and saponification of the acetyl groups in hot aqueous barium hydroxide, and then 
purification on Sephadex and lyophilization from aqueous acetic acid gave the 2’-N-methyl 
neomycin B 59 in the form of its peracetate salt with 29% yield (Scheme 5). Similarly, reductive 
amination of 57 with acetaldehyde gave the 2’-N-ethylated intermediate 60 in 58% yield, which 
upon saponification in hot aqueous barium hydroxide, and then purification on Sephadex and 
lyophilization from aqueous acetic acid gave the 2’-N-ethyl neomycin B 61 in the form of its 
peracetate salt in 22% yield (Scheme 5). The precise location of the methyl and ethyl group was 
confirmed by heteronuclear multiple bond coherence (HMBC) correlations between the methyl 
group and the 2’-position in the case of 2’-N-methyl neomycin B 59, and between the ethyl 
methylene group and the 2’-position in the case of 2’-N-ethyl neomycin B 61. 
          For the synthesis of 2’-deamino neomycin B 64, the neomycin B pentaacetamide 57 was 
treated with acetic formic anhydride191 and pyridine in N, N-dimethylformamide to give the 
corresponding 2’-formamido intermediate and this crude intermediate was per-acetylated using 
acetic anhydride in pyridine to give the fully protected 2’-formamido derivative 62 with an overall 
65% yield for the two steps. Dehydration of the 2’-formamido derivative 62 with phosphoryl 
chloride and triethyl amine in dichloromethane gave the corresponding isonitrile intermediate, 
which was subjected to radical deamination conditions using tris(trimethylsilyl) silane (TTMS) 
and azobisisobutyronitrile (AIBN) in a hot mixture of toluene and acetonitrile to give the fully 
acetylated 2’-deamino intermediate 63 with an overall 44% yield for the two steps (Scheme 6). 
The mechanism for the replacement of the isonitrile moiety with a hydrogen atom is shown in 
Scheme 7. AIBN serves as the radical initiator, and upon heating generates two isobutyronitrile 
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radicals with the liberation of a nitrogen molecule. The isobutyronitrile radical abstracts a 
hydrogen atom from TTMS to generate the tris(trimethylsilyl)silyl radical, which adds to the 
isonitrile to give an imidoyl radical intermediate. This imidoyl radical undergoes fragmentation to 
generate the alkyl radical and this alkyl radical abstracts a hydrogen atom from TTMS to give the 
corresponding alkane along with another tris(trimethylsilyl)silyl radical (Scheme 7).192-194 
Saponification of the acetyl groups in hot aqueous barium hydroxide, and then purification on 
Sephadex and lyophilization from aqueous acetic acid gave the 2’-deamino neomycin B 64 as the 
peracetate salt in 28% yield (Scheme 6).  
          For the synthesis of 2-deamino-2’-hydroxy neomycin B 70,162 a glycosylation strategy was 
adopted. The glycosyl acceptor 67 was synthesized from paromomycin as described in the 
literature.162,189 Treatment of paromomycin free base with acetic anhydride in the presence of 
equimolar 1N HCl in aqueous methanol gave the tetra-N-acetyl paromomycin derivative 65 as a 
major product with 40% yield. Protection of the 2’-amino group as the benzyl carbamate using 
benzyl chloroformate and then per-acetylation using acetic anhydride in pyridine gave the fully 
protected intermediate 66 with an overall 57% yield for the two steps. Finally, removal of the 
benzyl carbamate by hydrogenolysis gave the 2’-amino intermediate, which upon diazotization 
with sodium nitrite in aqueous acetic acid smoothly gave the glycosyl acceptor 67 with an overall 
52% yield for the two steps (Scheme 8). The selective cleavage of ring I in this manner confirms 
the regioselectivity of the acetamide forming process when conducted in the presence of dilute 
HCl. The formation of the glycosyl acceptor from the 2’-amine is proposed to proceed via the 
formation of an unstable diazonium salt, which rearranges to a fused bicyclo oxonium ion with 
expulsion of nitrogen. The three membered ring is then opened with the aid of a lone pair on the 
glycosidic oxygen affording an oxocarbenium ion, whose hydrolysis results in the glycosyl 
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acceptor 67 (Scheme 9).163,195,196 
 
Scheme 5. Synthesis of 2’-N-alkyl neomycin B derivatives 59 and 61. 
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Scheme 6. Synthesis of 2’-deamino neomycin B 64. 
          The glycosyl acceptor 67 and thioglycoside 68153 were coupled using N,N-
dimethylformamide modulated highly α-selective glycosylation  conditions.197 The thioglycoside 
68 was activated by N-iodosuccinimide and trimethylsilyl triflate in the presence of  N,N-
dimethylformamide to give an intermediate glycosyl imidate, which upon nucleophilic attack by 
glycosyl acceptor 67 gave the glycosylated product 69 in 29% yield (Scheme 10). It is proposed 
that activation of the thioglycoside generates an oxacarbenium ion pair that is trapped by N,N-
dimethylformamide to give an equilibrium mixture of α- and β-glycosyl imidates. Subsequent 
nucleophilic attack of the glycosyl acceptor on the more reactive β-glycosyl imidate gives the 
desired α-glycosylation product as the major product (Scheme 11).197 Finally, application of a two-
step deprotection procedure, involving hydrogenolysis of the benzyl ethers and azides, followed 
by saponification in hot aqueous sodium hydroxide, and then purification on Sephadex and 
lyophilization from aqueous acetic acid gave the 2’-deamino-2’-hydroxy neomycin B 70 as the 
peracetate salt in 34% yield (Scheme 10). 
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Scheme 7. Proposed radical mechanism for replacement of isonitrile with a hydrogen atom (R-
NC represents a fully acetylated neomycin B derivative with a isonitrile group at 2’-position). 
          The synthesis of 2’-N-(2-aminoacetyl)-neomycin B 75 started with the selective acetylation 
of neomycin B using the conditions described before to give penta-N-acetyl neomycin B derivative 
57. The crude preparation of 57 was treated with imidazolesulfonyl azide157,158 in the presence of 
potassium carbonate and catalytic copper sulfate to give the corresponding 2’-azido derivative. 
Then further reaction of the amidic nitrogen atoms with di-tert-butyl dicarbonate and 4-
(dimethylamino) pyridine in hot tetrahydrofuran, followed by protection of the hydroxy groups 
with acetic anhydride in pyridine gave the fully protected neomycin B derivative 71 with an overall 
13% yield for the four steps (Scheme 12). Cleavage of all the acetyl groups with sodium methoxide 
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in methanol, followed by Staudinger reaction with trimethylphosphine155 to reduce 2’-azide gave 
the penta-N-tert-butoxycarbonyl-neomycin B 72 in 53% yield over two steps. Subsequent 
treatment of 72 with 2-azidoacetic acid 73, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride and 1-hydroxybenzotriazole gave the intermediate 74 in 68% yield. Finally, 
application of two step deprotection protocol, involving azide reduction by hydrogenolysis, 
followed by cleavage of the tert-butyl carbamates with trifluoracetic acid,164 and then purification 
on Sephadex and lyophilization from aqueous acetic acid gave the 2’-N-(2-aminoacetyl)-neomycin 
B 75 in the form of its peracetate salt in 48% yield (Scheme 12). The precise location of the 2-
aminoacetyl group was confirmed by heteronuclear multiple bond coherence (HMBC) correlation 
between the carbonyl carbon of the 2-aminoacetyl group and the hydrogen atom at the 2’-position. 
The corresponding 2’-N-formyl neomycin B 76 and 2’-N-acetyl neomycin B 77 (Figure 22) 
derivatives were also synthesized analogously from intermediate 72 by Dr. Vikram Sarpe in the 
Crich laboratory for comparison purposes. 
 
Scheme 8. Synthesis of glycosyl acceptor 67. 
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Scheme 9. Proposed mechanism for the formation of glycosyl acceptor 67 from the 2’-amino 
intermediate (R = ring II, III and IV of paromomycin derivative 66). 
 
 
 
Scheme 10. Synthesis of 2’-deamino-2’-hydroxy neomycin B 70. 
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Scheme 11. Proposed mechanism for DMF mediated α-selective glycosylation. 
 
 
 
Figure 22. Structures of 2’-N-formyl neomycin B 76 and 2’-N-acetyl neomycin B 77. 
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Scheme 12. Synthesis of 2’-N-(2-aminoacetyl)-neomycin B 75. 
2.2.3. Biological evaluations: 
          The newly synthesized 2’-modified neomycin B derivatives 59, 61, 64, 70, and 75 were 
screened for their antiribosomal activities in cell free translational assays employing wild type 
bacterial ribosomes and recombinant hybrid bacterial ribosomes (Table 6). Their antiribosomal 
activities were also compared with those of the parent neomycin B 9, of 2’-N-formyl neomycin B 
76, and of 2’-N-acetyl neomycin B 77 (Table 6). The activity of neomycin B against the bacterial 
ribosome is not affected by 2’-N-alkylation (59 and 61, Table 6), which is consistent with the 
earlier reports on the antibacterial activity of 2’-N-alkylated derivatives of sisomicin series183-188 
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and 2’-N-ethyl paromomycin.189 In these compounds the secondary amines at the 2’-position can 
still be protonated and contribute to binding to the bacterial A-site. These results also demonstrate 
that the bacterial ribosomal binding A-site can accommodate at least a two carbon substituent at 
this position. The 2’-deamino neomycin B 64 also shows no reduction in activity against the 
bacterial ribosome, which invalidates the literature hypothesis on the importance of the 2’-5’’-
hydrogen bond in enforcing the correct conformation for binding. Continuing the trend, the 2’-
deamino-2’-hydroxy derivative 70 shows comparable activity against the bacterial ribosome to the 
parent neomycin B 9, consistent with the earlier report on antibacterial activity of 70.162 In contrast, 
all the 2’-amido derivatives 75, 76, and 77 showed a marked decrease in their activity against the 
bacterial ribosomes. Presumably, this is due to the fact that the amidic nitrogen is not basic, is not 
protonated at physiological pH, and cannot contribute to binding through electrostatic interaction. 
The 2’-N-formyl derivative 76 shows slightly better activity as compared to 2’-N-(2-aminoacetyl) 
derivative 75 and 40-fold higher activity than the 2-N-acetyl derivative 77. This is presumably due 
to steric reasons as the formyl group is sterically less cumbersome than the acetyl and 2-
aminoacetyl groups. The 2’-N-(2-aminoacetyl) 75 and 2’-N-acetyl 77 modifications have similar 
steric bulk but the 2’-N-(2-aminoacetyl) derivative 75 is 30-fold more active than the 2’-N-acetyl 
compound 77. This is due to the presence of the additional basic amine in 2’-N-(2-aminoacetyl) 
group, which can be protonated under physiological conditions and so contribute electrostatically 
to binding. 
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Table 6. Antiribosomal activities (IC50, µM) and selectivities of 2’-modified neomycin B 
derivatives (selectivities are obtained by dividing the eukaryotic values by the bacterial values). 
  
Compound 
In vitro M. smegmatis (IC50, µM) 
Bacterial 
Mit13 
(Selectivity) 
A1555G 
(Selectivity) 
Cyt14 
(Selectivity) 
Neo B 9 0.04 4.3 (108) 0.4 (10) 35 (875) 
59 0.01 4.7 (470) 1.1 (110) 37 (3700) 
61 0.01 11 (1100) 1.6 (160) 43 (4300) 
64 0.03 22 (733) 0.9 (30) 85 (2833) 
70 0.03 36 (1200) 2.7 (90) 108 (3600) 
75 0.16 11 (69) 1.2 (75) 25 (156) 
76 0.12 54 (450) 13 (108) 127 (1058) 
77 5.3 93 (17) 28 (5) 147 (28) 
 
          To facilitate comparison of the influence of each modification on ribosomal selectivity, the 
raw selectivity data presented in Table 6 have been converted into selectivity quotients (SelQ) with 
respect to the parent neomycin as presented in Table 7. It is evident that the 2’-N-alkyl modification 
of neomycin B increases selectivity for the bacterial over mutant mitochondrial ribosome to a 
greater extent than over the wild type mitochondrial ribosome (59 and 61, entries 1 and 2, Table 
7). Probably, the looser wild type mitochondrial A-site better accommodates the 2’-N-alkyl groups 
than the tighter and more rigid mutant mitochondrial A-site. The 2’-deamino and 2’-deamino-2’-
hydroxy derivatives show only a modest increase in selectivity pattern (64 and 70, entries 3 and 4, 
Table 7). Compounds 64 and 70 also show a modest increase in selectivity for the bacterial over 
the cytosolic ribosome as is the case for the 2’-N-alkylated derivatives 59 and 61. The 2’-N-(2-
aminoacetyl) derivative also showed greater increase in selectivity for the bacterial over mutant 
mitochondrial ribosome than over the wild type mitochondrial ribosome (75, Entry 5, Table 7). 
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This can also be explained in terms of the looser wild type mitochondrial A-site better 
accommodating the 2’-N-(2-aminoacetyl) group as compared to the rigid mutant mitochondrial A-
site. The 2’-N-formyl and 2’-N-acetyl derivatives (76 and 77, entries 6 and 7, Table 7) showed a 
similar pattern of ribosomal selectivity as the 2’-N-(2-aminoacetyl) derivative 75. It is interesting 
to note that the 2’-N-(2-aminoacetyl) 75 and 2’-N-acetyl 77 showed a significant decrease in 
selectivity for the bacterial over cytosolic ribosome due to a comparatively smaller change in 
affinity for the cytosolic ribosomes. The 2’-N-formyl derivative 76 showed a minor increase in 
selectivity for the bacterial over cytosolic ribosome.    
          All compounds were screened for their antibacterial activities against methicillin-resistant 
clinical isolates of the Gram-positive bacterium Staphylococcus aureus (MRSA) and against 
clinical isolates of the Gram-negative bacterium Escherichia coli and Pseudomonas aeruginosa, 
obtained from the Diagnostic Division of the Institute of Medical Microbiology, University of 
Zurich (Table 8). The 2’-N-alkylated 59 and 61, 2-deamino 64 and 2-deamino-2’-hydroxy 70 
derivatives showed similar antibacterial profiles as the parent neomycin B against MRSA and E. 
coli. On the other hand, the 2’-N-formyl derivative 76 showed better antibacterial activity in some 
of the MRSA and E. coli strains as compared to the 2’-N-(2-aminoacetyl) and 2’-N-acetyl 
derivatives 75 and 77, consistent with the pattern of antiribosomal activities. No significant activity 
was observed against the clinical isolates of the Gram-negative bacterium Pseudomonas 
aeruginosa.   
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Table 7. Change in antiribosomal selectivity (selectivity quotient = selectivity of 
derivative/selectivity of parent) of 2’-modified derivatives with respect to parent neomycin B. 
Entry Compounds 
Selectivity Quotient (SelQ) 
Mit13 A1555G Cyt14 
1 59 4.35 11 4.23 
2 61 10.18 16 4.9 
3 64 6.79 3 3.24 
4 70 11.11 9 4.11 
5 75 0.64 7.5 0.18 
6 76 4.17 10.8 1.21 
7 77 0.16 0.5 0.03 
 
 
Table 8. Antibacterial activities of 2’-modified neomycin B derivatives (MIC, µg/mL). 
 Compound 
MRSA E. coli P. aeruginosa 
AG038 AG039 AG042 AG044 AG001 AG055 AG003 AG031 AG032 AG033 
Neo B 9 0.25 128 128 1 1 1-2 1 8 8 64 
59 0.5 >32 >32 0.54 1 1 1 64 64 >64 
61 0.5 >32 >32 1 1-2 1 1 >64 >64 >64 
64 1 32 32-64 2 2 2 1-2 32 64 >64 
70 2 >128 >128 2 2-4 2-4 2-4 128 128 >128 
75 4 >32 >32 - 16 16 32 >32 >32 >32 
76 2-4 >32 >32 - 4-8 2 4-8 >32 >32 >32 
77 >32 >32 >32 - >32 >32 >32 >32 >32 >32 
 
          All Compounds were also screened against wild type and recombinant Escherichia coli 
strains carrying defined resistance determinants39 in order to determine their susceptibility to 
common AMEs (Table 9). The 2’-N-methyl and 2’-N-ethyl derivatives 59 and 61 completely evade 
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modification by the AAC-(2’) resistance mechanism and show strong antibacterial activity against 
the resistant strain, which is consistent with the earlier reports in the sisomicin series that 2’-N-
alkylated derivatives retain their activity against AAC-(2’) class of AMEs.183-188 The 2’-deamino 
64 and 2’-deamino-2’-hydroxy 70 derivatives, both lacking the 2’-amino substituent retain their 
antibacterial activity and are not susceptible to modification by AAC-(2’) class of AMEs. The 2’-
N-(2-aminoacetyl) derivative 75 does not show good antibacterial activity in general for either 
wild type or resistance strains, similar to 2’-N-acetyl neomycin B 77, which is a completely 
inactive compound that validates the concept of inactivation by the AAC-(2’) class of AMEs. 
116,166,178-182 The 2’-N-formyl derivative 76 retains antibacterial activity against resistant strains 
bearing AAC-(2’). None of the 2’-modifications were helpful in providing protection from 
modification by AAC-(6’), ANT-(4’, 4’’), and APH-(3’, 5’’) classes of AMEs. None of the 2’-
modifications of neomycin B are not affected by the 16s-rRNA methyl transferase as demonstrated 
by the E. coli strain carrying ArmA mechanism for which they show similar antibacterial activity 
as for wild type strain.  
Table 9. Antibacterial data of 2’-modified neomycin B derivatives against wild type and 
engineered strains of E. coli carrying specific resistance determinants (MIC, µg/ml). 
Strain: AG006 AG106 pH434 AG009 AG036 AG037 pGB2 
Resistance 
Mechanism: 
Wild 
Type 
AAC 
(2’)-Ia 
AAC (2’)-
Ib 
AAC (6’) 
ANT 
(4’, 4”) 
APH 
(3’, 5”) 
ArmA 
Neo B 9 0.5-1 8 >64 4 4-8 >64 0.25-0.5 
59 0.5 0.5 4 16-32 16 >64 1 
61 0.5-1 1 4 32 16 >64 1 
64 1 1 8 >64 ≥64 >64 1 
70 0.5-1 1 4 >64 64-128 >64 1 
75 8-16 16-32 - >256 32 >256 16 
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76 2 2 8-16 >64 64 >64 8 
77 128 128 - >512 256 >512 128-156 
 
2.2.4. Conclusion: 
          The 2’-N-alkylation, 2’-deamino, and 2’-deamino-2’-hydroxy modifications of neomycin B 
do not cause any significant reduction in antibacterial activity and lead to moderately enhanced 
selectivity for the bacterial ribosome over mitochondrial and mutant mitochondrial ribosomes. 
These modifications also effectively suppress the action of the AAC (2’) resistance determinants. 
The 2’-amido modifications are less advantageous as they generally result in both reduced 
antibacterial activities and selectivities. 
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CHAPTER 3. MODIFICATIONS TO PAROMOMYCIN. 
3.1. N2’-modifications to paromomycin. 
3.1.1. Introduction: 
          Paromomycin belongs to the 4,5-series AGAs and is a broad-spectrum antibiotic. It is also 
active against some protozoa and cestodes.198 It was first discovered from Streptomyces 
krestomuceticus in 1950’s and came into medical use in 1960’s.198,199 It has been used to treat 
intestinal infections such as cryptosporidiosis, amoebiasis, and other diseases like leishmaniasis. 
It is also included on the WHO's list of essential medicines. The medical use of paromomycin was 
reduced due to the continued emergence of resistant bacteria and the inherent adverse effects, 
mainly ototoxicity. The only difference between neomycin B and paromomycin is the 6’-
substituent, an amino group in neomycin B and a hydroxy group in paromomycin. This change of 
a 6’-amino to a 6’-hydroxy groups brings some advantageous effects to paromomycin over 
neomycin B as it does not cause a significant reduction in antibacterial activity but renders 
paromomycin significantly less ototoxic.55,56,70,74,75,138 Paromomycin is also not affected by the 
AAC-(6’) resistance mechanism as it lacks the 6’-amino substituent.110,139-148 However, the 
disadvantage is that paromomycin shows stronger affinity towards the cytosolic A-site than 
neomycin B. This is because the 6’-hydroxyl group of paromomycin can accept the hydrogen 
bonds from the 1408G residue in cytosolic ribosome in contrast to the repulsive interaction 
between protonated 6’-amino group of neomycin B and G1408.166,167 The same 6’-OH-G1408 
interaction is responsible for the paromomycin’s antiprotozoal activity as the decoding A-site of 
protozoa are related in structure to the human cytosolic A-site.173,200 In recent years, several reports 
have been published for development of improved paromomycin derivatives. Most recently, 
certain 4’-O-alkyl, 4’,6’-O-alkylidene, and 4’-O-glycosyl derivatives have been shown to have 
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comparable antibacterial activities to the parent and to cause little to no ototoxicity.167,174,201 
Extrapolating from the studies in the neomycin series, and the earlier report on the antibacterial 
activity of 2’-N-ethyl paromomycin,189 the 2’-position in paromomycin was targeted. Thus, several 
2’-N-alkylated derivatives and 2’-deamino-2’-hydroxy variant were synthesized, and screened for 
their antiribosomal and antibacterial activities.   
3.1.2. Synthesis: 
          The 2’-N-methyl, 2’-N-ethyl, and 2’-N-propyl paromomycin derivatives 79, 81, and 83 were 
readily prepared from tetra-N-acetyl paromomycin intermediate 65. Following the same one pot 
double reductive amination conditions applied for the synthesis of 2’-N-methyl neomycin 59, the 
tetra-N-acetyl paromomycin intermediate 65 was converted to corresponding 2’-N-benzyl-N-
methyl intermediate 78 with an overall 42% yield for the two steps. A two-step deprotection 
procedure, involving hydrogenolysis to the cleave benzyl group and saponification of acetamido 
groups in hot aqueous sodium hydroxide, and then purification on Sephadex and lyophilization 
from aqueous acetic acid afforded the 2’-N-methyl paromomycin 79 as per-acetate salt in 27% 
yield (Scheme 13). Reductive amination of 65 with acetaldehyde gave the 2’-N-ethyl intermediate 
80 in 64% yield, which upon saponification in hot aqueous sodium hydroxide, and then 
purification on Sephadex and lyophilization from aqueous acetic acid afforded the 2’-N-ethyl 
paromomycin 81 as peracetate salt in 43% yield (Scheme 13). Similarly, reductive amination of 
65 with propionaldehyde gave the 2’-N-propyl intermediate 82 in 70% yield, which upon 
saponification, and then purification on Sephadex and lyophilization from aqueous acetic acid gave 
the 2’-N-ethyl paromomycin 83 as peracetate salt in 49% yield (Scheme 13). The exact position of 
the alkyl groups was confirmed by heteronuclear multiple bond coherence (HMBC) correlations 
between the methyl and the 2’-position in the case of 2’-N-methyl paromomycin 79, and between 
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the N-methylene and the 2’-position in the case of both 2’-N-ethyl paromomycin 81 and 2’-N-
propyl paromomycin 83. 
 
Scheme 13. Synthesis of 2’-N-alkyl paromomycin derivatives 79, 81 and 83. 
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          2’-Deoxy-2’-hydroxy paromomycin 86 was synthesized using the same N,N-
dimethylformamide mediated α-selective glycosylation method applied for the synthesis of 2’-
deoxy-2’-hydroxy neomycin B 70 (Scheme 10). The glycosylation reaction between thioglycoside 
donor 84202,203 and glycosyl acceptor 67 gave the α-glycosylated product 85 in 46% yield (Scheme 
14).197 Finally, a two-step deprotection procedure, involving hydrogenolysis to deprotect the 
benzyl ethers, followed by saponification of the acetyl groups in hot aqueous sodium hydroxide, 
and then purification on Sephadex and lyophilization from aqueous acetic acid afforded the 2’-
deamino-2’-hydroxy  paromomycin 86 as the peracetate salt in 42% yield (Scheme 14). 
 
Scheme 14. Synthesis of 2’-deamino-2’-hydroxy paromomycin 86. 
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3.1.3. Biological evaluations: 
          The 2’-modified paromomycin derivatives 79, 81, 83, and 86 were screened for their 
antiribosomal activities in cell free translational assays employing wild type bacterial ribosomes 
and recombinant hybrid bacterial ribosomes (Table 10). Their antiribosomal activities were also 
compared with those of the parent paromomycin 21. The activity of paromomycin against the 
bacterial ribosome is not affected by 2’-N-alkylation (79, 81 and 83, Table 10), which is consistent 
with the earlier reports on antibacterial activity of 2’-N-ethyl paromomycin189 2’-N-alkylated 
derivatives of sisomicin,183-188 and the results presented in section 2.2.3. on the 2’-N-alkylated 
neomycin B derivatives (59 and 61, Table 6). The 2’-deamino-2’-hydroxy paromomycin 86 on the 
other hand showed a 30-fold reduction in antiribosomal activity against the bacterial ribosome as 
compared to parent paromomycin (86, Table 10). This observation contrasts with the analogous 
replacement of the 2’-amino with a 2’-hydroxy group in neomycin B, which does not cause any 
change in antiribosomal activity towards bacterial A-site (70, Table 6). This difference between 
the paromomycin and neomycin series is attributed to the stronger A1408-6’NH3+ hydrogen bond 
in neomycin that compensates for the loss of activity due to the replacement of 2’-amino group 
with a 2-hydroxy group, whereas the weaker A1408-6’OH hydrogen bond in the paromomycin-
ribosome complex is less capable of doing this.67  
          To compare the effect of each modification on ribosomal selectivity, the data presented in 
Table 10 have been converted into selectivity quotients (SelQ) with respect to the parent 
paromomycin as presented in Table 11. Similar to the 2’-N-alkylated derivatives of neomycin B, 
the 2’-N-alkyl modification of paromomycin increases selectivity for the bacterial over mutant 
mitochondrial ribosome to a greater extent than over the wild type mitochondrial ribosome (79, 
81, and 83, Entries 1, 2 and 3, Table 7). It is interesting to note that the selectivity for bacterial 
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over the cytosolic ribosome constantly decreases as the size of the 2’-alkyl group increases. The 
2’-deamino-2’-hydroxy modification is not helpful for increasing the selectivity of paromomycin 
(86, Entry 4, Table 11), whereas the analogous modification in neomycin B does increase the 
selectivity for the bacterial over mitochondrial and cytosolic ribosomes. 
Table 10. Antiribosomal activities (IC50, µg/mL) and selectivities of 2’-modified paromomycin 
derivatives (selectivities are obtained by dividing the eukaryotic values by the bacterial values). 
  
Compound 
In vitro M. smegmatis (IC50, µg/mL) 
Bacterial 
Mit13 
(Selectivity) 
A1555G 
(Selectivity) 
Cyt14 
(Selectivity) 
Paromomycin 21 0.04 47 (1175)  5 (125) 12 (300) 
79 0.03 95 (3167) 34 (1133) 38 (1267) 
81 0.03 141 (4700) 54 (1800) 27 (900) 
83 0.05 153 (3060) 38 (760) 21 (420) 
86 1.36 408 (300) 193 (142) 275 (202) 
 
 
Table 11. Change in antiribosomal selectivity (selectivity quotient = selectivity of 
derivative/selectivity of parent) of 2’-modified derivatives with respect to parent paromomycin.  
Entry Compounds 
Selectivity Quotient (SelQ) 
Mit13 A1555G Cyt14 
1 79 2.7 9.06 4.22 
2 81 4 14.4 3 
3 83 2.6 6.08 1.4 
4 86 0.25 1.14 0.67 
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          All compounds were also screened for their antibacterial activities. The MIC data against 
the clinical isolates of the Gram-positive bacterium methicillin-resistant Staphylococcus aureus 
(MRSA) and Gram-negative bacterium Escherichia coli and Pseudomonas aeruginosa are 
presented in Table 12. The 2’-N-alkylated derivatives 79, 81 and 83 showed comparable 
antibacterial activity to the parent paromomycin against MRSA and E. coli. The 2’-deoxy-2’-
hydroxy derivative 86 is significantly less active as compared to paromomycin and 2’-N-alkylated 
derivatives, which is also reflected in the antiribosomal data (Table 12). Most of the compounds 
were found to be inactive against clinical isolates of the Gram-negative bacterium Pseudomonas 
aeruginosa. 
Table 12. Antibacterial activities of 2’-modified paromomycin derivatives (MIC, µg/mL). 
 Compound 
MRSA E. coli P. aeruginosa 
AG038 AG039 AG042 AG044 AG001 AG055 AG003 AG031 AG032 AG033 
Paromo. 21 4 >256 >256 4-8 16-32 8 8-16 >128 >128 >128 
79 8 >128 >128 4 16 16 16 >128 >128 >128 
81 8 >128 >128 4-8 16 16 16 >128 >128 >128 
83 8-16 >128 >128 4 16 16 16 >128 >128 >128 
86 64-128 >128 >128 64-128 >128 >128 >128 >128 >128 >128 
 
          These 2’-modified paromomycin derivatives were screened against wild type and 
recombinant Escherichia coli strains carrying defined resistance determinants in order to 
investigate their susceptibility to AAC (2’) resistance mechanism (Table 13). The 2’-N-alkylated 
derivatives 79, 81 and 83 retain their antibacterial activity and generally are not susceptible to 
modification by AAC (2’) class of AMEs. The 2’-alkyl paromomycin derivatives are active against 
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E. coli strain carrying the ArmA gene and thus are not affected by the 16s-rRNA methyl transferase 
mechanism of resistance. The 2’-deoxy-2’-hydroxy derivative 86 does not show good antibacterial 
activity in general for wild type and resistance strain. 
Table 13. Antibacterial data of 2’-modified paromomycin derivatives against wild type and 
engineered strains of E. coli carrying specific resistance determinants (MIC, µg/ml). 
Strain: AG006 AG106 pH434 pGB2 
Resistance 
Mechanism: 
Wild Type AAC (2’)-Ia AAC (2’)-Ib ArmA 
Paromomycin 21 1-2 >64 >64 2 
79 2-4 4 8 4-8 
81 2 - 4 4-8 
83 2 - 4 4-8 
86 32 - - - 
 
3.1.4. Conclusion: 
          The 2’-N-alkylated paromomycin derivatives show comparable antibacterial activity to the 
parent paromomycin with moderately enhanced selectivity for the bacterial ribosome over 
mitochondrial and mutant mitochondrial ribosomes. These derivatives are not modified by the 
action of AAC-(2’) mechanism of resistance and possess good antibacterial against the AAC-(2’) 
resistant strains. The 2’-deoxy-2’-hydroxy modification of paromomycin shows significantly 
reduced antibacterial activity and selectivity. 
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3.2. 5’’-modifications to paromomycin. 
3.2.1. Introduction: 
          After modifying of the 2’-position in paromomycin, the 5’-position was targeted. In the 
decoding A-site the 5’’-hydroxy group present in paromomycin, neomycin B and other members 
of 4,5-series of AGAs makes a hydrogen bond with N7 of the 1491G residue. It also makes an 
intramolecular hydrogen bond with the protonated 2’-amino group that is hypothesized to enforce 
correct conformation for binding with the bacterial A-site (Figures 11 and 20),135,177 albeit the data 
reported in the sections 2.2.3 and 3.1.3 in neomycin series do not support the need for this 
intramolecular hydrogen bond. Crucially, the 5’’-hydroxy group is susceptible to modification by 
APH-(3’, 5’’) class of AMEs. These APH-(3’, 5’’) enzymes are capable of modifying both the 3’ 
and/or 5’’-hydroxy groups by attaching a negatively charged phosphate group and hence 
decreasing the antibacterial activity of AGAs.27,120,121 These enzymes cause a significant amount 
of resistance to a broad range of AGAs and thus represent a serious threat. Several attempts have 
been made in the past to modify the 5’’-position in paromomycin and other 4,5-series AGAs to 
circumvent the action of these enzymes. Thus, the 5’’-deoxy 87, 5’’-O-alkyl 88, and 5’’-fluoro 89 
modifications of paromomycin are known to cause a significant loss of antibacterial activity 
(Figure 23).204 Similarly, 5’’-deoxy lividomycin B 91 and 5’’-fluoro lividomycin B 92 are eight 
fold less active than the parent lividomycin B 90.205 The 5’’-carboxylic acid 93135 and 5’’-
carboxamide 94206 derivatives of paromomycin are inactive compounds (Figure 23). Cyclic 2’,5’’-
anhydro derivatives of neomycin B and paromomycin having structures like 95 and 96 are also 
significantly less active than their parents (Figure 23).135,207 In contrast, 5’’-deoxy-5’’-amino 
derivatives of paromomycin and  neomycin B (97 and 98) retain the antibacterial activity of their 
parents.208 The 5’’-deoxy-5’’-amino butirosin A 100 is more potent compound than the parent 
70 
 
 
 
butironin A 99 (Figure 23).209 However, these 5’’-deoxy-5’’-amino modifications shows stronger 
affinity towards cytosolic ribosome and cause toxicity for cytosolic ribosomes, which forms the 
basis of the use of such compounds for the read through treatment of diseases like cystic fibrosis 
and the treatment of Leishmaniosis caused by protozoal parasites.171-173 Some 5’’-O-glycosylated 
neomycin B derivatives, especially the β-D-ribofuranoside 101 (Figure 23) show, comparable 
activity to the parent neomycin B and are poor substrate for APH-(3’)-IIIa.141 Simple mono- and 
di-peptide derivatives like 102 of 5’’-deoxy-5’’-amino neomycin B 98 retain good antibacterial 
activity (Figure 23).142 Presumably, these 5’’-amido derivatives have additional amino group and 
leading to the extra binding through electrostatic attraction. There are recent reports on neomycin 
B dimers like 103 and neomycin B-Anthroquinone conjugates like 104, linked at 5’’-position 
through urea and thiourea linkages and possess good antibacterial activity (Figure 24).146,210 Again, 
these compounds have additional polar functionalities and help for the binding. Overall, the 
literature precedence indicates that the presence of a hydrogen bond donor substituent at 5’’-
position is critical for binding. Based on these observations, the 5’’-hydroxy group of 
paromomycin was modified to simple amide and urea type functionalities with the minimum 
unfunctionalized group tolerated, and their antiribosomal and antibacterial activities were 
screened.   
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Figure 23. Some of the 5’’-modified derivatives of paromomycin, lividomycin B, neomycin B a 
neomycin B, and butirosin A. 
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Figure 24. Neomycin B dimer and neomycin B-anthraquinone conjugated linked at 5’’-position. 
3.2.2. Synthesis: 
          The 5’’-deoxy-5’’-formamido, 5’’-deoxy-5’’-acetamido, and 5’’-deoxy-5’’-ureido 
paromomycin derivatives 110, 112, and 114 were prepared from intermediate 105, which was 
readily obtained from paromomycin 21 by following the literature protocol.211 Selective 
sulfonylation of 105 with 2,4,6-triisopropylbenzenesulfonyl chloride gave 106 in 58% yield, which 
upon displacement with azide afforded 73% yield of 107. Staudinger reaction to reduce the azide 
with trimethylphosphine in hot aqueous tetrahydrofuran afforded the 5’’-deoxy-5’’-amino 
intermediate 108211 in 85% yield (Scheme 15). Treatment of 108 with formic acetic anhydride191 
in dichloromethane gave the corresponding 5’’-deoxy-5’’-formamido intermediate 109 in 69% 
yield. Global deprotection by hydrogenolysis, followed by purification on Sephadex and 
lyophilization from aqueous acetic acid gave the 5’’-deoxy-5’’-formamido paromomycin 110 as 
peracetate salt in 30% yield (Scheme 16). For the synthesis of the 5’’-deoxy-5’’-acetamido analog 
112, treatment of the 5’’-deoxy-5’’-amino intermediate 108 with acetic anhydride in 
dichloromethane gave the corresponding 5’’-deoxy-5’’-acetamido intermediate along with the 
complete cleavage of the 4’,6’-O-benzylidene acetal. Treatment with acetic anhydride in pyridine 
then gave the fully protected intermediate 111 with an overall 79% yield for the two steps. Finally, 
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saponification of acetates by sodium methoxide in methanol, followed by hydrogenolysis to 
deprotect the benzyl carbamates, and then purification on sephadex and lyophilization from 
aqueous acetic acid gave 5’’-deoxy-5’’-acetamido paromomycin 112 as peracetate salt in 49% 
yield (Scheme 16). Treatment of the intermediate amine 108 with benzyl isocyanide in 
dichloromethane gave the corresponding benzyl protected 5’’-deoxy-5’’-ureido derivative 113 in 
64% yield. Global deprotection by hydrogenolysis, followed by purification on Sephadex and 
lyophilization from aqueous acetic acid gave 5’’-deoxy-5’’-ureido paromomycin 114 as the 
peracetate salt in 42% yield (Scheme 16). 
 
 
Scheme 15. Synthesis of 5’’-deoxy-5’’-amino intermediate 108. 
          The rotation around the carbon-nitrogen bond in amides is restricted due to its partial double 
bond character, and because of this restricted rotation amides can exist either in the cis-
configuration (E-configuration) or in the trans-configuration (Z-configuration). However, the 
trans-configurations predominates over the cis-configuration and this can be explained on the basis 
of steric interactions and the cis-configuration is destabilized by repulsion between R1 and R2 
group (Figure 25).212,213 This preference for the trans-configuration has been shown by dipole 
moment and dielectric constant measurements and by ultraviolet, infrared, and Raman 
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spectroscopy.214-222 Similarly, the small ring lactams mostly exist in the cis-configurations, 
whereas in the large ring lactams the trans-configuration predominates over cis-
configurations.223,224 
 
 
Scheme 16. Synthesis of 5’’-modified paromomycin derivatives 110, 112, and 114. 
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          It was interesting to note that the 5’’-deoxy-5’’-formamido paromomycin 110 exhibited both 
cis- and trans-configurations.  The relative integration of formyl hydrogen peak in the 1H-NMR 
spectrum of 5’’-deoxy-5’’-formamido paromomycin 110 clearly indicated the presence of cis-
conformer approximately in 13%. Whereas, the 5’’-deoxy-5’’-acetamido paromomycin 112 and 
5’’-deoxy-5’’-ureido paromomycin 114 existed only in trans-configuration and did not show any 
indication of cis-configuration. Similar observations have been made in the literature and 
formamides have been reported to show both cis- and trans-conformers.212,213 The percentage of 
cis- and trans-conformers reported for N-methylformamide, N-ethylformamide, N-
isopropylformamide, N-tert-butylformamide and the corresponding acetamides,212 and their 
comparison with the 5’’-modified paromomycin derivatives are presented in Table 14. It is clear 
that none of the acetamides show the cis-conformer and this most probably due to the increased 
steric hindrance between the methyl group and the substituent present on the nitrogen atom. On 
the other hand, formyl hydrogen in formamides is sterically less cumbersome and consequently 
show significant amount of cis-conformer (Figure 25). 
Table 14. Percentage of cis- and trans-conformers in various N-monosubstituted amides. 
S.N. Amide % of Cis (E) % of Trans (Z) 
1. N-Methylformamide 8 92 
2. N-Methylacetamide 0 100 
3. N-Ethylformamide 12 88 
4. N-Ethylacetamide 0 100 
5. N-Isopropylformamide 12 88 
6. N-Isopropylacetamide 0 100 
7. N-tert-Butylformamide 18 82 
8. N-tert-Butylacetamide 0 100 
9. 5’’-Deoxy-5’’-formamido paromomycin 110 13 87 
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10. 5’’-Deoxy-5’’-acetamido paromomycin 112 0 100 
11. 5’’-Deoxy-5’’-ureido paromomycin 114 0 100 
 
 
 
 
Figure 25. Cis (E)- and trans (Z)-configurations in N-monosubstituted amides. 
3.2.3. Biological evaluations: 
          The 5’’-modified paromomycin derivatives 110, 112, and 114 were screened for their 
antiribosomal activities in cell free translational assays employing wild type bacterial ribosomes 
and recombinant hybrid bacterial ribosomes (Table 14). Their antiribosomal activities were also 
compared with those of the parent paromomycin 21. The 5’’-formamido modification did not 
cause any reduction in the activity of paromomycin (110, Table 14). Presumably, the 5’’-amidic 
NH can also serve as a hydrogen bond donor for the N7 of the G1491 residue. Consequently, the 
change from a 5’’-hydroxy to a 5’’-formamide does not have any significant effect on the binding 
affinity. Similarly, the 5’’-ureido derivative 114 which also has a 5’’-amidic NH group, possesses 
the comparable activity to the parent paromomycin. On the other hand, the 5’’-acetamido 
derivative 112 showed an eight fold reduction in activity. A similar trend in loss of activity was 
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observed earlier in neomycin B series when going from 2’-N-formyl neomycin B to 2’-N-acetyl 
neomycin B (76 and 77, Table 6). 
Table 15. Antiribosomal activities (IC50, µg/mL) and selectivities of 5’’-modified paromomycin 
derivatives (selectivities are obtained by dividing the eukaryotic values by the bacterial values). 
  
Compound 
In vitro M. smegmatis (IC50, µg/mL) 
Bacterial 
Mit13 
(Selectivity) 
A1555G 
(Selectivity) 
Cyt14 
(Selectivity) 
Paromomycin 21 0.04 47 (1175)  5 (125) 12 (300) 
110 0.04 144 (3600) 30 (750) 90 (2250) 
112 0.3 195 (650) 13 (43) 39 (130) 
114 0.03 70 (2333) 28 (933) 89 (2967) 
 
          The antiribosomal activity data presented in Table 14 have been converted into selectivity 
quotients (SelQ) to compare the effect of each modification on ribosomal selectivity with respect 
to the parent paromomycin (Table 15). The 5’’-formamido 110 and 5’’-ureido 114 modifications 
of paromomycin showed a slight increase in selectivity for the bacterial over mitochondrial and 
mutant mitochondrial ribosome (Entries 1 and 3, Table 15). These two modifications also caused 
a moderate increase in selectivity for the bacterial over cytosolic ribosome (Entries 1 and 3, Table 
15). The 5’’-acetamido 112 derivative showed both reduced activity and selectivity (Entry 2, Table 
15).  
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Table 16. Change in antiribosomal selectivity (selectivity quotient = selectivity of 
derivative/selectivity of parent) of 5’’-modified derivatives with respect to parent paromomycin.  
Entry Compounds 
Selectivity Quotient (SelQ) 
Mit13 A1555G Cyt14 
1 110 3.06 6 7.5 
2 112 0.55 0.34 0.43 
3 114 1.98 7.46 7.42 
 
          The newly synthesized 5’’-derivatives 110, 112, and 114 were screened against the clinical 
isolates of the Gram-positive bacterium methicillin-resistant Staphylococcus aureus (MRSA) and 
Gram-negative bacterium Escherichia coli and Pseudomonas aeruginosa in order to establish their 
antibacterial activity and the MIC data is presented in Table 16. The 5’’-formamido 110 and 5’’-
ureido 114 modifications to paromomycin do not bring any significant change in antibacterial 
activities and have the similar antibacterial profile. The 5’’-acetamido 112 modification generally 
caused a marked decrease in antibacterial activity against the clinical isolates of MRSA and E. 
coli. All the compounds including parent paromomycin are inactive against clinical isolates of P. 
aeruginosa. 
          The 5’’-modified paromomycin derivatives 110, 112, and 114 were also screened against 
wild type and recombinant Escherichia coli strains carrying various APH-(3’) resistance enzyme 
in order to validate the usefulness of these 5’’- modifications in circumventing the APH-(3’) 
mechanism of resistance (Table 17). As indicated by the data presented in Table 17, none of the 
compounds show a good antibacterial activity against the resistant strain carrying the APH-(3’) 
resistance mechanism. This is because APH-(3’) enzymes can modify both the 3’ and 5’’-hydroxy 
group by attaching a negatively charged phosphate group and hence decreasing the antibacterial 
activity of AGAs. 27,120,121 Although in the present compounds the 5’’-position is protected by 
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amide modifications, all still have a 3’-hydroxy substituent that is susceptible for modification by 
APH-(3’) class of AMEs.   
Table 17. Antibacterial activities of 5’’-modified paromomycin derivatives (MIC, µg/mL). 
 Compound 
MRSA E. coli P. aeruginosa 
AG038 AG039 AG042 AG044 AG001 AG055 AG003 AG031 AG032 AG033 
Paromo. 21 4 >256 >256 4-8 16-32 8 8-16 >128 >128 >128 
110 4 >128 >128 2-4 4 4 4 ≥128 128 >128 
112 16-32 >128 >128 16 64 32 32-64 >128 >128 >128 
114 4-8 >128 >128 4 16 16 16 >128 >128 >128 
 
 
Table 18. Antibacterial data of 5’’-modified paromomycin derivatives against wild type and 
engineered strains of E. coli carrying specific resistance determinants (MIC, µg/ml). 
Strain: pH430 pH421 pH422 AG037 pH423 
Resistance 
Mechanism: 
Wild Type APH (3’)-I APH (3’)-II APH (3’)-III APH (3’)-VI 
Paromomycin 21 1-2 >128 >128 >128 >128 
110 1-2 >64 >64 128 >64 
112 8-16 >64 >64 - >64 
114 2-4 >64 >64 - >64 
 
3.2.4. Conclusion: 
          The 5’’-formamido and 5’’-ureido modifications does not cause any reduction in 
antibacterial activity of paromomycin and slightly increase the selectivity for the bacterial 
ribosome over mitochondrial, mutant mitochondrial and cytosolic ribosomes. The 5’’-acetamido 
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derivative shows reduced antibacterial activity and selectivity. In combination with modifications 
at the 3’-position to subvert the effect of the AME at that position, the 5’’-formamido and ureido 
modifications should provide compounds that are active in the presence of all classes of APH-
(3’,5’’) enzymes.  Such compounds are currently under investigation in the Crich laboratory. 
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CHAPTER 4. SYNTHESIS OF 3-N-ALKYL PYRIMIDIN-2,4-DIONE 
DERIVATIVES. 225 
5.1. Introduction: 
          Nitrogen-based heterocycles are very commonly present in biologically active compounds 
and approved pharmaceuticals. The pyridines and pyrimidines are the most widespread nitrogen 
based heterocycles in approved drugs.226-228 The pyrimidin-2,4-dione derivatives are a very 
important class of compounds and are widespread in nature. They are one of the basic constituents 
of nucleic acids. The pyrimidin-2,4-dione ring structure is also found in various biologically active 
natural products.229 The medicinal properties of the pyrimidine-2,4-dione derivatives are well 
recognized and include antibacterial, antiviral, antineoplastic, antimalarial and antiparasitic 
activities.229 Therefore the development of new synthetic methods for substituted pyrimidine-
based heterocycles is of inherent importance in drug discovery process. In the course of ongoing 
studies in our laboratory there was an occasion to react 2,3-diphenyl-N-trifloxymaleimide 115 with 
3,4-dimethoxyphenylethylamine 116 in N,N-dimethylformamide in the presence of potassium 
carbonate at room temperature, with the goal and expectation of obtaining the maleimide-protected 
hydrazine derivative 117. However, the unexpected major product was the pyrimidine-2,4-dione 
derivative 118, which was formed together with the minor product amido urea 119 (Scheme 17). 
In this way, a new method was discovered for the synthesis of 3-N-alkyl pyrimidin-2,4-dione 
derivatives from readily available maleic anhydride via reaction of the derived N-
trifloxymaleimides with amines. This novel two step entry into 3-N-alkyl pyrimidin-2,4-dione 
derivatives from N-hydroxymaleimindes, themselves readily accessible the corresponding 
maleimides and hydroxylamine and primary amines is described in this chapter (Scheme 18).  
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Scheme 17. Unexpected formation of the 3-N-alkyl pyrimidin-2,4-dione derivative 118. 
 
 
 
Scheme 18. Overall synthesis of the 3-N-alkyl pyrimidin-2,4-dione derivatives from maleic 
anhydrides. 
5.2. Synthesis: 
          Commercially available 2,3-dimethyl maleic anhydride 120 and 2,3-diphenyl maleic 
anhydride 121 were converted to the corresponding N-hydroxy maleimides 122 and 123 by 
refluxing with hydroxylamine hydrochloride and sodium acetate in a mixture of water and ethanol 
in 74% and 80% yields respectively (Scheme 19).230 The 2-methyl-3-phenyl maleic anhydride 126 
was synthesized by refluxing sodium pyruvate 124 and phenyl acetic acid 125 in acetic anhydride 
in 53% yield.231 Treatment of 2-methyl-3-phenyl maleic anhydride 126 with hydroxyl amine 
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hydrochloride and sodium acetate in aqueous ethanol at room temperature afforded 2-methyl-3-
phenyl-N-hdroxy maleimide 127 in 90% yield (Scheme 20). Treatment of commercial 
cyclohexene-1,2-dicarboxylic anhydride 128 with hydroxylamine hydrochloride and sodium 
acetate in hot mixture of water and ethanol gave the intermediate hydroxamic acid, which upon 
refluxing in acetic anhydride cyclized to the N-acetoxy imide 129 with an overall 25% yield for 
the two steps.230,232 The acetyl group was deprotected using benzylamine in chloroform232 to give 
the N-hydroxyimide derivative 130233 in 62% yield (Scheme 21). All the N-hydroxymaleimides 
122, 123, 127, and 130 were converted to the corresponding N-trifloxymaleimides 131, 115, 132, 
and 133 by treatment with triflic anhydride in the presence of pyridine in dichloromethane 
(Scheme 22).   
 
Scheme 19. Synthesis of N-hydroxy maleimide derivatives 122 and 123. 
 
 
Scheme 20. Synthesis of N-hydroxymaleimide derivative 127. 
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Scheme 21. Synthesis of N-hydroxymaleimide derivative 130. 
 
 
Scheme 22. Synthesis of N-trifloxymaleimide derivatives 131, 115, 132, and 133. 
          For the crucial reaction forming the 3-N-alkyl pyrimidin-2,4-dione derivatives, a general 
reaction protocol was established. According to this reaction protocol, a stirred suspension of N-
trifloxymaleimide derivative and potassium carbonate in N,N-dimethylformamide was treated with 
a solution of primary amine in N,N-dimethylformamide at room temperature and then stirred for 4 
hours at room temperature (Scheme 23). By following the same reaction protocol a series of 3-N-
alkyl pyrimidin-2,4-dione derivatives were synthesized from the corresponding N-trifloxy 
maleimides and primary amines with the results are summarized in Table 18. 
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Scheme 23. Common reaction procedure for the synthesis of 3-N-alkyl pyrimidin-2,4-dione 
derivatives. 
 
Table 19.  Examples of synthesized 3-N-alkyl pyrimidin-2,4-dione derivatives. 
Entry N-trifloxy imide Amine Pyrimidindione, % yield 
1 
  
 
2  
 
 
3  
  
4 
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5  
 
 
6  
  
7 
 
 
 
8  
 
 
9  
 
 
87 
 
 
 
10 
 
 
 
11  
 
 
 
5.3. Discussion: 
          The examples shown in Table 18 demonstrate that the reaction methodology works 
smoothly to give the variously substituted 3-N-alkyl pyrimidin-2,4-dione derivatives in moderate 
to good yields. The method functions well with a variety of 2,3-disubstituted N-hydroxymaleimide 
derivatives including dimethyl (Entries 1-3), diphenyl (Entries 4-6), mixed methyl, phenyl (Entries 
7-9), and fused bicyclic system (Entries 10 and 11). The synthesized 3-N-alkyl pyrimidin-2,4-
dione derivatives also demonstrate the successful incorporation of variety of primary amines with 
different steric environments and functionalities. As expected, in the case of unsymmetrical 2-
methyl-3-phenyl-N-trifloxymaleimide 132 two regioisomeric products were formed (Entries 7-9, 
Table 18). There was a modest preference for the formation of the isomer coming from the 
nucleophilic attack by the amine to the carbonyl carbon adjacent to the larger substituent. This 
modest preference for the nucleophilic attack to the carbonyl carbon adjacent to the larger 
substituent is due to the lesser steric hindrance for the approach of the nucleophile along the Burgi-
Dunitz trajectory. Similar regioselectivities were observed in the past for the metal hydride 
reductions of 2,2-dimethylsuccinic anhydride and 2,2-dimethyl succinimide.234,235 The formation 
of 3-N-alkyl pyrimidin-2,4-diones was also accompanied with the formation of typical amido urea 
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byproducts, although their formation can be minimized to an extent by using a slight excess of 
electrophilic N-trifloxymaleimides as compared to the amine during the reaction.     
          Mechanistically, the formation of 3-N-alkyl pyrimidin-2,4-diones involve the nucleophilic 
attack by the amine to one of the carbonyl carbons of the N-trifloxymaleimide to give an O-triflyl 
amido hydroxamic acid intermediate. This hydroxamic acid derivative undergoes rapid Lossen 
rearrangement236,237 to give an amido isocyanate. Finally, intramolecular nucleophilic attack of the 
amidic nitrogen atom to the isocyanate produces the major product 3-N-alkyl pyrimidin-2,4-dione. 
External nucleophilic attack by the amine on the amido isocyanate produces the amido urea 
byproducts (Scheme 23). 
 
Scheme 24. Reaction mechanism for the formation of the 3-N-alkyl pyrimidin-2,4-dione. 
          The proposed reaction mechanism for the formation of the 3-N-alkyl pyrimidin-2,4-dione is 
also supported by litrature precedent. Thus, Hurd and coworkers reported formation of 3-N-
benzoyloxy quinazolinedione 153 by refluxing the disodium salt of O,O’-dibenzoyl 
phthalohydroxamic acid 151 in water. This process was considered to involve Lossen 
rearrangement of a hydroxamic acid derivative to give an isocyanate 152 which was 
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intramolecularly trapped by nucleophilic attack of the second hydroxamate (Scheme 25).238 Hurd 
and coworkers also reported Lossen rearrangement of sodium succinohydroxamate 154 on reaction   
with benzenesulfonyl chloride to afford 3-N-benzenesulfonyloxy dihydrouracil 156 via the 
isocyanate intermediate 155  (Scheme 26).239 Nucleophilic ring opening of N-toluenesulfonyloxy 
phthalimide 157 and maleimide derivative 160 by either borohydride or hydroxide followed by 
Lossen rearrangement of the intermediate N-toluenesulfonyloxy hydroxamic acid derivative was 
also reported by Barton and coworkers (Scheme 27).232,240 
 
 
Scheme 25. Formation of 3-N-benzoyloxy quinazolinedione 151. 
  
 
 
Scheme 26. Formation of 3-N-benzenesulfonyloxy dihydrouracil 154. 
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Scheme 27. Lossen rearrangement of N-toluenesulfonyloxy phthalimide 157 and maleimide 
derivative 160. 
5.4. Conclusion: 
          In conclusion, an efficient and facile method was developed for the synthesis of highly 
substituted pyrimidin-2,4-dione derivatives. This is a novel two step entry into a very important 
heterocyclic scaffold pyrimidin-2,4-dione, from easily accessible and inexpensive N-hydroxy 
maleimides and primary amines. This synthetic method compliments and extends the existing 
routes for the synthesis of pyrimidine derivatives and the use of cyclic anhydrides241 and 
thioanhydrides242-245 in multicomponent reactions. 
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CHAPTER 5. OVERALL CONCLUSIONS. 
          With a goal of developing a new generation of resistance-proof and less ototoxic 
aminoglycoside antibiotics, the 4,5- series AGAs neomycin B and paromomycin were selected for 
modifications. A series of individual modifications were made to these AGAs, and their influence 
on activity and selectivity was determined by antiribosomal activity in cell free translation assays. 
In order to determine their antibacterial activity, the compounds were screened against clinical 
isolates of methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli and 
Pseudomonas aeruginosa. They were also screened against genetically engineered Escherichia 
coli strains carrying specific resistance enzymes to investigate if these modifications are helpful in 
circumventing modification by common AMEs. Such studies of individual modifications permit 
the informed design of advanced compounds incorporating multiple modifications and should 
ultimately lead to the resistance proof and less ototoxic compounds.  
          In the neomycin B series, the most important modifications were made at the 6’-, 4’-, and 
2’-positions. The 6’-N-(2-hydroxyethyl) modification brings a moderate increase in selectivity 
without any reduction in activity. Moreover, the compound showed strong activity in the presence 
of the AAC-(6’) mechanism of resistance. The 4’-O-ethyl modification did not cause any reduction 
in antibacterial activity and effectively blocked the action of ANT-(4’, 4’’). However, combination 
of 6’-N-(2-hydroxyethylation) and 4’-O-ethylation caused a significant decrease in activity 
without much improvement in selectivity. Modifications at the 2’-positions showed the most 
encouraging results. The 2’-N-alkyl, 2’-deamino, and 2-deamino-2’-hydroxy modifications did not 
cause any reduction in activity and moderately increased the selectivity. These modifications were 
able to circumvent the AAC-(2’) mechanism of resistance. Interestingly, the 2’-deamono 
neomycin B was equally active as the parent neomycin B, which invalidates the hypothesis that 
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the 2’-amino group is necessary to enforce the correct conformation for binding through internal 
hydrogen bonding with 5’’-hydroxy group. Unfortunately, simple amide type modifications of 2’-
amino group caused a significant decrease in activity. 
          In the paromomycin series, the 2’- and 5’’-positions were selected for modification. The 2’-
N-alkylated paromomycin derivatives showed comparable activity to paromomycin with a slight 
increase in selectivity. These 2’-N-alkylated derivatives were able to evade modification by the 
AAC-(2’) class of AMEs. These results also demonstrate that the bacterial ribosomal A-site can 
accommodate at least a three carbon substituent at this position. The 2’-deamino-2’-hydroxy 
paromomycin derivative showed a thirty fold decrease in activity, whereas the identical 
modification in neomycin B did not cause any change in activity. This observation clearly 
demonstrates the difference between paromomycin and neomycin B. In neomycin B, the stronger 
A1408-6’NH3+ hydrogen bond compensates for the loss of activity, whereas the weaker A1408-
6’OH hydrogen bond in paromomycin is less capable of doing this. The 5’’-deoxy-5’’-formamido 
and 5’’-deoxy-5’’-ureido derivatives did not show any reduction in activity, constituting one of 
the most important findings of this project. Presumably, the 5’’-amidic NH can also make the 
crucial interaction with the G1491 residue through hydrogen bonding. Combination of these 5’’-
modifications with modifications at 3’-position should give the compounds which completely 
evade the action of APH-(3’,5’’) class of AMEs. The 5’’-acetamido derivative shows reduced 
antibacterial activity and selectivity. 
          The results obtained in the neomycin B and paromomycin series clearly show that there are 
several advantageous modification has been made and some compounds show strong antibacterial 
activity even in the presence of common AMEs with improved selectivity. Overall, these results 
demonstrate that it is possible to develop the new generation of resistance-proof and less ototoxic 
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AGAs by rational design. 
          In addition to the synthesis of novel AGAs, a new and facile method for the synthesis of 3-
N-alkyl pyrimidin-2,4-dione derivatives was developed. The pyrimidinediones are one of the 
important class of nitrogen based heterocycles and commonly found in biologically active 
compounds and pharmaceutical agents. This synthetic method provides an easy access to highly 
substituted pyrimidine-2,4-dione derivatives from easily available and inexpensive maleic 
anhydrides and primary amines.   
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CHAPTER 6. EXPERIMENTAL SECTION.  
          General Experimental: All experiments were carried out under a dry argon atmosphere 
unless otherwise specified. All reagents and solvents were purchased from commercial suppliers 
and were used without further purification unless otherwise specified. Chromatographic 
purifications were carried over silica gel (230-400 mesh). Thin layer chromatography was 
performed with pre-coated glass backed plates (w/UV 254). TLC were visualized by UV 
irradiation (254 nm) and by charring with sulfuric acid in ethanol (20:80, v/v) or ceric ammonium 
molybdate solution [Ce(SO4)2: 4 g, (NH4)6Mo7O24: 10 g, H2SO4: 40 mL, H2O: 360 mL]. Reversed-
phase HPLC was operated by using Varian Star Chromatography Workstation software (version 
6) with Varian HPLC equipment with two PrepStar model 218 pumps, a ProStar model 330 diode 
array detector and a ProStar model 701 fraction collector. Optical rotations were measured at 589 
nm and 23 ºC on an Autopol III polarimeter (Rudolph Research Analytical, Hackettstown, NJ) 
with a path length of 10 cm. Melting points are not corrected. 1H and 13C NMR spectra of all 
compounds were recorded using 400 and 600 MHz instrument. ESIHRMS were recorded using a 
Waters LCT Premier Xe TOF mass spectrometer. 
          1,3,2′,2′′′,6′′′-Pentazido-6,3′,2′′,5′′,3′′′,4′′′-hexa-O-benzyl-6′-O-(2,4,6-
triisopropylbenzene sulfonyl)- 1,3,2′,2′′′,6′′′-pentadeamino paromomycin (24). A stirred 
solution of compound 23 (550 mg, 0.43 mmol) in DCM (2.7 mL) was treated with triethyl amine 
(0.48 mL, 3.42 mmol) at RT and 2,4,6-triisopropybenzenesulfonyl chloride (388 mg, 1.28 mmol) 
was added while stirring. After stirring for 24 h at RT the reaction was quenched with water (20 
mL). The DCM layer was separated and water layer was extracted with DCM (2 x 20 mL). The 
combined organic layers were washed with water, dried over Na2SO4, and concentrated under 
reduced pressure. The residue was purified by column chromatography on silica gel eluting with 
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ethyl acetate/hexane (1:4) to give the desired product 24 (350 mg, 53%).  [α]RTD +65.7 (c 2.4, 
CHCl3).  
1H NMR (600 MHz, CDCl3) δ 7.47 – 7.02 (m, 32 H), 6.14 (d, J = 3.5 Hz, 1H), 5.67 (d, J 
= 5.9 Hz, 1H), 4.99 (d, J = 10.6 Hz, 1H), 4.91 – 4.89 (m, 2H), 4.70 (d, J = 10.8 Hz, 1H), 4.68 (d, 
J = 11.4 Hz, 1H), 4.63 (d, J = 11.8 Hz, 2H), 4.50 (d, J = 9.3 Hz, 2H), 4.46 (d, J = 11.9 Hz, 1H), 
4.43 (d, J = 12.0 Hz, 1H), 4.33 (d, J = 12.0 Hz, 1H), 4.30 – 4.21 (m, 5H), 4.18 (sep, J = 6.7 Hz, 
2H), 4.15 – 4.10 (m, 2H), 3.87 (d, J = 9.5 Hz, 1H), 3.82 (dd, J1 = 10.1 Hz, J2 = 1.3 Hz, 1H), 3.80 
– 3.75 (m, 2H), 3.69 – 3.62 (m, 2H), 3.57 (dd, J1 = 10.3 Hz, J2 = 2.9  Hz, 1H), 3.47 – 3.34 (m, 4H), 
3.29 (t, J = 9.4 Hz, 1H), 3.13 (br s, 1H), 2.95 – 2.87 (m, 2H), 2.85 (dd, J1 = 10.3 Hz, J2 = 3.6 Hz, 
1H), 2.26 (d, J = 3.6 Hz, 1H), 2.22 (dt, J1 = 13.0 Hz, J2 = 4.5 Hz, 1H), 1.38 (q, J = 12.9 Hz, 1H), 
1.29 (d, J = 6.8 Hz, 12 H), 1.27 – 1.25 (m, 6 H). 13C NMR (150 MHz, CDCl3) δ 153.8, 150.9, 
138.1, 138.0, 137.9, 137.6, 137.0, 136.9, 129.2, 128.7, 128.6, 128.5, 128.4, 128.4, 128.4, 128.3, 
128.2, 128.2, 128.1, 128.0, 127.9, 127.8, 127.8, 127.5, 127.4, 127.2, 123.8, 106.0, 98.7, 96.0, 84.2, 
82.5, 82.07, 81.83, 79.5, 75.6, 75.1, 74.9, 74.6, 74.3, 73.4, 73.2, 72.9, 72.4, 71.7, 71.5, 70.1, 70.0, 
69.9, 68.0, 62.4, 60.4, 60.1, 57.3, 51.1, 34.2, 32.5, 29.7, 24.9, 24.8, 23.5.  ESIHRMS calculated 
for C80H93N15O16SNa [M+Na]
+, 1574.6543; found, 1574.6583.  
          1,3,2′,6′,2′′′,6′′′-Hexaazido-6,3′,2′′,5′′,3′′′,4′′′-hexa-O-benzyl-1,3,2′,6′,2′′′,6′′′-hexa 
deamino neomycin B (25). To a stirred solution of 24 (260 mg, 0.17 mmol) in DMF (2.6 mL) was 
added sodium azide (109 mg, 1.67 mmol). The reaction mixture was stirred for 3 h at 80 0C then 
cooled to RT and quenched with water (10 mL). The water layer was extracted with ethyl acetate 
(3 x 10 mL). The combined organic layers were washed with water followed by brine, dried over 
Na2SO4, and concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel eluting with ethyl acetate/hexane (1:3) to give the desired product 25 
(160 mg, 73%). [α]RTD +75.9 (c 1.45, CHCl3). 1H NMR (600 MHz, CDCl3) δ 7.55 – 6.99 (m, 30 
96 
 
 
 
H), 6.22 (d, J = 3.4 Hz, 1H), 5.70 (d, J = 5.8 Hz, 1H), 5.06 – 4.84 (m, 3H), 4.73 (d, J = 10.6 Hz, 
1H), 4.66 – 4.60 (m, 3H), 4.56 – 4.45 (m, 3H), 4.43 (d, J = 11.9 Hz, 1H), 4.33 (d, J = 12.0 Hz, 
1H), 4.33 – 4.26 (m, 2H), 4.26 (d, J = 12.0 Hz, 1H), 4.09 – 4.02 (m, 1H), 4.01 – 3.94 (m, 2 H), 
3.90 – 3.74 (m, 4H), 3.74 – 3.63 (m, 2H), 3.58 (dd, J1 = 10.1 Hz, J2 = 2.8 Hz, 1H), 3.52 – 3.40  (m, 
3H), 3.39 – 3.28 (m, 3H), 3.24 (t, J = 9.3 Hz, 1H), 3.13 (br s, 1H), 2.95 – 2.83 (m, 2H), 2.24 (dt, 
J1 = 12.8 Hz, J2 = 4.2 Hz, 1H), 1.43 (q, J = 12.8 Hz, 1H). 
13C NMR (150 MHz, CDCl3) δ 138.2, 
137.9, 137.9, 137.6, 137.0, 136.9, 128.8, 128.7, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 
128.1, 127.8, 127.8, 127.8, 127.5, 127.3, 106.1, 98.6, 95.8, 84.3, 82.5, 82.1, 81.7, 79.7, 75.6, 75.1, 
75.0, 74.9, 74.4, 73.3, 73.3, 72.9, 72.4, 71.7, 71.5, 71.2, 71.0, 70.2, 62.6, 60.4, 60.2, 57.2, 51.6, 
51.1, 32.6. ESIHRMS calculated for C65H70N18O13Na [M+Na]
+, 1333.5267; found, 1333.5288.  
          1,3,2′,6′,2′′′,6′′′-Hexaazido-6,3′,2′′,5′′,3′′′,4′′′-hexa-O-benzyl-4′-O-ethyl-
1,3,2′,6′,2′′′,6′′′-hexadeamino neomycin B (26). To a stirred suspension of sodium hydride (10 
mg, 0.24 mmol) in DMF (0.3 mL) was added a solution of 25 (160 mg, 0.12 mmol) in DMF (1.3 
mL) at 0 0C. After stirring for 3 h at 0 0C the reaction was quenched with water (10 mL). The water 
layer was extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with 
water followed by brine, dried over Na2SO4, and concentrated under reduced pressure. The residue 
was purified by column chromatography on silica gel eluting with ethyl acetate/hexane (1:4) to 
give the desired product 26 (120 mg, 73%). [α]RTD +86.3 (c 1.71, CHCl3). 1H NMR (600 MHz, 
CDCl3) δ 7.47 – 7.12 (m, 30H), 6.17 (d, J = 3.7 Hz, 1H), 5.69 (d, J = 5.7 Hz, 1H), 4.98 (d, J = 10.7 
Hz, 1H), 4.93 (d, J = 1.5 Hz, 1H), 4.87 – 4.78 (m, 2H), 4.74 (d, J = 10.7 Hz, 1H), 4.64 (d, J = 12.3 
Hz, 1H), 4.62 (d, J = 12.3 Hz, 1H), 4.56 (d, J = 11.9 Hz, 1H), 4.48 (dd, J1 = 11.8 Hz, J2 = 4.2 Hz, 
2H), 4.44 (d, J = 12.0 Hz, 1H), 4.34 (d, J = 12.0 Hz, 1H), 4.32 – 4.25 (m, 3H), 4.09 (ddd, J1 = 8.2 
Hz, J2 = 5.7 Hz, J3 = 2.1 Hz, 1H), 3.98 (t, J = 5.2 Hz, 1H), 3.97 – 3.92 (m, 2H), 3.85 – 3.76 (m, 
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4H), 3.72 – 3.64 (m, 2H), 3.62 – 3.55 (m, 2H), 3.52 (dd, J1 = 13.0,  J2 = 2.1 Hz, 1H), 3.50 – 3.41 
(m, 2H), 3.40 – 3.31 (m, 3H), 3.15 (br s, 1H), 3.08 (t, J = 9.4 Hz, 1H), 3.00 (dd, J1 = 10.4 Hz, J2 = 
3.7 Hz, 1H), 2.90 (dd, J1 = 12.9 Hz, J2 = 3.9 Hz, 1H), 2.25 (dt, J1 = 13.0 Hz, J2 = 4.4 Hz, 1H), 1.45 
(q, J = 12.8 Hz, 1H), 1.18 (t, J = 7.0 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 138.3, 138.1, 137.9, 
137.7, 137.0, 137.0, 128.7, 128.5, 128.4, 128.4, 128.4, 128.3, 128.3, 128.2, 128.1, 127.8, 127.8, 
127.8, 127.5, 106.2, 98.6, 95.6, 84.2, 82.5, 82.1, 81.7, 79.7, 79.1, 77.3, 77.1, 76.9, 75.6, 75.3, 75.1, 
74.4, 73.3, 72.9, 72.4, 71.7, 71.50, 71.1, 70.2, 68.5, 63.1, 60.4, 60.0, 57.3, 51.4, 51.1, 32.5, 15.7. 
ESIHRMS calculated for C67H74N18O13Na [M+Na]
+, 1361.5580; found, 1361.5559.  
          4′-O-Ethyl neomycin B acetate salt (27). To a stirred suspension of Pd/C (240 mg) in 10% 
AcOH (1.5 mL) was added a solution of 26 (120 mg, 0.09 mmol) in dioxane (1.5 mL) at RT. The 
reaction mixture was stirred under a hydrogen atmosphere (45 psi) for 24 h, filtered, concentrated 
and purified by Sephadex C-25 column chromatography (1.0% ammonium hydroxide). The 
product-containing fractions were concentrated under reduced pressure. The residue was dissolved 
in 10% AcOH and freeze dried to give the desired product 27 as the peracetate salt (37 mg, 41%). 
[α]RTD +46.3 (c 1.06, H2O). 1H NMR (600 MHz, D2O) δ 5.76 (d, J = 3.7 Hz, 1H), 5.14 (d, J = 2.1 
Hz, 1H), 5.01 (d, J = 1.2 Hz, 1H), 4.21 (t, J = 5.7 Hz, 1H), 4.11 (dd, J1 = 4.6 Hz, J2 = 2.4 Hz, 1H), 
4.03 (t, J = 4.4 Hz, 1H), 3.92 – (m, 2H), 3.82 (t, J = 10.7 Hz, 1H), 3.80 (t, J = 10.3 Hz, 1H), 3.65 
(t, J = 7.8 Hz, 1H), 3.65 – 3.56 (m, 3H), 3.54 (br s, 1H), 3.50 – 3.43 (m, 2H), 3.41 (t, J = 9.9 Hz, 
1H), 3.30 (br s, 1H), 3.25 – 3.11 (m, 4H), 3.11 – 2.95 (m, 3H), 2.20 (dt, J1 = 12.5 Hz,  J2 = 4.2 Hz, 
2H), 1.75 (S, 18H), 1.61 (q, J = 12.6 Hz, 1H) 0.90 (t, J = 7.0 Hz, 2H). 13C NMR (150 MHz, D2O) 
δ 178.0, 109.9, 95.2, 94.7, 84.6, 81.4, 78.5, 75.1, 75.0, 73.4, 72.2, 70.0, 69.1, 68.9, 67.8, 67.4, 67.1, 
59.9, 53.1, 50.7, 49.6, 48.2, 40.2, 39.9, 27.8, 21.3, 14.5. ESIHRMS calculated for C25H51N6O13 
[M+H]+, 643.3514; found, 643.3500.  
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          6′-N-Benzyloxycarbonyl neomycin B (28), 6′′′-N-Benzyloxycarbonyl neomycin B (29) 
and 6′,6′′′-Bis-N-(benzyloxycarbonyl) neomycin B (30). A stirred solution of neomycin B 
sulfate salt (5 g, 7.02 mmol) in water (200 mL) was treated with sodium carbonate (4.5 g, 42.12 
mmol) at RT and cooled to 0 0C before a solution of N-(benzyloxycarbonyloxy)-succinimide (1.8 
g, 7.22 mmol) in dioxane (200 mL) was added dropwise over a period of 6 h. The reaction was 
slowly allowed to warm to RT and stirring was continued for 18 h. Then the reaction was 
concentrated under reduced pressure and the residue was purified by column chromatography on 
silica gel eluting with CHCl3/MeOH/NH4OH (2:2:1) to give an inseparable 1:1 mixture of 28 and 
29 (1.7 g, 32%, ESIHRMS calculated for C31H53N6O15 [M+H]
+, 749.3569; found, 749.3555.). This 
regioisomeric mixture was used for next reaction without further purification. Along with the 
mono-Cbz compounds the di-Cbz compound 30 was also obtained (1.8 g, 29%). [α]RTD +69.6 (c 
.25, MeOH). ESIHRMS calculated for C39H59N6O17 [M+H]
+, 883.3937; found, 883.3917.  
          6′-N-Benzyloxycarbonyl-1,3,2′,2′′′,6′′′-pentaazido-1,3,2′,2′′′,6′′′-pentadeamino 
neomycin B (31) and 6′′′-N-Benzyloxycarbonyl-1,3,2′,6′,2′′′, -pentaazido-1,3,2′,6′,2′′′,-
pentadeamino neomycin B (32). A stirred solution of 1:1 mixture of 28 and 29 (4.2 g, 5.61 mmol) 
in a mixture of methanol and water (2:3, 100 mL) was treated with potassium carbonate (6.2 g, 
44.9 mmol) at RT and cooled to 0 0C before imidazole-1-sulfonyl azide hydrochloride (7.0 g, 33.67 
mmol) and copper (II) sulfate (90 mg, 0.56 mmol) were added. The reaction was slowly allowed 
to warm to RT and stirring was continued for 18 h. Then the reaction was concentrated roughly to 
half of the initial volume under reduced pressure and extracted with ethyl acetate/THF (1:1, 3 x 50 
mL). The combined organic layer was dried over Na2SO4 and concentrated under reduced pressure. 
The residue was purified by column chromatography on silica gel eluting with CHCl3/MeOH (9:1) 
to give an inseparable 1:1 mixture of 31 and 32 (2.6 g, 53%). This regioisomeric mixture was used 
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for next reaction without further purification. ESIHRMS calculated for C31H42N16O15Na [M+Na]
+, 
901.2896; found, 749.3555. 
          1,3,2′,2′′′,6′′′-Pentaazido-1,3,2′,2′′′,6′′′-pentadeamino neomycin B (33) and 
1,3,2′,6′,2′′′-Pentaazido-1,3,2′,6′,2′′′,-pentadeamino neomycin B (34). To a stirred solution of 
1:1 mixture of 31 and 32 (2.5 g, 2.86 mmol) in dioxane (30 mL) was added 2M NaOH (30 mL). 
After stirring for 18 h at 60 0C the reaction was concentrated to dryness, dissolved in methanol 
(150 mL), and the precipitate was filtered off. The filtrate was concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel eluting with 
CHCl3/MeOH/NH4OH (14:5:1) to give a 1:1 mixture of 33 and 34 (1.2 g, 57%).  Careful separation 
of the mixture of 33 and 34 on silica gel eluting with CHCl3/MeOH/NH4OH (14:5:1) gave the pure 
samples of regioisomers 33 and 34. 
          1,3,2′,2′′′,6′′′-Pentaazido-1,3,2′,2′′′,6′′′-pentadeamino neomycin B (33). [α]RTD +89.7 (c 
1.09, MeOH). 1H NMR (600 MHz, CD3OD) δ 5.83 (d, J = 3.6 Hz, 1H), 5.38 (br s, 1H), 5.11 (d, J 
= 1.2 Hz, 1H), 4.43 (dd, J1 = 6.7 Hz, J2 = 4.7 Hz, 1H), 4.28 (d, J = 3.1 Hz, 1H), 4.10 – 4.16 (m, 
1H), 4.04 – 3.98 (m, 1H), 3.94 – 3.86 (m, 3H), 3.82 (dd, J1 = 11.9 Hz, J2 = 2.4 Hz, 1H), 3.74 – 
3.61 (m, 5H), 3.57 – 3.49 (m, 1H), 3.47 (t, J = 9.3 Hz, 1H), 3.44 – 3.40 (m, 2H), 3.37 (dd, J1 = 
12.9 Hz, J2 = 4.3 Hz, 1H), 3.24 (t, J = 9.4 Hz, 1H), 3.08 (dd, J1 = 10.5 Hz, J2 = 3.6 Hz, 1H), 3.04 
(d, J = 13.4 Hz, 1H), 2.78 (dd, J1 = 13.4 Hz, J2 = 6.7 Hz, 1H), 2.17 (dt, J1 = 12.5 Hz, J2 = 4.1 Hz, 
1H), 1.40 (q, J = 12.5 Hz, 1H). 13C NMR (150 MHz, CD3OD) δ 107.7, 98.3, 96.4, 84.0, 81.9, 75.7, 
75.6, 74.9, 74.2, 73.6, 72.0, 72.0, 70.7, 69.7, 68.1, 63.2, 61.9, 60.4, 60.3, 60.2, 51.0, 42.1, 31.6. 
ESIHRMS calculated for C23H37N16O13 [M+H]
+, 745.2726; found, 745.2722.  
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          1,3,2′,6′,2′′′-Pentaazido-1,3,2′,6′,2′′′,-pentadeamino neomycin B (34). [α]RTD +101.8 (c 
1.0, MeOH). 1H NMR (600 MHz, CD3OD) δ 5.76 (d, J = 3.7 Hz, 1H), 5.37 (br s, 1H), 5.11 (br s, 
1H), 4.52 (dd, J1 = 6.7 Hz, J2 = 4.7 Hz, 1H), 4.32 (d, J = 4.2 Hz, 1H), 4.19 – 4.13 (m, 1H), 4.13 – 
4.08 (m, 1H), 3.98 (d, J = 6.8 Hz, 1H), 3.93 (m, 1H), 3.85 (t, J = 9.6 Hz, 1H), 3.82 (dd, J1 = 12.0 
Hz, J2 = 3.3 Hz, 1H), 3.74 (dd, J1 = 12.0 Hz, J2 = 3.9 Hz, 1H), 3.70 – 3.60 (m, 3H), 3.56 – 3.46 
(m, 3H), 3.46 – 3.39 (m, 3H), 3.34 (t, J = 9.4 Hz, 1H), 3.27 – 3.13 (m, 1H), 3.11 (dd, J1 = 10.5 Hz, 
J2 = 3.7 Hz, 1H), 3.05 – 2.93 (m, 1H), 2.21 (dt, J1 = 12.6 Hz, J2 = 3.9 Hz, 1H), 1.37 (q, J = 12.6 
Hz, 1H). 13C NMR (150 MHz, CD3OD) δ 108.1, 98.4, 97.0, 83.5, 81.4, 76.1, 75.7, 75.2, 73.5, 
73.36, 71.7, 71.2, 70.7, 69.9, 68.7, 63.2, 60.9, 60.5, 60.2, 59.7, 51.2, 41.2, 31.6. ESIHRMS 
calculated for C23H37N16O13 [M+H]
+, 745.2726; found, 745.2704.  
          6′-N-(2-Benzyloxyethyl)-1,3,2′,2′′′,6′′′-pentaazido-1,3,2′,2′′′,6′′′-pentadeamino 
neomycin B (35) and 6′′′-N-(2-Benzyloxyethyl)-1,3,2′,6′,2′′′, -pentaazido-1,3,2′,6′,2′′′,-
pentadeamino neomycin B (36). To a stirred solution of 1:1 mixture of 33 and 34 (400 mg, 0.54 
mmol) in methanol (9 mL) was added a solution of benzyloxyacetaldehyde (97 mg, 0.64 mmol) in 
methanol (1 mL) at RT. After stirring for 0.5 h at RT to the reaction was added glacial acetic acid 
(62 µL, 1.07 mmol) and sodium cyanoborohydride (68 mg, 1.07 mmol) and stirring was continued 
for 5 h. The reaction was quenched with aq. NaHCO3 (5 mL) followed by addition of DABCO 
(121 mg, 1.07 mmol) at RT. After stirring for 0.5 h the reaction was concentrated to dryness, 
dissolved in methanol (20 mL), and the precipitate was filtered off. The filtrate was concentrated 
under reduced pressure. The residue was purified by column chromatography on silica gel eluting 
with CHCl3/MeOH (3:1) to give a 1:1 mixture of 35 and 36 (220 mg, 47%). The mixture of 35 and 
36 was separated by preparative reversed-phase HPLC [column: Varian Microsorb 100-5 C18, 
Dynamax 21.4 x 250 mm, 5.0 micron, protected by a Varian Dynamax HPLC guard column (21.4 
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mm, compression module, Microsorb Guard-8 C18); temperature: ambient; flow rate: 21.5 mL 
min-1; mobile phase: (A) water, (B) acetonitrile; gradient program: 0-30 min, 22.5% B, detector 
wavelength: 220 nm] to give pure samples of 35 and 36. 
          6′-N-(2-Benzyloxyethyl)-1,3,2′,2′′′,6′′′-pentaazido-1,3,2′,2′′′,6′′′-pentadeamino 
neomycin B (35). [α]RTD +89.6 (c 0.87, MeOH). 1H NMR (600 MHz, CD3OD) δ 7.34 (m, 5H), 
5.93 (d, J = 3.3 Hz, 1H), 5.35 (br s, 1H), 5.11 (br s, 1H), 4.59 (br s, 2H), 4.37 (t, J = 5.5 Hz, 1H), 
4.31 (d, J1 = 3.9 Hz, 1H), 4.21 (t, J = 8.5 Hz, 1H), 4.11 (td, J1 = 6.0 Hz, J2 = 2.2 Hz, 1H), 4.02 – 
3.97 (m, 1H), 3.94 – 3.91 (m, 1H), 3.86 (t, J = 9.6 Hz, 1H), 3.82 (dd, J1 = 11.8 Hz, J2 = 1.4 Hz, 
1H), 3.77 – 3.54 (m, 8H), 3.49 – 3.28 (m, 8H), 3.24 (t, J = 9.4 Hz, 1H), 3.15(dd, J1 = 6.0 Hz, J2 = 
2.2 Hz, 1H), 2.19 (dt, J1 = 12.6 Hz, J2 = 4.1 Hz, 1H), 1.28 (q, J = 12.5 Hz, 1H). 
13C NMR (150 
MHz, CD3OD) δ 137.3, 128.2, 127.8, 127.7, 109.0, 98.4, 96.7, 84.0, 82.1, 76.1, 75.9, 75.7, 74.2, 
73.7, 73.1, 72.2, 70.5, 69.7, 68.1, 67.5, 64.4, 62.9, 62.3, 60.4, 60.3, 60.1, 51.1, 48.8, 47.2, 31.7. 
ESIHRMS calculated for C32H47N16O14 [M+H]
+, 878.3458; found, 878.3412.  
          6′′′-N-(2-Benzyloxyethyl)-1,3,2′,6′,2′′′, -pentaazido-1,3,2′,6′,2′′′,-pentadeamino 
neomycin B (36). [α]RTD +71.3 (c 1.5, MeOH). 1H NMR (600 MHz, CD3OD) δ 7.42 – 7.24 (m, 
5H), 5.74 (d, J = 3.7 Hz, 1H), 5.34 (d, J = 1.2 Hz, 1H), 5.15 (d, J = 1.4 Hz, 1H), 4.65 – 4.56 (m, 
2H), 4.1  (dd, J1 = 4.5 Hz, J2 = 6.8 Hz, 1H), 4.30 (d, J = 4.5 Hz, 1H), 4.25 – 4.19 (m, 1H), 4.18 – 
4.13 (m, 1H), 4.08 (dt, J1 = 6.9 Hz, J2 = 3.4 Hz, 1H), 3.96 (t, J = 3.2 Hz, 1H), 3.85 (t, J = 10.3 Hz, 
1H), 3.79 (dd, J1 = 12.2 Hz, J2 = 3.5 Hz, 1H), 3.77 – 3.70 (m, 3H), 3.68 – 3.57 (m, 3H), 3.57 – 
3.48 (m, 3H), 3.47 (dd, J1 = 13.3 Hz, J2 = 8.1 Hz, 1H), 3.42 (dd, J1 = 13.2 Hz, J2 = 5.5 Hz, 1H), 
3.41 – 3.37 (m, 2H), 3.36 – 3.26 (m, 4H), 3.10 (dd, J1 = 10.5 Hz, J2 = 3.8 Hz, 1H), 2.20 (dt, J1 = 
12.5 Hz, J2 = 4.2 Hz, 1H), 1.34 (q, J = 12.5 Hz, 1H). 
13C NMR (150 MHz, CD3OD) δ 137.4, 128.2, 
127.8, 127.7, 108.1, 98.5, 97.1, 83.6, 81.1, 76.2, 75.7, 75.4, 73.5, 72.9, 71.7, 71.2, 70.6, 70.0, 69.6, 
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68.7, 64.1, 63.2, 60.5, 60.5, 59.7, 59.7, 51.2, 48.5, 47.4, 31.5. ESIHRMS calculated for 
C32H46N16O14Na [M+Na]
+, 901.3277; found, 901.3257.  
          6′-N-(2-Hydroxyethyl) neomycin B acetate salt (37). To a stirred solution of 35 (35 mg, 
0.04 mmol) in a mixture of THF and water (1:1, 1.5 mL) was added 1M NaOH (0.5 mL) and 
trimethylphosphine (1M in THF, 0.26 mL). After stirring for 3 h at 60 0C the reaction was 
concentrated to dryness under reduced pressure. The residue was roughly purified by column 
chromatography on silica gel eluting with CHCl3/MeOH/NH4OH (2:2:1). The product-containing 
fractions were concentrated under reduced pressure to give an off-white solid (20 mg). The solid 
was dissolved in methanol (1 mL) and added to a stirred suspension of Pd(OH)2/C (20 mg) in 10% 
AcOH (1 mL) at RT. The reaction mixture was stirred under a hydrogen atmosphere (1 atm) for 4 
h, filtered, concentrated and purified by Sephadex C-25 column chromatography (1.5% 
ammonium hydroxide). The product-containing fractions were concentrated under reduced 
pressure. The residue was dissolved in 10% AcOH and freeze dried to give the desired product 37 
as the peracetate salt (10 mg, 23 %). [α]RTD +27.8 (c 0.14, H2O). 1H NMR (600 MHz, D2O) δ 5.85 
(d, J = 3.9 Hz, 1H), 5.22 (d, J = 2.3 Hz, 1H), 5.08 (d, J = 1.4 Hz, 1H), 4.29 (dd, J1 = 6.3 Hz, J2 = 
5.1 Hz, 1H), 4.20 (dd, J1 = 4.8 Hz, J2 = 2.4 Hz, 1H), 4.12 – 4.07 (m, 1H), 4.12 – 4.07 (m, 2H), 
3.89 (t, J = 9.7 Hz, 1H), 3.83 – 3.76 (m, 2H), 3.73 (t, J = 9.2 Hz, 1H), 3.70 (dd, J1 = 12.4 Hz, J2 = 
2.7 Hz, 1H), 3.68 – 3.63 (m, 2H), 3.63 – 3.59 (m, 1H), 3.54 (dd, J1 = 12.3 Hz, J2 = 5.0 Hz, 1H), 
3.58 (t, J = 9.8 Hz, 1H), 3.39 – 3.36 (m, 1H), 3.34 (dd, J1 = 13.2 Hz, J2 = 3.2 Hz, 1H), 3.33 – 3.28 
(m, 1H), 3.26 (t, J = 9.5 Hz, 1H), 3.25 – 3.18 (m, 2H), 3.18 – 3.11 (m, 3H), 3.08 – 3.02 (m, 2H), 
2.27 (dt, J1 =12.6 Hz, J2 = 4.0 Hz , 1H), 1.81 (s, 18H), 1.67 (q, J = 12.6 Hz, 1H). 
13C NMR (150 
MHz, D2O) δ 178.1, 110.1, 95.3, 95.3, 84.7, 81.5, 75.1, 75.1, 73.5, 72.4, 70.9, 70.0, 69.2, 67.8, 
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67.5, 67.2, 60.0, 56.1, 53.3, 50.7, 49.9, 49.7, 48.2, 48.2, 40.3, 28.0, 21.2. ESIHRMS calculated for 
C25H50N6O14Na [M+Na]
+, 681.3283; found, 681.3286. 
          6′′′-N-(2-Hydroxyethyl) neomycin B acetate salt (38). To a stirred solution of 36 (75 mg, 
0.08 mmol) in a mixture of THF and water (1:1, 3 mL) was added 1M NaOH (1 mL) and 
trimethylphosphine (1M in THF, 0. 6 mL). After stirring for 3 h at 60 0C the reaction was 
concentrated to dryness under reduced pressure. The residue was roughly purified by column 
chromatography on silica gel eluting with CHCl3/MeOH/NH4OH (2:2:1). The product-containing 
fractions were concentrated under reduced pressure to give an off-white solid (50 mg). The solid 
was dissolved in methanol (2 mL) and added to a stirred suspension of Pd(OH)2/C (50 mg) in 10 
%-AcOH (2 mL) at RT. The reaction mixture was stirred under a hydrogen atmosphere (1 atm) 
for 4 h, filtered, concentrated and purified by Sephadex C-25 column chromatography (1.5% 
ammonium hydroxide). The product-containing fractions were concentrated under reduced 
pressure. The residue was dissolved in 10% AcOH and freeze dried to give the desired product 38 
as the peracetate salt (25 mg, 26 %). [α]RTD +39.0 (c 0.5, H2O). 1H NMR (600 MHz, D2O) δ 5.83 
(d, J = 4.0 Hz, 1H), 5.22 (d, J = 2.3 Hz, 1H), 5.09 (d, J = 1.3 Hz, 1H), 4.29 (t, J = 5.8 Hz, 1H), 
4.22 – 4.16 (m, 2H), 4.05 – 3.99 (m, 2H), 3.87 (t, J = 9.7 Hz, 1H), 3.79 (dd, J1 = 10.7 Hz, J2 = 9.2 
Hz, 1H), 3.77 – 3.68 (m, 3H), 3.66 (t, J = 5.2 Hz, 2H), 3.63 – 3.60 (m, 1H), 3.53 (dd, J1 = 12.3 Hz, 
J1 = 5.0 Hz, 1H), 3.48 (t, J = 9.8 Hz 1H), 3.41 – 3.27 (m, 3H), 3.27 – 3.20 (m, 4H), 3.14 (dt, J1 = 
10.9 Hz, J2 = 3.5 Hz, 1H), 3.10 – 3.02 (m, 3H), 2.27 (dt, J1 = 12.6 Hz, J2 = 4.1 Hz, 1H), 1.83 (s, 
18H), 1.68 (q, J = 12.6 Hz, 1H). 13C NMR (150 MHz, D2O) δ 178.9, 110.1, 95.3, 84.7, 81.4, 75.2, 
75.1, 73.4, 72.4, 70.6, 69.7, 69.3, 67.9, 67.5, 67.1, 60.00, 56.3, 53.4, 50.7, 49.7, 49.6, 48.8, 48.3, 
47.9, 40.1, 28.1, 21.8. ESIHRMS calculated for C25H50N6O14Na [M+Na]
+, 681.3283; found, 
681.3262.  
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          6′,6′′′-Bis-N-(benzyloxycarbonyl)-1,3,2′,2′′′-tetraazido-1,3,2′,2′′′-tetradeamino 
neomycin B (39). A stirred solution of 30 (1.7 g, 1.93 mmol) in a mixture of methanol and water 
(1:1, 50 mL) was treated with potassium carbonate (2.13 g, 15.41 mmol) at RT and cooled to 0 0C 
before imidazole-1-sulfonyl azide hydrochloride (2.0 g, 9.63 mmol) and copper (II) sulfate (31 
mg, 0.19 mmol) were added. The reaction was slowly allowed to warm to RT and stirring was 
continued for 18 h. Then the reaction was concentrated roughly to half of the initial volume under 
reduced pressure and extracted with ethyl acetate/THF (1:1, 3 x 50 mL). The combined organic 
layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was roughly 
purified by column chromatography on silica gel eluting with CHCl3/MeOH (9:1) to give the 
desired product 39 (500 mg, 26%). [α]RTD +72.0 (c 1.33, MeOH). ESIHRMS calculated for 
C39H50N14O17Na [M+Na]
+, 1009.3376; found, 1009.3319.  
          1,3,2′,2′′′-Tetraazido-1,3,2′,2′′′-tetradeamino neomycin B (40). To a stirred solution of 
39 (450 mg, 0.46 mmol) in dioxane (10 mL) was added 4M NaOH (10 mL). After stirring for 18 
h at 60 0C the reaction was concentrated to dryness, dissolved in methanol (20 mL), and the 
precipitate was filtered off. The filtrate was concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel eluting with CHCl3/MeOH/NH4OH (3:2:1) to 
give the desired product 24 (190 mg, 58%). [α]RTD +123.9 (c 0.67, MeOH). 1H NMR (600 MHz, 
CD3OD) δ 5.76 (d, J = 3.4 Hz, 1H), 5.38 (br s, 1H), 5.09 (br s, 1H), 4.54 (dd, J1 = 6.8 Hz, J2 = 4.6 
Hz, 1H), 4.28 (d, J = 4.2 Hz, 1H), 4.14 – 4.08 (m, 1H), 3.95 – 3.85 (m, 3H), 3.81 (dd, J1 = 11.9 Hz 
, J2 = 2.7 Hz, 1H), 3.77 – 3.71 (m, 2H), 3.66 (t, J = 9.3 Hz, 1H), 3.62 (br s, 1H), 3.56 – 3.50 (m, 
1H), 3.50 (t, J = 9.5 Hz, 1H), 3.46 (br s, 1H), 3.44 – 3.37 (m, 1H), 3.25 (t, J = 9.2 Hz, 1H), 3.10 
(dd, J1 = 10.4 Hz, J2 = 3.6 Hz, 1H), 3.15 – 2.98 (m, 2H), 2.93 – 2.72 (m, 2H), 2.17 (dt, J1 = 12.7 
Hz, J2 = 4.3 Hz, 1H), 1.40 (q, J = 12.6 Hz, 1H). 
13C NMR (150 MHz, CD3OD) δ 106.9, 98.4, 96.4, 
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83.5, 81.6, 75.2, 75.1, 74.8, 73.4, 72.2, 72.0, 70.7, 70.0, 68.9, 63.3, 60.6, 60.4, 60.3, 60.2, 42.0, 
41.6, 31.6. ESIHRMS calculated for C23H39N14O13 [M+H]+, 719.2821; found, 719.2794.  
          6′,6′′′-Bis-N-(2-hydroxyethyl) neomycin B acetate salt (42). To a stirred solution of 24 
(190 mg, 0.26 mmol) in methanol (3 mL) was added a solution of benzyloxyacetaldehyde (92 mg, 
0.61 mmol) in methanol (0.5 mL) at RT. After stirring for 0.5 h at RT to the reaction was added 
glacial acetic acid (60 µL, 1.06 mmol) and sodium cyanoborohydride (67 mg, 1.06 mmol) and 
stirring was continued for 4 h. The reaction was quenched with aq. NaHCO3 (2 mL) followed by 
addition of DABCO (120 mg, 1.06 mmol) at RT. After stirring for 0.5 h the reaction was 
concentrated to dryness, dissolved in methanol (10 mL), and the precipitate was filtered off. The 
filtrate was concentrated under reduced pressure. The residue was roughly purified by column 
chromatography on silica gel eluting with CHCl3/MeOH (4:1) to give the desired product 41 (150 
mg, 57%). The compound used for next reaction without further purification. ESIHRMS calculated 
for C41H59N14O15Na [M+Na]
+, 987.4284; found, 987.4246. 
          To a stirred solution of 41 (150 mg, 0.15 mmol) in a mixture of THF and water (1:1, 4 mL) 
was added 1M NaOH (2 mL) and trimethylphosphine (1M in THF, 0. 8 mL). After stirring for 3 h 
at 60 0C the reaction was concentrated to dryness under reduced pressure. The residue was roughly 
purified by column chromatography on silica gel eluting with CHCl3/MeOH/NH4OH (2:2:1). The 
product-containing fractions were concentrated under reduced pressure to give an off-white solid 
(100 mg). The solid was dissolved in methanol (3 mL) and added to a stirred suspension of 
Pd(OH)2/C (100 mg) in 10% AcOH (3 mL) at RT. The reaction mixture was stirred under a 
hydrogen atmosphere (1 atm) for 12 h, filtered, concentrated and purified by Sephadex C-25 
column chromatography (0.6% ammonium hydroxide). The product-containing fractions were 
concentrated under reduced pressure. The residue was dissolved in 10% AcOH and freeze dried to 
106 
 
 
 
give the desired product 42 as the peracetate salt (25 mg, 15%). [α]RTD +63.3 (c 0.67, H2O). 1H 
NMR (600 MHz, D2O) δ 5.84 (d, J = 3.8 Hz, 1H), 5.22 (d, J = 2.1 Hz, 1H), 5.08 (br s, 1H), 4.28 
(t, J = 5.5 Hz, 1H), 4.21 – 4.16 (m, 2H), 4.05 – 3.98 (m, 2H), 3.89 (t, J = 9.7 Hz, 1H), 3.83 – 3.77 
(m, 2H), 3.72 (t, J = 9.1 Hz, 1H), 3.70 (dd, J1 = 11.5 Hz, J2 = 2.4 Hz, 1H), 3.65 (t, J = 5.0 Hz, 4H), 
3.60 (br s, 1H), 3.52 (dd, J1 = 12.5 Hz, J2 = 4.9 Hz, 1H), 3.47 (t, J = 9.7 Hz, 1H), 3.38 (br s, 1H), 
3.34 (dd, J1 = 13.4 Hz, J2 = 4.8 Hz, 1H), 3.30 (dd, J1 = 10.5 Hz, J2 = 3.7 Hz, 1H), 3.28 – 3.20 (m, 
4H), 3.18 – 3.10 (m, 2H), 3.09 – 3.02 (m, 4H), 2.27 (dt, J1 = 12.5 Hz, J2 = 3.8 Hz, 1H), 1.80 (s, 18 
H), 1.67 (q, J = 12.6 Hz, 1H). 13C NMR (150 MHz, D2O) δ 178.1, 110.1, 95.3, 95.2, 84.8, 81.4, 
75.1, 73.5, 72.4, 70.9, 69.7, 69.2, 67.8, 67.4, 67.1, 60.0, 56.3, 56.2, 53.4, 50.7, 49.9, 49.7, 49.6, 
48.8, 48.3, 48.2, 47.9, 28.0, 21.3. ESIHRMS calculated for C27H54N6O15Na [M+Na]+, 725.3545; 
found, 725.3514.  
          6′-N-Acetyl-1,3,2′,2′′′,6′′′-pentaazido-1,3,2′,2′′′,6′′′-pentadeamino neomycin B (43). To 
a stirred solution of 33 (90 mg, 0.12 mmol) in MeOH (1 mL) was added acetic anhydride (1 mL) 
at RT. After stirring for 24 h at RT the reaction was concentrated to dryness under reduced 
pressure. The residue was purified by column chromatography on silica gel eluting with 
CHCl3/MeOH (9:1) to give the desired product 43 (60 mg, 63%). [α]RTD +95.2 (c 0.9, MeOH). 1H 
NMR (600 MHz, CD3OD) δ 5.74 (d, J = 3.8 Hz, 1H), 5.36 (d, J = 6.5 Hz, 1H), 5.11 (d, J = 1.2 Hz, 
1H), 4.42 (dd, J1 = 6.5 Hz, J2 = 4.7 Hz, 1H), 4.29 (d, J = 3.3 Hz, 1H), 4.13 (m, 1H), 4.03 – 3.99 
(m, 1H), 3.98 – 3.94 (m, 1H), 3.93 (t, J = 3.3 Hz, 1H), 3.86 (t, J = 9.6 Hz, 1H), 3.82 (dd, J1 = 11.8 
Hz, J2 = 2.4 Hz, 1H), 3.72 – 3.60 (m, 5H), 3.57 (dd, J1 = 11.2 Hz, J2 = 4.8 Hz, 1H), 3.55 – 3.47  
(m, 2H), 3.47 – 3.40 (m, 2H), 3.38 (dd, J1 = 13.0 Hz, J2 = 4.4 Hz, 1H), 3.34 – 3.28 (m, 1H), 3.17 
(t, J = 9.4 Hz, 1H), 3.08 (dd, J1 = 10.5 Hz, J2 = 3.8 Hz, 1H), 2.19 (dt, J1 = 12.2 Hz, J2 = 3.9 Hz, 
1H), 1.96 (s, 2H), 1.33 (q, J = 12.3 Hz, 1H). 13C NMR (150 MHz, CD3OD) δ 172.5, 107.9, 98.3, 
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96.8, 83.8, 82.0, 75.8, 75.7, 75.5, 74.2, 73.7, 72.4, 71.8, 71.0, 70.5, 69.7, 68.2, 63.2, 63.0, 62.1, 
60.4, 60.3, 59.9, 51.1, 40.0, 31.7, 21.2. ESIHRMS calculated for C25H38N16O14Na [M+Na]
+, 
809.2651; found, 809.2642.  
          6′-N-Acetyl neomycin B acetate salt (44). To a stirred suspension of Pd/C (110 mg) in 10% 
AcOH (1 mL) was added a solution of 43 (55 mg, 0.07 mmol) in dioxane (2.0 mL) at RT. The 
reaction mixture was stirred under a hydrogen atmosphere (1 atm) for 18 h, filtered, concentrated 
and purified by Sephadex C-25 column chromatography (0.6% ammonium hydroxide). The 
product-containing fractions were concentrated under reduced pressure. The residue was dissolved 
in 10% AcOH and freeze dried to give the desired product 44 as the peracetate salt (30 mg, 44%). 
[α]RTD +45.0 (c 0.4, H2O).  1H NMR (600 MHz, D2O) δ 5.58 (d, J = 4.0 Hz, 1H), 5.12 (d, J = 2.0 
Hz, 1H), 5.00 (d, J = 1.5 Hz, 1H), 4.24 (dd, J1 = 6.7 Hz, J2 = 4.9 Hz, 1H), 4.13 (dd, J1 = 4.7 Hz, J2 
= 2.2 Hz, 1H), 4.05 – 4.01 (m, 1H), 3.97 – 3.91 (m, 2H), 3.75 (t, J = 9.6 Hz, 1H), 3.69 – 3.58 (m, 
3H), 3.57 – 3.44 (m, 3H), 3.41 (t, J = 9.9 Hz, 1H), 3.36 – 3.28 (m, 2H), 3.28 – 3.19 (m, 2H), 3.19 
– 3.02 (m, 5H), 2.22 (dt, J1 = 12.6 Hz, J2 = 4.0 Hz, 1H), 1.74 (s, 18H), 1.59 (q, J = 12.6 Hz, 1H). 
13C NMR (150 MHz, D2O) δ 178.1, 178.0, 174.5, 109.9, 95.3, 95.1, 84.3, 81.2, 75.8, 75.1, 73.3, 
72.2, 71.8, 70.0, 70.0, 68.3, 67.4, 67.1, 60.0, 53.5, 50.7, 49.6, 48.5, 40.2, 39.2, 27.9, 21.7, 21.3. 
ESIHRMS calculated for C25H49N6O14 [M+H]
+, 657.3307; found, 657.3300.  
          1,3,2′,6′,2′′′-Pentaazido-6′′′-hydroxy-1,3,2′,6′,2′′′,6′′′-hexadeamino neomycin B (45). 
A stirred solution of 34 (140 mg, 0.19 mmol) in 5% AcOH (3 mL) was treated with sodium nitrite 
(65 mg, 0.94 mmol) at 0 0C. After stirring for 2 h at 0 0C the reaction was quenched with aq. 
NaHCO3 (5 mL). Then the reaction was concentrated to dryness, dissolved in methanol (20 mL), 
and the precipitate was filtered off. The filtrate was concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel eluting with CHCl3/MeOH (6:1) to 
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give the desired product 45 (55 mg, 39%). [α]RTD +50.4 (c 1.0, MeOH). 1H NMR (600 MHz, 
CD3OD) δ 5.76 (d, J = 3.8 Hz, 1H), 5.35 (d, J = 1.1 Hz, 1H), 5.08 (d, J = 1.7 Hz, 1H), 4.49 (dd, J1 
= 7.0 Hz, J2 = 4.6 Hz, 1H), 4.32 (dd, J1 = 4.4 Hz, J2 = 1.1 Hz, 1H), 4.15 (ddd, J1 = 9.7 Hz, J2 = 5.7 
Hz, J3  = 2.2 Hz, 1H), 4.13 – 4.09 (m, 1H), 3.94 – 3.89 (m, 2H), 3.88 – 3.79 (m, 3H), 3.74 (dd, J1 
= 7.4 Hz, J2 = 4.6 Hz, 1H), 3.72 (dd, J1 = 7.4 Hz, J2 = 6.8 Hz, 1H), 3.66 – 3.60 (m, 3H), 3.54 – 
3.47 (m, 3H), 3.42 (m, 3H), 3.33 (t, J = 9.4 Hz, 1H), 3.12 (dd, J1 = 10.5 Hz, J2 = 3.8 Hz, 1H), 2.21 
(dt, J1 = 12.5 Hz, J2 = 4.2 Hz, 1H), 1.37 (q, J = 12.5 Hz, 1H). 
13C NMR (150 MHz, CD3OD) δ 
108.0, 98.4, 97.0, 83.5, 81.8, 76.1, 75.7, 75.6, 75.4, 73.5, 71.7, 71.2, 70.8, 69.8, 68.3, 63.2, 61.5, 
61.4, 60.6, 60.4, 59.7, 51.2, 31.6. ESIHRMS calculated for C23H35N15O14Na [M+Na]+, 768.2386; 
found, 768.2352.  
          6′′′-Deamino-6′′′-hydroxy neomycin B acetate salt (46). A stirred solution of 45 (55 mg, 
0.15 mmol) in a mixture of THF and water (1:1, 2 mL) was added 1M NaOH (1 mL) and 
trimethylphosphine (1M in THF, 0.5 mL). After stirring for 3 h at 60 0C the reaction was 
concentrated to dryness under reduced pressure. The residue was purified by Sephadex C-25 
column chromatography (1.0 % ammonium hydroxide). The product-containing fractions were 
concentrated under reduced pressure. The residue was dissolved in 10% AcOH and freeze dried to 
give the desired product 46 as the peracetate salt (25 mg, 35%). [α]RTD +42.9 (c 0.68, H2O). 1H 
NMR (600 MHz, D2O) δ 5.80 (d, J = 2.9 Hz, 1H), 5.19 (br s, 1H), 5.00 (br s, 1H), 4.29 – 4.27 (t, 
J = 5.3 Hz, 1H), 4.21 – 4.18 (m, 1H), 4.03 – 3.96 (m, 2H), 3.87 – 3.83 (m, 1H), 3.83 (t, J = 9.8 Hz, 
1H), 3.77 (t, J = 10.0 Hz, 1H), 3.74 – 3.67 (m, 3H), 3.67 – 3.56 (m, 3H), 3.54 (d, J = 1.3 Hz, 1H), 
3.46 (t, J = 9.8 Hz, 1H), 3.32 (d, J = 1.3 Hz, 1H), 3.32 – 3.18 (m, 4H), 3.12 (ddd, J1 = 10.9 Hz, J2 
= 8.7 Hz, J3 = 3.8 Hz, 1H), 3.04 (dd J1 = 13.1 Hz, J2 = 6.3 Hz, 1H), 2.25 (dt, J1 = 12.8 Hz, J2 = 3.9 
Hz, 1H), 1.75 (s, 15H), 1.65 (q, J = 12.8 Hz, 1H). 13C NMR (150 MHz, D2O) δ 179.5, 110.0, 95.4, 
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95.4, 84.6, 81.4, 75.4, 75.1, 74.9, 73.6, 72.4, 70.5, 69.3, 67.9, 67.6, 66.4, 61.1, 59.9, 53.5, 51.1, 
49.7, 48.3, 40.0, 28.1, 22.1. ESIHRMS calculated for C23H46N5O14 [M+H]+, 616.3041; found, 
616.3030.  
          1,3,2′,2′′′,6′′′-Pentazido-4′-O-(ethyl)-1,3,2′,2′′′,6′′′-pentadeamino paromomycin (47). 
A stirred solution of 22 (500 mg, 0.53 mmol) in a mixture of methanol and water (1:2, 15 mL) was 
treated with potassium carbonate (732 mg, 5.30 mmol) at RT and cooled to 0 0C before imidazole-
1-sulfonyl azide hydrochloride (667 mg, 3.18 mmol) and copper (II) sulfate (8.5 mg, 0.05 mmol) 
were added. The reaction was slowly allowed to warm to RT and stirring was continued for 18 h. 
Then the reaction was concentrated to dryness, dissolved in methanol (50 mL), and the precipitate 
was filtered off. The filtrate was concentrated under reduced pressure. The residue was purified by 
column chromatography on silica gel eluting with CHCl3/MeOH (9:1) to give the desired product 
47 (235 mg, 57%). [α]RTD +97.8 (c 1.0, MeOH). 1H NMR (600 MHz, CD3OD) δ 5.77 (d, J = 3.6 
Hz, 1H), 5.36 (d, J = 1.2 Hz, 1H), 5.12 (d, J = 1.3 Hz, 1H), 4.44 (dd, J1 = 6.4 Hz, J2 = 4.8 Hz, 
1H)), 4.28 (dd, J1 = 4.4 Hz, J2 = 1.4 Hz, 1H), 4.16 – 4.10 (m, 1H), 4.03 – 3.97 (m, 2H), 3.93 (t, J 
= 3.3 Hz, 1H), 3.92 – 3.86 (m, 2H), 3.82 (dd, J1 = 12.0 Hz, J2 = 2.5 Hz, 1H), 3.79 (dd, J1 = 11.9 
Hz, J2 = 2.1 Hz, 1H), 3.74 – 3.64 (m, 6H), 3.63 (dd, J1 = 12.9 Hz, J2 = 8.5 Hz, 1H), 3.52 – 3.38 
(m, 4H), 3.38 (dd, J1 = 13.0 Hz, J2 = 4.6 Hz, 1H), 3.24 (t, J = 9.4 Hz, 1H), 3.07 (dd, J1 = 10.6 Hz, 
J2 = 3.7 Hz, 1H), 2.16 (dt, J1 = 12.8 Hz, J2 = 4.3 Hz, 1H), 1.36 (q, J = 12.7 Hz, 1H), 1.18 (t, J = 
12.7 Hz, 3H). 13C NMR (151 MHz, CD3OD) δ 107.5, 98.3, 96.5, 83.8, 82.0, 78.2, 75.7, 75.5, 75.0, 
74.1, 73.7, 71.9, 70.9, 69.7, 68.1, 68.0, 63.3, 61.8, 60.5, 60.4, 60.4, 60.0, 51.0, 31.6, 14.6. 
ESIHRMS calculated for C25H39N15O14Na [M+Na]+, 796.2699; found, 796.2679.  
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          1,3,2′,2′′′,6′′′-Pentazido-4′-O-ethyl-6′-O-(p-toluenesulfonyl)-1,3,2′,2′′′,6′′′-
pentadeamino paromomycin (48), 1,3,2′,2′′′,6′′′-Pentazido-4′-O-ethyl-5′′-O-(p-
toluenesulfonyl)-1,3,2′,2′′′,6′′′-pentadeamino paromomycin (49), and 1,3,2′,2′′′,6′′′-
Pentazido-4′-O-ethyl-6′,5′′-bis-O-(p-toluenesulfonyl)-1,3,2′,2′′′,6′′′-pentadeamino 
paromomycin (50). A stirred solution of 47 (150 mg, 0.19 mmol) in pyridine (1.5 mL) was treated 
with tosyl chloride (92 mg, 0.48 mmol) at RT. After stirring for 18 h at RT the reaction was 
quenched with methanol (10 mL) and concentrated to dryness under reduced pressure. The residue 
was purified by column chromatography on silica gel eluting with CHCl3/MeOH (12:1) to give an 
inseparable 1:0.7 mixture of 48 and 49 (55 mg, 30%, ESIHRMS calculated for C32H45N15O16NaS 
[M+Na]+, 950.2787; found, 950.2798.). This regioisomeric mixture was used for next reaction 
without further purification. Along with the mono-tosylated compounds the di-tosylated 
compound 50 was also obtained (21 mg, 10%).  
          1,3,2′,2′′′,6′′′-Pentazido-4′-O-ethyl-6′,5′′-bis-O-(p-toluenesulfonyl)-1,3,2′,2′′′,6′′′-
pentadeamino paromomycin (50). [α]RTD +58.0 (c 0.25, MeOH). 1H NMR (600 MHz, CD3OD) 
δ 7.81 (d, J = 3.6 Hz, 2H), 7.79 (d, J = 3.6 Hz, 2H), 7.44 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.0 Hz, 
2H), 5.69 (d, J = 3.7 Hz, 1H), 5.28 (d, J = 1.9 Hz, 1H), 5.06 (d, J = 1.4 Hz, 1H), 4.32 – 4.25 (m, 
4H), 4.24 – 4.19 (m, 2H), 4.19 (dd, J1 = 10.7 Hz, J2 = 1.7 Hz, 1H),  4.13 – 4.08 (m, 1H), 3.98 (ddd, 
J1 = 6.6 Hz, J2 = 4.6 Hz, J3 = 1.6 Hz, 1H), 3.92 (t, J = 3.3 Hz, 1H), 3.91 – 3.83 (m, 2H), 3.65 (br 
s, 1H), 3.60 (dd, J1 = 12.8 Hz, J2 = 8.5 Hz, 1H), 3.53 (t, J = 8.9 Hz, 1H), 3.49 (dd, J1 = 9.2 Hz, J2 
= 7.0 Hz, 1H), 3.45 – 3.40 (m, 2H), 3.39 (t, J = 5.0 Hz, 1H), 3.38 – 3.32 (m, 2H), 3.23 (t, J = 9.5 
Hz, 1H), 3.13 (t, J = 9.5 Hz, 1H), 2.92 (dd, J1 = 10.5 Hz, J1 = 3.8 Hz, 1H), 2.45 (s, 3H), 2.43 (s, 
3H), 2.14 (dt, J1 = 12.5 Hz, J2 = 4.5 Hz, 1H), 1.25 (q, J = 12.5 Hz, 1H), 1.06 (t, J = 7.0 Hz, 3H). 
13C NMR (150 MHz, CD3OD) δ 145.2, 145.2, 132.8, 132.8, 129.9, 129.7, 127.8, 127.8, 110.0, 
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98.7, 96.2, 84.3, 79.2, 77.8, 76.4, 76.3, 75.7, 74.1, 73.4, 71.5, 70.2, 69.6, 69.1, 68.8, 68.1, 68.1, 
63.4, 60.3, 60.2, 59.7, 50.9, 29.3, 20.4, 20.3, 14.6. ESIHRMS calculated for C39H59N6O17 [M+H]
+, 
883.3937; found, 883.3917).  
          1,3,2′,2′′′,6′′′-Pentazido-4′-O-ethyl-6′-N-(2-hydroxyethyl)-1,3,2′,2′′′,6′′′-pentadeamino 
neomycin B (51), 1,3,2′,2′′′,6′′′-Pentazido-4′-O-ethyl)-5′′-deoxy-5′′-(2-hydroxyethylamino)-
1,3,2′,2′′′,6′′′-pentadeamino paromomycin (52). The 1:0.7 mixture of 48 and 49 (55 mg, 0.06 
mmol) was dissolved in ethanolamine (0.5 mL) and the solution was stirred for 18 h at RT. Then 
the reaction was concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel eluting with CHCl3/MeOH (3:1) to give an inseparable 1:0.7 mixture 
of 51 and 52 (25 mg, 52 %). The mixture of 51 and 52 was separated by preparative reversed-
phase HPLC [column: Varian Microsorb 100-5 C18, Dynamax 21.4 x 250 mm, 5.0 micron, 
protected by a Varian Dynamax HPLC guard column (21.4 mm, compression module, Microsorb 
Guard-8 C18); temperature: ambient; flow rate: 21.5 mL min-1; mobile phase: (A) water, (B) 
acetonitrile; gradient program: 0-30 min, 11% B, detector wavelength: 220 nm] to give reasonably 
pure samples of 35 (ESIHRMS calculated for C27H45N16O14 [M+H]
+, 817.3301; found, 817.3293) 
and 36 (ESIHRMS calculated for C27H45N16O14 [M+H]
+, 817.3301; found, 817.3296).  These 
compounds were used for the next reactions without further purification and characterization. 
          4′-O-Ethyl-6′-N-(2-hydroxyethyl) neomycin B acetate salt (53). To a stirred solution of 
51 (12 mg, 0.015 mmol) in a mixture of THF and water (1:1, 0.5 mL) was added 1M NaOH (0.25 
mL) and trimethylphosphine (1M in THF, 150 µL). After stirring for 2 h at 60 0C the reaction was 
concentrated to dryness under reduced pressure. The residue was purified by Sephadex C-25 
column chromatography (0.8% ammonium hydroxide). The product-containing fractions were 
concentrated under reduced pressure. The residue was dissolved in 10% AcOH and freeze dried to 
112 
 
 
 
give the desired product 53 as the peracetate salt (6.5 mg, 42%). [α]RTD +46.4 (c 0.22, H2O). 1H 
NMR (600 MHz, D2O) δ 5.85 (d, J = 3.8 Hz, 1H), 5.23 (d, J = 2.4 Hz, 1H), 5.09 (d, J = 1.3 Hz, 
1H), 4.29 (t, J = 5.7 Hz, 1H), 4.19 (dd, J1 = 4.7 Hz, J2 = 2.6 Hz, 1H), 4.11 (t, J = 4.9 Hz, 1H), 4.06 
– 4.01 (m, 2H), 3.91 (t, J = 9.6 Hz, 1H), 3.89 (t, J = 9.7 Hz, 1H), 3.81 (td, J1 = 9.0 Hz, J2 = 2.6 Hz, 
1H), 3.76 – 3.64 (m, 5H), 3.62 (d, J = 1.7 Hz, 1H), 3.58 – 3.51 (m, 2H), 3.49 (t, J = 9.8 Hz, 1H), 
3.39 (d, J = 1.2 Hz, 1H), 3.35 – 3.30 (m, 2H), 3.28 (dd, J1 = 10.6 Hz, J2 = 3.9 Hz, 1H), 3.25 – 3.12 
(m, 5H), 3.07 (t, J = 4.3 Hz, 2H), 2.28 (dt, J1 = 12.5 Hz, J2 = 4.1 Hz, 1H), 1.85 (s, 18H), 1.68 (q, 
J = 12.5 Hz, 1H), 0.99 (t, J = 7.0 Hz, 3H). 13C NMR (150 MHz, D2O) δ 177.3, 110.1, 95.4, 94.8, 
84.6, 81.4, 78.7, 75.3, 75.2, 73.6, 72.4, 70.0, 69.3, 68.8, 67.8, 67.5, 67.2, 60.1, 56.2, 53.1, 50.7, 
49.8, 49.7, 48.2, 48.1, 40.3, 30.0, 20.8, 14.6. ESIHRMS calculated for C27H54N6O14Na [M+Na]
+, 
709.3596; found, 709.3571.  
          4′-O-Ethyl-5′′-deoxy-5′′-(2-hydroxyethylamino) paromomycin acetate salt (54). To a 
stirred solution of 52 (8 mg, 0.01 mmol) in a mixture of THF and water (1:1, 0.5 mL) was added 
1M NaOH (0.25 mL) and trimethylphosphine (1M in THF, 98 µL). After stirring for 2 h at 60 0C 
the reaction was concentrated to dryness under reduced pressure. The residue was purified by 
Sephadex C-25 column chromatography (0.8% ammonium hydroxide). The product-containing 
fractions were concentrated under reduced pressure. The residue was dissolved in 10% AcOH and 
freeze dried to give the desired product 54 as the peracetate salt (4.5 mg, 44%). [α]RTD +59.1 (c 
0.22, H2O). 
1H NMR (600 MHz, D2O) δ 5.58 (d, J = 3.4 Hz, 1H), 5.24 (d, J = 1.1 Hz, 1H), 5.11 
(d, J = 1.4 Hz, 1H), 4.39 (dd, J1 = 7.0 Hz, J2 = 4.9 Hz, 1H), 4.27 (dd, J1 = 4.8 Hz, J2 = 1.1 Hz, 1H), 
4.20 – 4.15 (m, 1H), 4.14 (t, J = 5.1 Hz, 1H), 4.04 (t, J = 3.0 Hz, 1H), 3.91 (t, J = 8.1 Hz, 1H), 
3.90 (t, J = 9.5 Hz, 1H), 3.77 (t, J = 9.1 Hz, 1H), 3.75 – 3.63 (m, 6H), 3.63 – 3.50 (m, 3H), 3.42 – 
3.32 (m, 4H), 3.28 – 3.13 (m, 5H), 3.11 – 3.08 (m, 2H), 2.28 (dt, J1 = 12.6 Hz, J1 = 4.1 Hz, 1H), 
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1.86 (s, 18H), 1.67 (q, J = 12.6 Hz, 1H), 1.00 (t, J = 7.0 Hz, 3H). 13C NMR (150 MHz, D2O) δ 
177.2, 108.8, 95.1, 93.0, 82.3, 77.3, 76.3, 76.1, 75.7, 74.5, 72.6, 71.4, 70.2, 68.4, 68.3, 67.5, 67.3, 
59.4, 56.3, 52.7, 50.7, 49.8, 49.8, 49.3, 48.8, 40.4, 27.6, 20.7, 14.5. ESIHRMS calculated for 
C27H55N6O14 [M+H]
+, 687.3776; found, 687.3758.  
           4′-O-Ethyl-6′-N-(2-hydroxyethyl)-5′′-deoxy-5′′-(2-hydroxyethylamino) neomycin B 
acetate salt (56). Compound 50 (50 mg, 0.05 mmol) was dissolved in ethanolamine (1 mL) and 
the solution was stirred for 18 h at RT. Then the reaction was concentrated under reduced pressure. 
The residue was roughly purified by column chromatography on silica gel eluting with 
CHCl3/MeOH/NH4OH (7:2.5:0.5) to give the desired product 55 (25 mg, 63%) and used for next 
reaction withoput further purification. ESIHRMS calculated for C29H50N17O14 [M+H]
+, 860.3723; 
found, 860.3712.  
          To a stirred solution of 55 (25 mg, 0.01 mmol) in a mixture of THF and water (1:1, 2 mL) 
was added 1M NaOH (1 mL) and trimethylphosphine (1M in THF, 0.3 mL). After stirring for 2 h 
at 60 0C the reaction was concentrated to dryness under reduced pressure. The residue was purified 
by Sephadex C-25 column chromatography (0.6% ammonium hydroxide). The product-containing 
fractions were concentrated under reduced pressure. The residue was dissolved in 10% AcOH and 
freeze dried to give the desired product 56 as the peracetate salt (18 mg, 44%). [α]RTD +48.9 (c 0.9, 
H2O). 
1H NMR (600 MHz, D2O) δ 5.53 (d, J = 2.4 Hz, 1H), 5.07 (br s, 1H), 4.97 (br s, 1H), 4.21 
(t, J = 5.7 Hz, 1H), 4.11 (d, J = 4.7 Hz, 1H), 4.09 – 4.03 (m, 1H), 3.99 (t, J = 5.7 Hz, 1H), 3.96 (d, 
J = 7.0 Hz, 1H), 3.94 – 3.87 (m, 2H), 3.60 (t, J = 9.2 Hz, 1H), 3.58 – 3.49 (m, 5H), 3.49 – 3.35 (m, 
4H), 3.34 – 3.22 (m, 4H), 3.22 – 3.16 (m, 1H), 3.13 – 2.98 (m, 5H), 2.98 – 2.92 (m, 4H), 2.79 (t, 
J = 5.2 Hz, 1H), 2.16 (dt, J1 = 12.6 Hz, J2 = 4.1 Hz, 1H), 1.70 (br s, 21H), 1.55 (q, J = 12.7 Hz, 
1H), 0.85 (t, J = 6.9 Hz, 3H). 13C NMR (150 MHz, D2O) δ 177.0, 108.9, 95.1, 92.4, 82.4, 77.2, 
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76.6, 76.5, 75.2, 72.7, 71.1, 70.8, 70.0, 67.9, 67.3, 67.2, 57.3, 56.1, 56.0, 51.6, 50.6, 49.7, 49.4, 
49.2, 48.4, 47.10, 41.0, 40.2, 27.5, 20.6, 14.3. ESIHRMS calculated for C29H59N7O14Na [M+Na]
+, 
752.4018; found, 752.3990. 
          1,3,6’,2”’,6”’-Penta-N-acetyl-neomycin B (57). A stirred solution of neomycin B sulfate 
salt (10 g, 14.04 mmol) in water (100 mL) was treated with conc. NH4OH (50 mL) then 
concentrated under vacuum to yield neomycin free base as an off white solid. The solid was taken 
up in a mixture of water and methanol (3:1, 120 mL) and treated with 1N HCl (14 mL) at RT 
before acetic anhydride (150 mL) was added dropwise over a period of 6 h followed by stirring 
for 24 h. At this stage LCMS analysis of the reaction mixture showed the incomplete reaction 
consequently the reaction mixture was concentrated under reduced pressure and the residue was 
re-subjected to the identical sequence of reaction conditions, after which LCMS analysis of the 
reaction mixture showed penta-N-acetyl neomycin B as a major product. Finally, the reaction 
mixture was concentrated to dryness under reduced pressure and the residue was purified by 
column chromatography on silica gel eluting with CHCl3/MeOH/NH4OH (5:4:1) to give the 
desired product 57 (4.5 g, 39%). [α]RTD +43.9 (c 1.33, MeOH). 1H NMR (600 MHz, CD3OD) δ 
5.40 (d, J = 3.4 Hz, 1H), 5.31 (d, J = 2.6 Hz, 1H), 4.94 (d, J = 1.8 Hz, 1H), 4.26 (t, J = 5.7 Hz, 
1H), 4.12 – 4.06 (m, 2H), 4.03 – 3.90 (m, 3H), 3.87 (t, J = 3.2 Hz, 1H), 3.79 (dd, J1 = 12.3 Hz, J2 
= 2.6 Hz, 1H), 3.76 – 3.69 (m, 2H), 3.66 (t, J = 9.1 Hz, 1H), 3.62 (dd, J1 = 12.3 Hz, J2 = 4.2 Hz, 
1H), 3.59 (dd, J1 = 14.1 Hz, J2 = 2.6 Hz, 1H), 3.52 (t, J = 9.7 Hz, 1H), 3.50 – 3.36  (m, 5H), 3.30 
– 3.25 (m, 1H), 3.06 (t, J = 9.4 Hz, 1H), 2.56 (dd, J1 = 10.1 Hz, J2 = 3.5 Hz, 1H), 2.01 (s, 3H), 1.97 
(s, 3H), 1.96 (s, 6H), 1.94 (s, 3H), 1.90 (dt, J1 = 12.9 Hz, J2 = 4.3 Hz, 1H), 1.40 (q, J = 12.8 Hz, 
1H). 13C NMR (150 MHz, CD3OD) δ 172.8, 172.5, 172.0, 171.9, 171.6, 108.3, 98.4, 98.1, 84.8, 
81.7, 76.7, 76.3, 74.6, 74.3, 73.1, 72.9, 71.7, 71.0, 69.9, 68.0, 60.5, 56.1, 51.2, 48.4, 48.3, 40.4, 
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39.9, 33.3, 21.9, 21.7, 21.4, 21.3, 21.2. ESIHRMS calculated for C33H57N6O18 [M+H]
+, 825.3729; 
found, 825.3737. 
          1,3,6’,2”’,6”’-Penta-N-acetyl-2’-N-benzyl-2’-N-methyl-6,3’,4’,2”,5”,3”’,4”’-hepta-O-
acetyl-neomycin B (58). To a stirred solution of 57 (400 mg, 0.485 mmol) in methanol (8 mL) 
was added benzaldehyde (74 µL, 0.73 mmol) at RT. After stirring for 0.5 h at RT glacial acetic 
acid (83 µL, 1.45 mmol) and sodium cyanoborohydride (92 mg, 1.45 mmol) were added and 
stirring was continued for 5 h after which 4Å-MS (1.2 g) were added followed by 37% 
formaldehyde solution (0.2 mL), glacial acetic acid (83 µL, 1.45 mmol) and sodium 
cyanoborohydride (92 mg, 1.45 mmol) at RT and stirring was continued for 2 h. The reaction was 
quenched with aq. NaHCO3 (10 mL) at RT. After stirring for 0.5 h the reaction mixture was 
concentrated to dryness under reduced pressure, dissolved in methanol (50 mL), and the precipitate 
was filtered off. The filtrate was concentrated under reduced pressure. The residue was dissolved 
in pyridine (8 mL) and treated with acetic anhydride (8 mL) at RT. The resulting mixture was 
stirred for 18 h before it was concentrated to dryness under reduced pressure and the residue was 
purified by column chromatography on silica gel eluting with CHCl3/MeOH (9:1) to give the 
desired product 58 (370 mg, 62%). [α]RTD +59.3 (c 1.43, MeOH). 1H NMR (600 MHz, CD3OD) δ 
7.38 (d, J = 7.4 Hz, 2H), 7.27 (t, J = 7.6 Hz, 2H), 7.19 (t, J = 7.3 Hz, 1H), 6.01 (d, J = 3.2 Hz, 1H), 
5.46 (d, J = 2.1 Hz, 1H), 5.44 (dd, J1 = 11.0 Hz, J2 = 9.1 Hz, 1H), 4.94 (dd, J1 = 5.0 Hz, J2 = 2.2 
Hz, 1H), 4.91 (t, J = 2.9 Hz, 1H), 4.82 – 4.79 (m, 2H), 4.77 – 4.72 (m, 2H), 4.40 (dd, J1 = 11.9 Hz, 
J2 = 1.9 Hz, 1H), 4.35 (t, J = 5.6 Hz, 1H), 4.22 (td, J1 = 6.0 Hz, J2 = 2.1 Hz, 1H), 4.13 (dd, J1 = 
11.9 Hz, J2 = 5.7 Hz, 1H), 4.11 – 4.04 (m, 4H), 3.98 – 3.89 (m, 3H), 3.68 (d, J = 14.1 Hz, 1H), 
3.59 (dd, J1 = 10.1 Hz, J2 = 8.7 Hz, 1H), 3.42 – 3.35 (m, 3H), 3.26 (dd, J1 = 14.2 Hz, J2 = 2.9 Hz, 
1H), 2.96 (dd, J1 = 11.2 Hz, J2 = 3.2 Hz, 1H), 2.35 (s, 3H), 2.12 (S, 6H), 2.08 (s, 3H), 2.07 (6H), 
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2.02 (s, 3H), 2.01 (s, 6H), 1.99 (s, 3H), 1.97 (s, 3H), 1.94 (s, 3H), 1.86 (s, 3H), 1.82 (dt, J1 = 12.8 
Hz, J2 = 4.4 Hz, 1H), 1.66 (q, J = 12.8 Hz, 1H). 
13C NMR (150 MHz, CD3OD) δ 172.5, 172.3, 
171.7, 171.6, 171.4, 171.1, 170.6, 170.2, 170.1, 169.7, 168.7, 140.4, 128.2, 127.7, 126.3, 107.0, 
98.1, 96.2, 82.5, 79.8, 76.2, 76.0, 74.4, 73.6, 72.2, 71.5, 70.0, 68.5, 66.8, 65.9, 64.6, 64.2, 59.1, 
47.8, 47.7, 47.5, 39.6, 39.0, 39.0, 32.4, 21.7, 21.6, 21.4, 21.3, 21.3, 21.1, 20.0, 19.9, 19.7, 19.4, 
19.3, 19.3, 19.2. ESIHRMS calculated for C55H78N6O25Na [M+Na]
+, 1245.4914; found, 
1245.4906. 
          2’-N-Methyl-neomycin B acetate salt (59). To a stirred suspension of Pd/C (70 mg) in 10% 
AcOH (1.5 mL) was added a solution of 58 (130 mg, 0.11 mmol) in MeOH (3 mL) at RT. The 
reaction mixture was stirred under a hydrogen atmosphere (1 atm) for 2 h, filtered and concentrated 
under reduced pressure. The residue was dissolved in aq. Ba(OH)2 (3 mL) and heated to reflux for 
72 h. The reaction mixture was acidified with 10% AcOH and then purified by Sephadex C-25 
column chromatography (1.2% NH4OH). The product-containing fractions were concentrated 
under reduced pressure and the residue was dissolved in 10% AcOH and freeze dried to give the 
desired product 59 as the peracetate salt (30 mg, 29%). [α]RTD +41.4 (c 0.29, H2O). 1H NMR (600 
MHz, D2O) δ 6.02 (d, J = 3.6 Hz, 1H), 5.20 (d, J = 2.0 Hz, 1H), 5.02 (br s, 1H), 4.24 (d, J = 5.6 
Hz, 1H), 4.11 (dd, J1 = 4.4 Hz, J2 = 2.3 Hz, 1H), 4.04 (t, J = 5.0 Hz, 1H), 3.98 – 3.92 (m, 2H), 3.91 
– 3.84 (m, 2H), 3.74 (t, J = 9.0 Hz, 1H), 3.67 – 3.62 (m, 1H), 3.61 (dd, J1 = 12.5 Hz, J2 = 3.0 Hz, 
1H), 3.55 (br s, 1H), 3.50 – 3.44 (m, 2H), 3.34 – 3.27 (m, 2H), 3.22 (t, J = 9.2 Hz, 1H), 3.25 – 3.12 
(m, 3H), 3.12 – 3.06 (m, 2H), 3.03 (dd, J1 = 13.6 Hz, J2 = 7.1 Hz, 1H), 2.64 (s, 3H), 2.21 (dt, J1 = 
12.7 Hz, J2 = 4.1 Hz, 1H), 1.77 (s, 18H), 1.62 (q, J = 9.2 Hz, 1H). 
13C NMR (150 MHz, D2O) δ 
177.3, 109.1, 95.4, 92.9, 83.9, 81.7, 75.6, 73.7, 73.5, 72.2, 70.4, 70.0, 69.3, 67.7, 67.4, 67.2, 60.0, 
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59.9, 50.7, 49.5, 48.6, 40.3, 39.8, 31.9, 27.8, 20.8. ESIHRMS calculated for C24H49N6O13 [M+H]
+, 
629.3358; found, 629.3331. 
           1,3,6’,2”’,6”’-Penta-N-acetyl-2’-N-ethyl neomycin B (60). To a stirred solution of 57 
(150 mg, 0.18 mmol) in methanol (5 mL) was added a 1M solution of acetaldehyde in DCM (0.3 
mL, 0.3 mmol) at RT. After stirring for 0.5 h at RT glacial acetic acid (31 µL, 0.55 mmol) and 
sodium cyanoborohydride (34 mg, 0.55 mmol) were added to the reaction mixture and stirring was 
continued for 2 h. The reaction was quenched with aq. NaHCO3 (1 mL) at RT. After stirring for 
0.5 h the reaction mixture was concentrated to dryness under reduced pressure and the residue was 
purified by column chromatography on silica gel eluting with CHCl3/MeOH/NH4OH (6:3:1) to 
give the desired product 60 (90 mg, 58%). [α]RTD +58.1 (c 0.94, MeOH). 1H NMR (600 MHz, 
CD3OD) δ 5.44 (d, J = 2.1 Hz, 1H), 5.26 (d, J = 2.5 Hz, 1H), 4.95 (d, J = 1.7 Hz, 1H), 4.30 (t, J = 
5.4 Hz, 1H), 4.11 (dd, J1 = 4.7 Hz, J2 = 2.7 Hz, 1H), 4.11 – 4.08 (m, 1H), 4.04 – 3.97 (m, 2H), 
3.96 – 3.91 (m, 1H), 3.87 (t, J = 3.3 Hz, 1H), 3.83 (dd, J1 = 12.3 Hz, J2 = 2.4 Hz, 1H), 3.77 – 3.66 
(m, 2H), 3.66 – 3.59 (m, 4H), 3.55 (t, J = 9.4 Hz, 1H), 3.52 – 3.43 (m, 3H), 3.40 (dd, J1 = 13.8 Hz, 
J2 = 8.2 Hz, 1H), 3.26 (dd, J1 = 14.2, J2 = 6.5 Hz, 1H), 3.08 (t, J = 9.3 Hz, 1H), 2.94 – 2.80 (m, 
2H), 2.60 (d, J = 10.0 Hz, 1H), 2.02 (s, 3H), 1.97 (s, 3H), 1.96 (s, 6H), 1.94 (s, 3H), 1.90 (dt, J1 = 
12.8 Hz, J2 = 4.2 Hz, 1H), 1.41 (q, J = 12.7 Hz, 1H), 1.16 (t, J = 7.2 Hz, 3H). 
13C NMR (150 MHz, 
CD3OD) δ 172.7, 172.5, 172.0, 171.9, 171.7, 108.5, 98.5, 96.3, 85.5, 82.0, 77.4, 76.6, 74.5, 74.2, 
73.1, 72.0, 71.0, 69.9, 68.0, 61.9, 60.5, 51.2, 49.8, 48.6, 48.5, 41.5, 40.5, 39.9, 33.1, 21.9, 21.7, 
21.4, 21.3, 21.2, 13.3. ESIHRMS calculated for C35H61N6O18 [M+H]
+, 853.4042; found, 853.4028. 
          2’-N-Ethyl-neomycin B acetate salt (61). Compound 60 (75 mg, 0.09 mmol) was dissolved 
in aq. Ba(OH)2 (2 mL) and heated to reflux for 24 h. The reaction mixture was acidified with 10% 
AcOH and then purified by Sephadex C-25 column chromatography (0.8% NH4OH). The product-
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containing fractions were concentrated under reduced pressure and the residue was dissolved in 
10% AcOH and freeze dried to give the desired product 61 as the peracetate salt (22 mg, 25%). 
[α]RTD +32.3 (c 0.7, H2O). 1H NMR (600 MHz, D2O) δ 6.07 (d, J = 3.7 Hz, 1H), 5.23 (d, J = 2.4 
Hz, 1H), 5.06 (d, J = 1.6 Hz, 1H), 4.27 (t, J = 5.5 Hz, 1H), 4.15 (dd, J1 = 4.8 Hz, J2 = 2.5 Hz, 1H), 
4.09 – 4.05 (m, 1H), 4.01 – 3.97 (m, 2H), 3.92 (t, J = 9.6 Hz, 1H), 3.89 (dd, J1 = 10.5 Hz, J2 = 8.8 
Hz, 1H) 3.77 (t, J = 9.0 Hz, 1H), 3.68 – 3.62 (m, 2H), 3.60 – 3.57 (m, 1H), 3.52 – 3.47 (m, 2H), 
3.37 – 3.30 (m, 2H), 3.29 – 3.12 (m, 6H), 3.11 (dd, J1 = 8.4 Hz, J2 = 4.2 Hz, 1H), 3.07 (dd, J1 = 
13.4, J2 = 6.9 Hz, 2H), 2.25 (dt, J1 = 12.6, J2 = 4.1 Hz, 1H), 1.81 (s, 18H), 1.65 (q, J = 12.7 Hz, 
1H), 1.10 (t, J = 7.3 Hz, 3H). 13C NMR (150 MHz, D2O) δ 177.0, 109.3, 95.4, 92.7, 84.1, 81.8, 
75.7, 73.7, 73.0, 72.2, 70.4, 70.0, 69.3, 67.7, 67.5, 67.2, 60.2, 58.4, 50.7, 49.5, 48.6, 41.9, 40.3, 
39.9, 27.8, 20.6, 10.6. ESIHRMS calculated for C25H51N6O13 [M+H]
+, 643.3514; found, 643.3512. 
          1,3,6’,2”’,6”’-Penta-N-acetyl-2’-N-formyl-6,3’,4’,2”,5”,3”’,4”’-hepta-O-acetyl 
neomycin B (62). A stirred solution of 57 (500 mg, 0.61 mmol) in DMF (10 mL) was treated with 
pyridine (0.15 mL) at RT and cooled to 0 0C before acetic formic anhydride (72 µL, 0.91 mmol) 
was added. The reaction mixture was stirred for 4 h at 0 0C before it was quenched with excess of 
MeOH (10 mL). Then the reaction mixture was concentrated to dryness under reduced pressure 
and the residue was dissolved in pyridine (5 mL) and treated with acetic anhydride (5 mL) at RT. 
The resulting mixture was stirred for 18 h before it was concentrated to dryness under reduced 
pressure and the residue was purified by column chromatography on silica gel eluting with 
CHCl3/MeOH (9:1) to give the desired product 62 (450 mg, 65%). [α]RTD +37.6 (c 1.33, MeOH). 
1H NMR (600 MHz, CD3OD) δ 8.06 (s, 1H), 5.74 (d, J = 3.6 Hz, 1H), 5.31 (d, J = 2.7 Hz, 1H), 
5.10  (dd, J1 = 10.5 Hz, J2 = 9.6 Hz,1H), 4.96 – 4.71 (m, 6H), 4.57 (br s, 1H), 4.37 – 4.18 (m, 4H), 
4.16 – 3.95 (m, 6H), 3.61 (d, J = 9.5 Hz, 1H), 3.47 – 3.30 (m, 4H), 2.14 (s, 3H), 2.12 (s, 3H), 2.11 
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(s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H), 2.00 (s, 3H), 1.99 (s, 3H), 1.97 (s, 3H), 1.97 (s, 
3H), 1.93 (s, 3H), 1.89 – 1.86 (m, 4H), 1.63 (q, J = 12.8 Hz, 1H). 13C NMR (150 MHz, CD3OD) 
δ 172.5, 172.3, 171.7, 171.6, 171.5, 171.4, 170.6, 170.4, 170.0, 169.8, 168.8, 162.3, 107.3, 98.0, 
95.6, 82.7, 79.6, 76.7, 75.8, 75.1, 74.6, 72.2, 72.2, 71.0, 69.7, 68.5, 67.7, 65.9, 62.7, 49.6, 47.8, 
47.6, 39.3, 39.0, 32.5, 21.7, 21.4, 21.3, 21.2, 21.1, 20.0, 19.8, 19.4, 19.3, 19.3, 19.3, 19.2. 
ESIHRMS calculated for C48H70N6O26Na [M+Na]
+, 1169.4237; found, 1169.4248. 
          2’-Deamino neomycin B acetate salt (64). A stirred solution of 62 (400 mg, 0.35 mmol) in 
DCM (8 mL) was treated with Et3N (2 mL) at RT before POCl3 (0.3 mL, 3.49 mmol) was added 
dropwise. The reaction mixture was stirred for 4 h at RT before it was quenched with aq. NaHCO3 
(5 mL). Then it was concentrated to dryness under reduced pressure and the residue was dissolved 
in acetone (50 mL). The precipitate was filtered off and the filtrate was concentrated under reduced 
pressure. The residue was dissolved in a mixture of toluene and MeCN (2:1, 16 mL) and the 
solution was degassed by sparging with argon before tris(trimethylsilyl)silane (1 mL, 3.5 mmol) 
was added at RT. Then the reaction temperature was raised to 90 0C and to this heated solution 
was added a solution of AIBN (12 mg, 0.07 mmol) in MeCN (1 mL) dropwise. The resulting 
mixture was stirred for 2 h at 90 0C before it was concentrated to dryness under reduced pressure 
and the residue was purified by column chromatography on silica gel eluting with CHCl3/MeOH 
(9:1) to give crude compound 63 (170 mg, 44%) that was used for next reaction without further 
purification and characterization. 
          Crude compound 64 (100 mg, 0.09 mmol) was dissolved in aq. Ba(OH)2 (2 mL) and heated 
to reflux for 24 h. The reaction mixture was acidified with 10% AcOH and then purified by 
Sephadex C-25 column chromatography (0.8% NH4OH). The product-containing fractions were 
concentrated under reduced pressure and the residue was dissolved in 10% AcOH and freeze dried 
120 
 
 
 
to give the desired product 35 as the peracetate salt (22 mg, 28%). [α]RTD +23.2 (c 0.43, H2O). 1H 
NMR (600 MHz, D2O) δ 5.42 (d, J = 1.7 Hz, 1H), 5.13 (d, J = 3.4 Hz, 1H), 5.07 (d, J = 1.4 Hz, 
1H), 4.26 (t, J = 5.3 Hz, 1H), 3.10 – 4.06 (m, 2H), 4.01 (t, J = 3.1 Hz, 1H), 3.96 (q, J = 9.6 Hz, 
1H), 3.77 – 3.74 (m, 2H), 3.70 – 3.64 (m, 2H), 3.62 – 3.57 (m, 2H), 3.56 – 3.51 (m, 2H), 3.47 (t, 
J = 9.8 Hz, 1H), 3.37 (br s, 1H), 3.26 – 3.17 (m, 3H), 3.15 (dd, J1 = 7.6 Hz, J2 = 3.4 Hz, 1H), 3.14 
– 3.10 (m, 2H), 3.08 (dd, J1 = 13.6 Hz, J2 = 6.4 Hz, 1H), 2.25 (dt, J1 = 12.5 Hz, J2 = 4.2 Hz, 1H), 
2.15 – 2.11 (m, 1H), 1.83 (s, 15H), 1.63 (q, J = 12.6 Hz, 1H), 1.58 – 1.51 (m, 1H). 13C NMR (150 
MHz, D2O) δ 177.2, 108.3, 98.4, 95.7, 82.5, 81.7, 76.4, 76.3, 73.2, 72.0, 71.6, 70.1, 69.7, 67.5, 
67.0, 66.8, 60.8, 50.7, 49.7, 48.6, 40.3, 40.1, 35.9, 27.8, 20.7. ESIHRMS calculated for 
C23H46N5O13 [M+H]
+, 600.3092; found, 600.3076. 
          1,3,2”’,6”’-Tetra-N-acetyl paromomycin (65). A stirred solution of paromomycin sulfate 
salt (10 g, 14.02 mmol) in water (100 mL) was treated with conc. NH4OH (50 mL) then 
concentrated under vacuum to yield paromomycin free base as an off white solid. Then the stirred 
solution of paromomycin free base in a mixture of water and methanol (2:1, 150 mL) was treated 
with 1N HCl (14 mL) at RT before acetic anhydride (150 mL) was added dropwise over a period 
of 6 h and stirring was continued for additional 18 h. LCMS analysis of the reaction mixture 
showed the incomplete reaction. Then the reaction mixture was concentrated under reduced 
pressure and the residue was re-subjected to the identical reaction conditions. After this LCMS 
analysis of the reaction mixture showed tetra-N-acetyl paromomycin as a major product. Then the 
reaction mixture was concentrated under reduced pressure and the residue was purified by column 
chromatography on silica gel eluting with CHCl3/MeOH/NH4OH (5:4:1) to give the desired 
product 65 (4.5 g, 41%). [α]RTD +53.2 (c 0.5, MeOH). 1H NMR (600 MHz, CD3OD) 5.47 (d, J = 
3.6 Hz, 1H), 5.34 (d, J = 2.3 Hz, 1H), 4.94 (d, J = 1.6 Hz, 1H), 4.29 – 4.27 (t, J = 5.6 Hz, 1H), 
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4.11 (dd, J1 = 4.9 Hz, J2 = 2.4 Hz, 1H), 4.09 (br s, 1H), 3.98 – 3.91 (m, 3H), 3.87 (t, J = 3.2 Hz, 
1H), 3.83 (d, J = 9.4 Hz, 1H), 3.78 (dd, J1 = 12.3 Hz, J2 = 2.5 Hz, 1H), 3.76 – 3.70 (m, 1H), 3.70 
– 3.59 (m, 5H), 3.50 (dd, J1 = 13.9 Hz, J2 = 5.0 Hz, 1H), 3.49 (br s, 1H), 3.43 (t, J = 9.5 Hz, 1H), 
3.42 (t, J = 9.6 Hz, 1H), (dd, J1 = 13.6 Hz, J2 = 8.4 Hz, 1H), 3.20 (t, J = 9.3 Hz, 1H), 2.60 (dd, J1 
= 10.2 Hz, J2 = 3.6 Hz, 1H), 1.98 (s, 3H), 1.96 (s, 6H), 1.94 (s, 3H), 1.92 (dt, J1 = 12.7 Hz, J2 = 
4.2 Hz, 1H), 1.41 (q, J = 12.7 Hz, 1H). 13C NMR (150 MHz, CD3OD) δ 172.6, 172.0, 171.9, 171.6, 
108.3, 98.3, 98.0, 85.2, 81.5, 76.4, 76.2, 74.8, 74.3, 73.3, 73.1, 73.1, 70.4, 69.9, 68.0, 61.5, 60.4, 
55.8, 51.2, 48.4, 48.4, 39.9, 33.2, 21.9, 21.7, 21.4, 21.3. ESIHRMS calculated for C31H54N5O18 
[M+H]+, 784.3464; found, 784.3436. 
          1,3,2”’,6”’-Tetra-N-acetyl-2’-N-benzyloxycarbonyl-6,3’,4’,6’,2”,5”,3”’,4”’-octa-O-
acetyl paromomycin (66). A stirred solution of 65 (3.5 g, 4.5 mmol) in a mixture of methanol and 
water (4:1, 50 mL) was treated with Na2CO3 (1.9 g, 17.9 mmol) at RT and cooled to 0 
0C before 
benzylchloroformate (1.0 mL, 6.7 mmol) was added. The reaction was slowly allowed to warm to 
RT and stirring was continued for 18 h. Then the reaction mixture was concentrated to dryness 
under reduced pressure, dissolved in methanol (100 mL), the precipitate was filtered off, and the 
filtrate was concentrated under reduced pressure. The residue was dissolved in pyridine (10 mL) 
and acetic anhydride (10 mL) was added at RT. After stirring for 18 h at RT the reaction mixture 
was concentrated to dryness under vacuum. The residue was purified by column chromatography 
on silica gel eluting with CHCl3/MeOH (19:1) to give the desired product 66 (3.2 g, 57%). [α]RTD 
+59.7 (c 0.33, MeOH). 1H NMR (600 MHz, CD3OD) δ 7.40 – 7.25 (m, 5H), 5.67 (d, J = 3.5 Hz, 
1H), 5.30 (d, J = 2.9 Hz, 1H), 5.12 – 5.02 (m, 3H), 5.01 (t, J = 9.7 Hz, 1H), 4.91 – 4.85 (m, 3H), 
4.72 (br s, 2H), 4.27 (dd, J1 = 12.5 Hz, J2 = 2.8 Hz, 1H), 4.23 – 4.19 (m, 2H), 4.12 (dd, J1 = 12.4 
Hz, J2 = 2.2 Hz, 1H), 4.07 – 3.94 (m, 8H), 3.89 (td, J1 = 10.4 Hz, J2 = 3.7 Hz, 1H), 3.58 (t, J = 9.5 
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Hz, 1H), 3.40 (dd, J1 = 13.7 Hz, J2 = 6.4 Hz, 1H), 3.29 (dd, J1 = 13.3 Hz, J2 = 7.2 Hz, 1H), 2.12 
(s, 3H), 2.11 (s, 3H), 2.08 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H), 2.01 (dt, J1 = 12.8 Hz, 
J2 = 3.5 Hz, 1H), 1.97 (s, 3H), 1.96 (s, 3H), 1.95 (s, 6H), 1.86 (s, 3H), 1.85 (s, 3H), 1.63 (q, J = 
12.8 Hz, 1H). 13C NMR (150 MHz, CD3OD) δ 172.2, 171.6, 171.5, 171.4, 171.3, 170.9, 170.5, 
170.5, 170.4, 169.7, 169.7, 168.7, 156.9, 137.0, 128.1, 127.6, 127.4, 107.2, 98.1, 97.0, 82.7, 79.3, 
78.5, 76.0, 74.8, 74.5, 72.1, 71.3, 68.5, 68.5, 67.7, 66.1, 65.8, 62.3, 61.2, 53.5, 48.4, 48.2, 38.9, 
32.5, 21.7, 21.3, 21.3, 21.1, 21.1, 19.9, 19.6, 19.3, 19.3, 19.3, 19.2, 19.2, 19.2. ESIHRMS 
calculated for C55H75N5O28Na [M+Na]
+, 1276.4496; found, 1276.4452. 
           5-O-[3-O-(2,6-Di-N-acetyl-2,6-dideoxy-3,4-di-O-acetyl-α-L-idopyranosyl)-2,5-O-
acetyl-β-D-ribofuranosyl]-1,3-di-N-benzyloxycarbonyl-6-O-acetyl-2-deoxystreptamine (67). 
To a stirred suspension of Pd/C (800 mg) in 10% AcOH (25 mL) was added a solution of 9 (3.2 g, 
2.5 mmol) in MeOH (25 mL) at RT. The reaction mixture was stirred under a hydrogen atmosphere 
(1 atm) for 2 h, filtered, and concentrated under reduced pressure. The residue was dissolved in 
5% AcOH (25 mL) and cooled to 0 0C before NaNO2 (880 mg, 12.7 mmol) was added slowly 
portion wise. The reaction was slowly allowed to warm to RT and stirring was continued for 18 h. 
Then the reaction was concentrated to dryness under reduced pressure. The residue was purified 
by column chromatography on silica gel eluting with CHCl3/MeOH (9:1) to give the desired 
product 67 (1.1 g, 52%). [α]RTD +29.7 (c 0.66, MeOH). 1H NMR (600 MHz, CD3OD) δ 5.21 (br s, 
1H), 5.05 (d, J = 4.9 Hz, 1H), 4.91 (t, J = 3.0 Hz, 1H), 3.43 – 3.31 (m, 1H), 4.81 (t, J = 10.0 Hz, 
1H), 4.74 (br s, 1H), 4.45 (dd, J1 = 7.5 Hz, J2 = 4.9 Hz, 1H), 4.41 (dd, J1 = 12.0 Hz, J2 = 2.3 Hz, 
1H), 4.29 (dd, J1 = 12.0 Hz, J2 = 6.2 Hz, 1H), 4.20 – 4.15 (m, 1H), 4.11 – 4.07 (m, 1H), 4.07 – 
3.97 (m, 2H), 3.82 – 3.75 (m, 1H), 3.61 (t, J = 9.3 Hz, 1H), 3.43 – 3.31 (m, 3H), 2.11 (s, 3H), 2.10 
(s, 3H), 2.07 (s, 3H), 2.05 – 3.31 (m, 1H), 2.03 (s, 3H), 1.98 (s, 3H), 1.97 (s, 3H), 1.96 (s, 3H), 
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1.93 (s, 3H), 1.85 (s, 3H), 1.48 (q, J = 12.7 Hz, 1H). 13C NMR (150 MHz, CD3OD) δ 172.3, 171.8, 
171.7, 171.4, 171.3, 170.7, 170.4, 169.7, 168.8, 106.9, 97.6, 82.9, 79.5, 75.5, 75.2, 74.2, 73.1, 72.1, 
68.5, 66.0, 63.9, 49.5, 47.7, 47.5, 38.9, 32.6, 21.2, 21.2, 21.1, 21.1, 19.5, 19.5, 19.3, 19.2, 19.1. 
ESIHRMS calculated for C35H52N4O19Na [M+Na]
+, 855.3123; found, 855.3137. 
          1,3,2”’,6”’-Tetra-N-acetyl-2’-benzyloxy-3’,4’-di-O-benzyl-6’-azido-6,2”,5”,3”’,4”’-
penta-O-acetyl-2’,6’-dideamino neomycin B (69). A mixture of thioglycoside 68 (273 mg, 0.48 
mmol) and freshly activated molecular sieves (AW300, 700 mg) was suspended in DCM (5 mL). 
Then DMF (112 µL, 1.44 mmol) was added and the resulting mixture was stirred for 0.25 h at RT 
before it was cooled to 0 0C and stirred for 0.25 h before NIS (110 mg, 0.48 mmol) and TMSOTf 
(87 µL, 0.48 mmol) were added. After stirring for an additional 1 h at 0 0C a solution of glycosyl 
acceptor 67 (200 mg, 0.24 mmol) in DCM (2.5 mL) was added and the reaction mixture was slowly 
allowed to warm to RT and stirring was continued for 24 h. Then the reaction was quenched with 
aq. Na2S2O3 (2 mL) and concentrated to dryness under reduced pressure. The residue was 
dissolved in MeOH (20 mL), the precipitate was filtered off, and the filtrate was concentrated 
under reduced pressure. The residue was purified by column chromatography on silica gel eluting 
with CHCl3/MeOH (19:1) to give the desired product 69 (90 mg, 29%). [α]RTD +86.0 (c 0.83, 
MeOH). 1H NMR (600 MHz, CD3OD) δ 7.41 – 7.16 (m, 15H), 6.05 (d, J = 3.3 Hz, 1H), 5.39 (br 
s, 1H), 5.01 (d, J = 4.6 Hz, 1H), 4.93 – 4.79 (m, 5H), 4.78 (d, J = 1.6 Hz, 1H), 4.74 (d, J = 11.2 
Hz, 1H), 4.73 (s, 1H), 4.69 (d, J = 11.2 Hz, 1H), 4.56 (d, J = 11.1 Hz, 1H), 4.49 (d, J = 9.8 Hz, 
1H), 4.32 (dd, J1 = 6.6 Hz, J2 = 4.8 Hz, 1H), 4.12 – 4.04 (m, 4H), 4.03 – 3.97 (m, 2H), 3.96 – 3.87 
(m, 3H), 3.74 (t, J = 9.3 Hz, 1H), 3.53 (dd, J1 = 13.1 Hz, J2 = 1.7 Hz, 1H), 3.47 (dd, J1 = 9.8 Hz, 
J2 = 3.5 Hz, 1H), 3.46 – 3.38 (m, 3H), 3.31 (dd, J1 = 13.5 Hz, J2 = 7.4 Hz, 1H), 2.10 (s, 6H), 2.09 
(s, 3H), 2.03 (s, 3H), 1.97 (s, 3H), 1.96 (s, 6H), 1.88 (s, 3H), 1.86 (s, 3H), 1.82 (dt, J1 = 12.9 Hz, 
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J2 = 4.4 Hz, 1H), 1.73 (q, J = 12.8 Hz, 1H). 
13C NMR (150 MHz, CD3OD) δ 172.3, 171.6, 171.4, 
171.3, 171.2, 170.6, 170.5, 169.7, 168.7, 138.7, 138.6, 138.3, 127.9, 127.8, 127.5, 127.4, 127.4, 
127.3, 127.2, 127.1, 107.5, 97.7, 94.6, 82.5, 81.3, 80.1, 79.3, 78.2, 76.0, 75.8, 75.6, 75.2, 74.6, 
74.0, 73.1, 72.3, 70.6, 68.5, 65.9, 63.7, 51.2, 47.9, 47.7, 47.5, 39.0, 32.3, 22.0, 21.35, 21.3, 21.1, 
20.0, 19.6, 19.4, 19.3, 19.2. ESIHRMS calculated for C62H79N7O23Na [M+Na]
+, 1312.5125; found, 
1312.5109. 
          2’-Deamino-2’-hydroxy neomycin B acetate salt (70). To a stirred suspension of Pd/C (90 
mg) in 10% AcOH (1.5 mL) was added a solution of 69 (45 mg, 0.03 mmol) in dioxane (1.5 mL) 
at RT. The reaction mixture was stirred under a hydrogen atmosphere (45 atm) for 12 h, filtered 
and concentrated under reduced pressure. The residue was dissolved in 2.5M NaOH (1.5 mL) and 
heated to reflux for 3 h. The reaction mixture was acidified with 10% AcOH and then purified by 
Sephadex C-25 column chromatography (1.0% NH4OH). The product-containing fractions were 
concentrated under reduced pressure and the residue was dissolved in 10% AcOH and freeze dried 
to give the desired product 70 as the peracetate salt (11 mg, 34%). [α]RTD +35.3 (c 0.73, H2O). 
[α]RTD +59.7 (c 0.31, H2O). 1H NMR (600 MHz, D2O) δ 5.43 (d, J = 3.9 Hz, 1H), 5.13 (d, J = 2.1 
Hz, 1H), 5.02 (br s, 1H), 4.26 (t, J = 5.6 Hz, 1H), 4.11 (dd, J1 = 4.7 Hz, J2 = 2.4 Hz, 1H), 4.06 – 
4.01 (m, 1H), 3.96 (t, J = 2.9 Hz, 1H), 3.95 – 3.90 (m, 1H), 3.76 (t, J = 9.7 Hz, 1H), 3.69 – 3.62 
(m, 2H), 3.60 (dd, J1 = 12.4 Hz, J2 = 3.1 Hz, 1H), 3.54 (br s, 1H), 3.52 (t, J = 9.6 Hz, 1H), 3.49 
(dd, J1 = 12.6 Hz, J2 = 5.1 Hz, 1H), 3.46 (t, J = 9.8 Hz, 1H), 3.38 (dd, J1 = 10.0 Hz, J2 = 3.9 Hz, 
1H), 3.34 – 3.27 (m, 2H), 3.19 – 3.05 (m, 5H), 3.00 (dd, J1 = 13.6 Hz, J2 = 6.2 Hz, 1H), 2.21 (dt, 
J1 = 12.7 Hz, J2 = 4.1 Hz, 1H), 1.78 (s, 15H), 1.60 (dd, J = 12.7 Hz, 1H). 
13C NMR (150 MHz, 
D2O) δ 177.0, 108.4, 97.1, 95.3, 82.3, 81.5, 75.9, 75.7, 73.3, 72.1, 71.3, 70.6, 70.4, 70.0, 68.8, 
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67.4, 67.0, 60.5, 50.6, 49.5, 48.4, 40.2, 40.0, 27.7, 20.5. ESIHRMS calculated for C23H45N5O14Na 
[M+Na]+, 638.2861; found, 638.2875.    
          1,3,6’,2”’,6”’-Penta-N-acetyl-1,3,6’,2”’,6”’-penta-N-tert-butoxycarbonyl-2’-azido-
6,3’,4’,2”,5”,3”’,4”’-hepta-O-acetyl-2’-deamino neomycin B (71). A stirred solution of 
neomycin B sulfate salt (10 g, 14.04 mmol) in water (100 mL) was treated with conc. NH4OH (50 
mL) then concentrated under vacuum to yield neomycin free base as an off white solid. This solid 
was taken up in a mixture of water and methanol (3:1, 120 mL) and treated with 1N HCl (14 mL) 
at RT before acetic anhydride (150 mL) was added dropwise over a period of 6 h and stirring was 
continued for additional 24 h. At this stage LCMS analysis of the reaction mixture showed 
incomplete reaction, consequently the reaction mixture was concentrated under reduced pressure 
and the residue was re-subjected to the same sequence of reaction conditions after which LCMS 
analysis of the reaction mixture showed penta-N-acetyl neomycin B as a major product. The 
reaction mixture was concentrated to dryness under reduced pressure and the residue was dissolved 
in MeOH (200 mL), the precipitate was filtered off and the filtrate was concentrated under reduced 
pressure. The residue was dissolved in a mixture methanol and water (2:3, 120 mL), treated with 
potassium carbonate (5.8 g, 42.1 mmol) at RT and cooled to 0 0C before imidazole-1-sulfonyl 
azide hydrochloride (4.4 g, 21.0 mmol) and copper (II) sulfate (224 mg, 1.4 mmol) were added. 
The reaction mixture was allowed to warm to RT and stirring was continued for 18 h after which 
it was concentrated to dryness under reduced pressure, dissolved in methanol (200 mL), the 
precipitate was filtered off and the filtrate concentrated under reduced pressure. The residue was 
dissolved in THF (100 mL) and (Boc)2O (45.9 g, 210.6 mmol) and DMAP (8.6 g, 70.2 mmol) 
were added followed by heating to reflux for 48 h. The reaction mixture was concentrated to 
dryness under reduced pressure and the residue was dissolved in pyridine (50 mL) and treated with 
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acetic anhydride (50 mL) at RT. The resulting mixture was stirred for 18 h before it was 
concentrated to dryness under reduced pressure. The residue was dissolved in ethyl acetate (500 
mL) and washed with water (2 x 250 mL) and brine (2 x 250 mL). The organic layer was dried 
over Na2SO4, concentrated under reduced pressure, and the residue was purified by column 
chromatography on silica gel eluting with ethyl acetate/hexane (1:1) to give the desired product 71 
(3 g, 13%). [α]RTD +56.2 (c 0.4, MeOH). ESIHRMS calculated for C72H108N8O35Na [M+Na]+, 
1667.6815; found, 1667.6802. 
          1,3,6’,2”’,6”’-Penta-N-tert-butoxycarbonyl neomycin B (72). To a stirred solution of 71 
(1.1 g, 0.67 mmol) in MeOH (11 mL) was added NaOMe (867 mg, 16.1 mmol) at RT followed by 
stirring for 3 h. The reaction mixture was neutralized with Amberlyst (H-form), filtered, and 
concentrated under reduced pressure. Then the residue was dissolved in a mixture of THF and 
water (2:1, 15 mL) and trimethylphosphine (1M in THF, 1.3 mL) was added at RT. After stirring 
for 3 h at 60 0C the reaction mixture was concentrated to dryness under reduced pressure and the 
residue was purified by column chromatography on silica gel eluting with CHCl3/MeOH (7:1) to 
give the desired product 72 (400 mg, 53%). [α]RTD +30.0 (c 0.48, MeOH). ESIHRMS calculated 
for C48H87N6O23 [M+H]
+, 1115.5823; found, 1115.5814. 
          1,3,6’,2”’,6”’-Penta-N-tert-butoxycarbonyl-2’-N-(2-azidoacetyl) neomycin B (74). To a 
stirred solution of 72 (150 mg, 0.13 mmol) and 2-azidoacetic acid 73 (27 mg, 0.27 mmol) in THF 
(1.5 mL) was added EDC.HCl (51 mg, 0.27 mmol), HOBt (36 mg, 0.27 mmol), and DIPEA (116 
µL, 0.67 mmol) at RT. After stirring for 2 h at RT the reaction mixture was quenched with 1N HCl 
(30 mL) and extracted with DCM (3 x 30 mL).  The combined DCM layer was dried over Na2SO4 
and concentrated under reduced pressure and the residue was purified by column chromatography 
on silica gel eluting with CHCl3/MeOH (9:1) to give the desired product 74 (110 mg, 68%). [α]RTD 
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+32.3 (c 1.16, MeOH). ESIHRMS calculated for C50H87N9O24Na [M+Na]
+, 1220.5762; found, 
1220.5723. 
          2’-N-(2-Aminoacetyl) neomycin B acetate salt (75). To a stirred suspension of Pd/C (50 
mg) in 10% AcOH (1 mL) was added a solution of 74 (100 mg, 0.08 mmol) in dioxane (2 mL) at 
RT. The reaction mixture was stirred under a hydrogen atmosphere (1 atm) for 2 h, filtered and 
concentrated under reduced pressure. The residue was dissolved in a mixture of 
TFA/Water/Anisole (90:7:3, 2 mL) and stirred for 1 h at RT before it was concentrated to dryness 
under reduced pressure. The residue was purified by Sephadex C-25 column chromatography 
(0.8% NH4OH). The product-containing fractions were concentrated under reduced pressure and 
the residue was dissolved in 10% AcOH and freeze dried to give the desired product 75 as the 
peracetate salt (40 mg, 48%). [α]RTD +34.7 (c 0.96, H2O). 1H NMR (600 MHz, D2O) δ 5.62 (d, J 
= 3.8 Hz, 1H), 4.86 (br s, 1H), 4.85 (br s, 1H), 4.12 (dd, J1 = 6.9 Hz, J2 = 4.7 Hz, 1H), 4.03 (d, J = 
4.3 Hz, 1H), 3.92 – 3.87 (m, 1H), 3.83 (t, J = 2.8 Hz, 1H), 3.73 (dd, J1 = 10.7 Hz, J2 = 3.8 Hz, 1H), 
3.69 – 3.65 (m, 1H), 3.64 (t, J = 9.5 Hz, 1H), 3.52 – 3.41 (m, 6H), 3.40 (d, J = 2.0 Hz, 1H), 3.33 – 
3.24 (m, 2H), 3.17 (br s, 1H), 3.14 – 2.99 (m, 4H), 2.98 – 2.90 (m, 2H), 2.86 (dd, J1 = 13.5 Hz, J2 
= 7.1 Hz, 1H), 2.06 (dt, J1 = 12.5 Hz, J2 = 4.0 Hz, 1H), 1.63 (s, 18H), 1.48 (dd, J = 12.7 Hz, 2H). 
13C NMR (150 MHz, D2O) δ 177.4, 167.0, 109.4, 95.3, 94.9, 84.0, 81.0, 75.2, 73.1, 73.1, 72.0, 
70.9, 70.0, 69.5, 68.7, 67.3, 66.9, 60.2, 52.3, 50.6, 49.6, 48.7, 40.3, 40.1, 40.1, 27.6, 20.9. 
ESIHRMS calculated for C25H50N7O14 [M+H]
+, 672.3416; found, 672.3400. 
           1,3,2”’,6”’-Tetra-N-acetyl-2’-N-benzyl-2’-N-methyl paromomycin (78). To a stirred 
solution of 65 (500 mg, 0.42 mmol) in methanol (10 mL) was added benzaldehyde (64 µL, 0.63 
mmol) at RT. After stirring for 0.5 h at RT glacial acetic acid (48 µL, 1.07 mmol) and sodium 
cyanoborohydride (68 mg, 1.07 mmol) were added and stirring was continued for 18 h after which 
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4Å-MS (2 g) were added followed by 37% formaldehyde solution (103 µL, 1.26 mmol), glacial 
acetic acid (48 µL, 1.07 mmol) and sodium cyanoborohydride (68 mg, 1.07 mmol) at RT and 
stirring was continued for 2 h. The reaction was quenched with aq. NaHCO3 (10 mL) at RT. After 
stirring for 0.5 h the reaction mixture was concentrated to dryness under reduced pressure, 
dissolved in methanol (50 mL), and the precipitate was filtered off. The filtrate was concentrated 
under reduced pressure and the residue was purified by column chromatography on silica gel 
eluting with CHCl3/MeOH/NH4OH (6:3:1) to give the desired product 78 (156 mg, 42%). [α]RTD 
+36.3 (c 0.27, MeOH). 1H NMR (600 MHz, CD3OD) δ 7.42 (d, J = 7.4 Hz, 2H), 7.33 (t, J = 7.5 
Hz, 2H), 7.26 (t, J = 7.3 Hz, 1H), 5.80 (d, J = 2.9 Hz, 1H), 5.40 (br s, 1H), 4.93 (d, J = 1.6 Hz, 
1H), 4.50 (dd, J1 = 7.2 Hz, J2 = 4.5 Hz, 1H), 4.12 (d, J = 4.4 Hz, 1H), 4.10 – 4.00 (m, 5H), 3.97 – 
3.92 (m, 1H), 3.91 (dd, J1 = 10.8 Hz, J2 = 8.5 Hz, 1H), 4.87 (t, J = 3.4 Hz, 1H), 3.97 – 3.83 (m, 
1H), 3.83 – 3.78 (m, 2H), 3.78 – 3.71 (m, 2H), 3.69 (dd, J1 = 12.1 Hz, J2 = 3.1 Hz, 1H), 3.65 (t, J 
= 5.8 Hz, 1H), 3.63 – 3.57 (m, 2H), 3.54 (dd, J1 = 13.9 Hz, J2 = 5.1 Hz, 1H), 3.49 (br s, 1H), 3.37 
(dd, J1 = 13.9 Hz, J2 = 8.4 Hz, 1H), 3.24 (t, J = 9.0 Hz, 1H), 2.80 (dd, J1 = 11.0 Hz, J2 = 2.9 Hz, 
1H), 2.58 (s, 3H), 1.98 (s, 3H), 1.97 (s, 3H), 1.96 (s, 3H), 1.94 (s, 3H), 1.91 – 1.86 (dt, J1 = 12.8 
Hz, J2 = 4.2 Hz), 1.43 (q, J = 12.7 Hz, 1H). 
13C NMR (150 MHz, CD3OD) δ 172.6, 172.0, 171.9, 
171.2, 138.0, 129.1, 128.0, 127.2, 104.9, 98.1, 94.9, 85.5, 81.5, 76.2, 74.4, 73.3, 73.3, 72.6, 71.8, 
71.5, 69.9, 69.1, 67.9, 65.4, 61.7, 59.9, 58.8, 51.1, 49.8, 48.0, 39.8, 38.6, 33.0, 21.8, 21.6, 21.3, 
21.3. ESIHRMS calculated for C39H62N5O18 [M+H]
+, 888.4090; found, 888.4103. 
          2’-N-Methyl paromomycin acetate salt (79). To a stirred suspension of Pd(OH)2/C (70 
mg) in MeOH (0.5 mL) was added a solution of 78 (70 mg, 0.08 mmol) in MeOH (2.0 mL) at RT. 
The reaction mixture was stirred under a hydrogen atmosphere (1 atm) for 1 h, filtered and 
concentrated under reduced pressure. The residue was dissolved in 2.5M NaOH (2 mL) and heated 
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to reflux for 15 h. The reaction mixture was acidified with 10% AcOH and then purified by 
Sephadex C-25 column chromatography (0.4% NH4OH). The product-containing fractions were 
concentrated under reduced pressure and the residue was dissolved in 10% AcOH and freeze dried 
to give the desired product 79 as the peracetate salt (20 mg, 27%). [α]RTD +39.1 (c 0.67, H2O). 1H 
NMR (600 MHz, D2O) δ 5.74 (d, J = 3.6 Hz, 1H), 5.17 (d, J = 3.2 Hz, 1H), 5.08 (br s, 1H), 4.29 
(t, J = 5.6 Hz, 1H), 4.12 – 4.05 (m, 2H), 4.01 (t, J = 2.9 Hz, 1H), 3.99 – 3.95 (m, 1H), 3.88 (t, J = 
9.5 Hz, 1H), 3.78 (t, J = 9.6 Hz, 1H), 3.73 (t, J = 9.1 Hz, 1H), 3.73 – 3.69 (m, 1H), 3.66 (dd, J1 = 
12.3 Hz, J2 = 2.7 Hz, 1H), 3.60 (d, J = 1.8 Hz, 1H), 3.73 – 3.69 (m, 4H), 3.42 – 3.34 (m, 2H), 3.28 
(t, J = 9.1 Hz, 1H), 3.24 – 3.10 (m, 4H), 2.66 (s, 3H), 2.27 (dt, J1 = 12.5 Hz, J2 = 4.0 Hz, 1H), 1.82 
(s, 15H), 1.64 (q, J = 12.6 Hz, 1H). 13C NMR (150 MHz, D2O) δ 177.3, 109.1, 95.5, 93.6, 83.4, 
81.5, 76.5, 75.3, 73.7, 73.2, 71.9, 70.1, 69.1, 68.6, 67.5, 67.1, 60.4, 60.1, 60.0, 50.7, 49.4, 49.0, 
40.3, 31.8, 27.9, 20.7. ESIHRMS calculated for C24H48N5O14 [M+H]
+, 630.3198; found, 630.3180. 
          1,3,2”’,6”’-Tetra-N-acetyl-2’-N-ethyl paromomycin (80). To a stirred solution of 65 (150 
mg, 0.19 mmol) in methanol (5 mL) was added a 1M solution of acetaldehyde in DCM (0.3 mL, 
0.3 mmol) at RT. After stirring for 0.5 h at RT glacial acetic acid (33 µL, 0.57 mmol) and sodium 
cyanoborohydride (36 mg, 0.57 mmol) were added to the reaction mixture and stirring was 
continued for 2 h. The reaction was quenched with aq. NaHCO3 (1 mL) at RT. After stirring for 
0.5 h the reaction mixture was concentrated to dryness under reduced pressure, and the residue 
was purified by column chromatography on silica gel eluting with CHCl3/MeOH/NH4OH (6:3:1) 
to give the desired product 80 (100 mg, 64%). [α]RTD +46.5 (c 1.0, MeOH). 1H NMR (600 MHz, 
CD3OD) δ 5.51 (br s, 1H), 5.28 (d, J = 2.3 Hz, 1H), 4.94 (d, J = 1.4 Hz, 1H), 4.31 (t, J = 5.6 Hz, 
1H), 4.12 (dd, J1 = 4.3 Hz, J2 = 2.3 Hz, 1H), 4.09 (br s, 1H), 4.02 – 3.98 (m, 1H), 3.97 – 3.91 (m, 
2H), 3.87 (t, J = 3.2 Hz, 1H), 3.82 (br s, 1H), 3.80 (br s, 1H), 3.76 – 3.70 (m, 1H), 3.69 – 3.58 (m, 
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6H), 3.52 – 3.44 (m, 3H), 3.40 (dd, J1 = 13.8 Hz, J2 = 8.3 Hz, 1H), 3.25 (t, J = 9.2 Hz, 1H), 2.91 
(br d, J = 6.7 Hz, 2H), 2.64 (br d, J = 9.3 Hz, 1H), 1.98 (s, 3H), 1.96 (s, 3H), 1.96 (s, 3H), 1.94 (s, 
3H), 1.90 (dt, J1 = 12.8 Hz, J2 = 4.3 Hz, 1H), 1.43 (q, J = 12.8 Hz, 1H), 1.17 (t, J = 7.1 Hz, 3H). 
13C NMR (150 MHz, CD3OD) δ 172.6, 172.0, 171.9, 171.7, 108.3, 98.4, 96.2, 85.8, 81.9, 76.8, 
76.3, 74.4, 74.1, 73.2, 72.9, 71.5, 70.6, 69.9, 67.9, 61.6, 61.3, 60.5, 51.1, 48.6, 48.4, 41.6, 39.8, 
33.0, 21.9, 21.7, 21.4, 21.3, 13.2. ESIHRMS calculated for C33H58N5O18 [M+H]
+, 812.3777; 
found, 812.3814. 
          2’-N-Ethyl-paromomycin acetate salt (81). Compound 80 (90 mg, 0.11 mmol) was 
dissolved in 2.5M NaOH (2 mL) and heated to reflux for 9 h. The reaction mixture was acidified 
with 10% AcOH and then purified by Sephadex C-25 column chromatography (0.6% NH4OH). 
The product-containing fractions were concentrated under reduced pressure and the residue was 
dissolved in 10% AcOH and freeze dried to give the desired product 81 as the peracetate salt (46 
mg, 43%). [α]RTD +50.0 (c 0.46, H2O). 1H NMR (600 MHz, D2O) δ 5.77 (d, J = 3.5 Hz, 1H), 5.11 
(d, J = 2.3 Hz, 1H), 5.00 (br s, 1H), 4.24 (t, J = 5.7 Hz, 1H), 4.06 – 4.03 (m, 1H), 4.03 – 4.00 (m, 
1H), 3.94 (t, J = 2.6 Hz, 1H), 4.06 – 4.03 (m, 1H), 3.82 (t, J = 9.5 Hz, 1H), 3.74 (t, J = 9.6 Hz, 
1H), 3.67 (t, J = 9.2 Hz, 1H), 3.63 (d, J = 11.7 Hz, 1H), 3.59 (dd, J1 = 12.4 Hz, J2 = 2.4 Hz, 1H), 
3.52 (d, J = 1.6 Hz, 1H), 3.51 – 3.41 (m, 4H), 3.33 – 3.25 (m, 2H), 3.22 (t, J = 9.2 Hz, 1H), 3.17 
(dd, J1 = 10.5 Hz, J2 = 3.6 Hz, 1H), 3.13 (dd, J1 = 13.7 Hz, J2 = 6.8 Hz, 1H), 3.10 – 2.97 (m, 4H), 
2.19 (dt, J1 = 12.7 Hz, J2 = 4.0 Hz, 1H), 1.75 (s, 15H), 1.58 (q, J = 12.7 Hz, 1H), 1.05 (t, J = 7.2 
Hz, 3H). 13C NMR (150 MHz, D2O) δ 177.3, 109.1, 95.3, 93.0, 83.7, 81.2, 75.1, 74.9, 73.5, 73.2, 
71.8, 70.0, 69.0, 68.4, 67.4, 67.0, 60.0, 60.0 58.6, 50.6, 49.4, 48.9, 41.7, 40.2, 27.7, 20.7, 10.4. 
ESIHRMS calculated for C25H50N5O14 [M+H]
+, 644.3354; found, 644.3347. 
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           1,3,2”’,6”’-Tetra-N-acetyl-2’-N-propyl paromomycin (82). To a stirred solution of 65 
(150 mg, 0.19 mmol) in methanol (5 mL) was added a 1M solution of propionaldehyde in DCM 
(0.3 mL, 0.3 mmol) at RT. After stirring for 0.5 h at RT glacial acetic acid (33 µL, 0.57 mmol) 
and sodium cyanoborohydride (36 mg, 0.57 mmol) were added to the reaction mixture and stirring 
was continued for 3 h. The reaction was quenched with aq. NaHCO3 (1 mL) at RT. After stirring 
for 0.5 h the reaction mixture was concentrated to dryness under reduced pressure, and the residue 
was purified by column chromatography on silica gel eluting with CHCl3/MeOH/NH4OH (6:3:1) 
to give the desired product 82 (110 mg, 70%). [α]RTD +38.6 (c 0.65, MeOH). 1H NMR (600 MHz, 
CD3OD) δ 5.55 (br s, 1H), 5.28 (d, J = 2.1 Hz, 1H), 4.94 (br s, 1H), 4.32 (t, J = 5.5 Hz, 1H), 4.14 
– 4.06 (m, 2H), 4.03 – 3.98 (m, 1H), 3.97 – 3.90 (m, 2H), 3.86 (t, J = 3.1 Hz, 1H), 3.83 – 3.78 (m, 
2H), 3.76 – 3.70 (m, 1H), 3.69 – 3.57 (m, 6H), 3.53 – 3.44 (m, 3H), 3.39 (dd, J1 = 13.8 Hz, J2 = 
8.3 Hz, 1H), 3.24 (t, J = 9.2 Hz, 1H), 2.83 (br s, 2H), 2.66 (br s, 1H), 1.97 (s, 3H), 1.96 (s, 3H), 
1.96 (s, 3H), 1.94 (s, 3H), 1.90 (dt, J1 = 12.8 Hz, J2 = 4.2 Hz, 1H), 3.83 – 3.78 (m, 2H), 1.44 (q, J 
= 12.8 Hz, 1H), 0.95 (t, J = 7.4 Hz, 3H). 13C NMR (150 MHz, CD3OD) δ 172.6, 172.0, 171.9, 
171.7, 108.2, 98.4, 95.8, 85.8, 81.9, 76.6, 76.5, 74.4, 74.0, 73.1, 72.8, 71.4, 70.6, 70.0, 67.9, 61.6, 
61.2, 60.5, 51.0, 49.2, 48.6, 48.3, 39.7, 33.0, 22.0, 21.9, 21.7, 21.4, 21.3, 10.7. ESIHRMS 
calculated for C34H60N5O18 [M+H]
+, 826.3933; found, 826.3929.  
          2’-N-Propyl paromomycin acetate salt (83). Compound 82 (110 mg, 0.13 mmol) was 
dissolved in 2.5M NaOH (2.5 mL) and heated to reflux for 15 h. The reaction mixture was acidified 
with 10% AcOH and then purified by Sephadex C-25 column chromatography (0.6% NH4OH). 
The product-containing fractions were concentrated under reduced pressure, and the residue was 
dissolved in 10% AcOH and freeze dried to give the desired product 83 as the peracetate salt (63 
mg, 49%). [α]RTD +54.3 (c 0.6, H2O). 1H NMR (600 MHz, D2O) δ 5.76 (d, J = 3.5 Hz, 1H), 5.07 
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(d, J = 2.6 Hz, 1H), 4.97 (br s, 1H), 4.21 (t, J = 5.7 Hz, 1H), 4.02 – 3.97 (m, 2H), 3.91 (t, J = 2.9 
Hz, 1H), 3.88 – 3.84 (m, 1H), 3.80 (t, J = 9.6 Hz, 1H), 3.71 (t, J = 9.6 Hz, 1H), 3.64 – 3.58 (m, 
2H), 3.56 (dd, J1 = 12.4 Hz, J2 = 2.6 Hz, 1H), 3.49 (d, J = 1.4 Hz, 1H), 3.48 – 3.38 (m, 4H), 3.29 
– 3.22 (m, 2H), 3.19 (t, J = 9.2 Hz, 1H), 3.14 (dd, J1 = 10.4 Hz, J2 = 3.6 Hz, 1H), 3.11 (dd, J1 = 
13.7 Hz, J2 = 6.9 Hz, 1H), 3.08 – 3.00 (m, 2H), 2.95 – 2.81 (m, 2H), 2.16 (dt, J1 = 12.6 Hz, J2 = 
4.1 Hz, 1H), 1.72 (s, 15H), 1.56 (q, J = 12.6 Hz, 1H), 1.50 – 1.34 (m, 2H), 0.66 (t, J = 7.4 Hz, 3H). 
13C NMR (150 MHz, D2O) δ 177.2, 109.1, 95.2, 92.9, 83.7, 81.2, 75.1, 74.8, 73.5, 73.2, 71.8, 70.0, 
69.0, 68.4, 67.4, 67.0, 60.0, 59.9, 58.8, 50.6, 49.4, 48.9, 47.7, 40.2, 27.7, 20.7, 18.9, 9.9. ESIHRMS 
calculated for C26H52N5O14 [M+H]
+, 658.3511; found, 658.3502. 
          1,3,2”’,6”’-Tetra-N-acetyl-2’-deamino-2’-benzyloxy-3’,4’,6’-tri-O-benzyl-
6,2”,5”,3”’,4”’-penta-O-acetyl paromomycin (85). A mixture of thioglycoside 84 (213 mg, 0.24 
mmol) and freshly activated molecular sieves (AW300, 600 mg) was suspended in DCM (5 mL). 
Then DMF (111 µL, 1.44 mmol) was added and the resulting mixture was stirred for 0.25 h at RT 
before it was cooled to 0 0C and stirred for 0.25 h before NIS (83 mg, 0.36 mmol) and TMSOTf 
(65 µL, 0.36 mmol) were added. After stirring for additional 0.5 h at 0 0C a solution of glycosyl 
acceptor 67 (200 mg, 0.24 mmol) in DCM (2.5 mL) was added to the reaction mixture and the 
reaction mixture was slowly allowed to warm to RT and stirring was continued for 18 h. Then the 
reaction was quenched with aq. Na2S2O3 (2 mL) and concentrated to dryness under reduced 
pressure. The residue was dissolved in MeOH (20 mL), precipitate was filtered off, and the filtrate 
was concentrated under reduced pressure. The residue was purified by column chromatography on 
silica gel eluting with CHCl3/MeOH (19:1) to give the desired product 85 (150 mg, 46 %). [α]RTD 
+134.5 (c 0.47, MeOH). 1H NMR (600 MHz, CD3OD) δ 7.40 – 7.31 (m, 6H), 7.31 – 7.17 (m, 
12H), 7.13 (d, J = 6.5 Hz, 2H), 6.01 (d, J = 3.3 Hz, 1H), 5.41 (br s, 1H), 5.02 (d, J = 4.4 Hz, 1H), 
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4.94 – 4.80 (m, 4H), 4.77 (d, J = 8.8 Hz, 2H), 4.74 (t, J = 10.7 Hz, 2H), 4.66 (d, J = 11.2 Hz, 1H), 
4.57 (d, J = 11.7 Hz, 1H), 4.54 – 4.48 (m, 2H), 4.46 (d, J = 10.8 Hz, 1H), 4.34 (t, J = 5.8 Hz, 1H), 
4.17 – 3.96 (m, 7H), 3.93 (t, J = 8.9 Hz, 1H), 3.89 (t, J = 9.0 Hz, 2H), 3.78 – 3.71 (m, 2H), 3.67 
(dd, J1 = 10.6 Hz, J2 = 4.6 Hz, 1H), 3.51 (t, J = 9.5 Hz, 1H), 3.46 (dd, J1 = 9.7 Hz, J2 = 3.3 Hz, 
1H), 3.40 (dd, J1 = 13.7 Hz, J2 = 6.0 Hz, 1H), 3.34 – 3.24 (m, 1H), 2.10 (s, 9H), 2.00 (s, 3H), 1.98 
(s, 3H), 1.96 (s, 3H), 1.95 (s, 3H), 1.85 (s, 3H), 1.83 (s, 3H), 1.79 (dt, J1 = 12.8 Hz, J2 = 4.4 Hz, 
1H), 1.65 (q, J = 12.8 Hz, 1H). 13C NMR (150 MHz, CD3OD) δ 172.3, 171.6, 171.4, 171.3, 171.2, 
170.6, 170.5, 169.6, 168.7, 138.7, 138.4, 137.9, 128.1, 127.9, 127.9, 127.8, 127.6, 127.5, 127.5, 
127.4, 127.2, 127.1, 127.0, 107.4, 97.7, 94.7, 82.6, 81.5, 80.0, 79.2, 77.7, 76.1, 75.4, 75.4, 75.1, 
74.5, 74.1, 73.4, 73.4, 73.2, 72.2, 70.9, 70.0, 68.5, 65.9, 63.5, 47.7, 47.5, 38.9, 32.4, 21.9, 21.3, 
21.3, 21.1, 20.0, 19.7, 19.3, 19.2, 19.2. ESIHRMS calculated for C69H86N4O24Na [M+Na]
+, 
1377.5530; found, 1377.5514. 
          2’-Deamino-2’-hydroxy paromomycin acetate salt (86). To a stirred suspension of 
Pd(OH)2/C (150 mg) in MeOH (0.5 mL) was added a solution of 85 (150 mg, 0.11 mmol) in MeOH 
(3.5 mL) at RT. The reaction mixture was stirred under a hydrogen atmosphere (1 atm) for 4 h, 
filtered and concentrated under reduced pressure. The residue was dissolved in 2.5 M NaOH (3 
mL) and heated to reflux for 8 h. The reaction mixture was acidified with 10% AcOH and then 
purified by Sephadex C-25 column chromatography (0.6% NH4OH). The product-containing 
fractions were concentrated under reduced pressure. The residue was dissolved in 10% AcOH and 
freeze dried to give the desired product 86 as the peracetate salt (40 mg, 42 %). [α]RTD +35.3 (c 
0.73, H2O). 
1H NMR (600 MHz, D2O) δ 4.96 (d, J = 2.6 Hz, 1H), 4.93 (d, J = 3.8 Hz, 1H), 4.89 
(br s, 1H), 4.12 (t, J = 5.7 Hz, 1H), 3.92 – 3.88 (m, 2H), 3.84 (br s, 1H), 3.79 – 3.74 (m, 1H), 3.57 
– 3.51 (m, 2H), 3.50 – 3.44 (m, 2H), 3.43 – 3.25 (m, 6H), 3.24 – 3.12 (m, 3H), 3.03 (dd, J1 = 13.5 
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Hz, J2 = 7.4 Hz, 1H), 2.99 (t, J = 9.6 Hz, 1H), 3.99 – 2.91 (m, 2H), 2.09 (dt, J1 = 12.6 Hz, J2 = 4.1 
Hz, 1H), 1.64 (s, 12H), 1.46 (q, J = 12.6 Hz, 1H). 13C NMR (150 MHz, D2O) δ 177.3, 108.4, 99.1, 
95.2, 82.0, 81.2, 79.4, 75.1, 73.3, 72.7, 72.3, 71.5, 71.1, 70.0, 69.3, 67.3, 66.8, 60.4, 60.1, 50.6, 
49.3, 49.2, 40.1, 27.7, 20.8. ESIHRMS calculated for C23H45N4O15 [M+H]
+, 617.2881; found, 
617.2891.  
          4’,6’-O-Benzylidene-penta-N-benzyloxycarbonyl-5”-O-(2,4,6-
triisopropylbenzenesulfonyl)-paromomycin (106). A stirred solution of 105 (2 g, 1.46 mmol) in 
pyridine (15 mL) was treated with 2,4,6-triisopropybenzenesulfonyl chloride (4.4 g, 14.56 mmol) 
(92 mg, 0.48 mmol) at RT. After stirring for 72 h at RT the reaction was quenched with methanol 
(15 mL) and concentrated to dryness under reduced pressure. The residue was purified by column 
chromatography on silica gel eluting with CHCl3/IPA (19:1) to give desired product 106 (1.4 g, 
58%). [α]RTD +27.7 (c 1.2, MeOH). ESIHRMS calculated for C85H101N5O26NaS [M+Na]+, 
1662.6353; found, 1662.6373.  
          4’,6’-O-Benzylidenepenta-N-benzyloxycarbonyl-5”-deoxy-5”-azido paromomycin 
(107). To a stirred solution of 106 (1.2 g, 0.73 mmol) in DMF (10 mL) was added sodium azide 
(951 mg, 14.64 mmol). The reaction mixture was stirred for 2 h at 80 0C and concentrated under 
to dryness under reduced pressure. The residue was dissolved in acetone (50 mL) and the 
precipitate was filtered off. The filtrate was concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel eluting with CHCl3/IPA (19:1) to give the desired 
product 107 (800 mg, 78%). [α]RTD +34.5 (c 1.0, MeOH). ESIHRMS calculated for 
C70H78N8O23Na [M+Na]
+, 1421.5078; found, 1421.5051. 
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          4’,6’-O-Benzylidenepenta-N-benzyloxycarbonyl-5”-deoxy-5”-amino paromomycin 
(108). To a stirred solution of 107 (600 mg, 0.43 mmol) in a mixture of THF and water (1:1, 12 
mL) was trimethylphosphine (1M in THF, 0.9 mL. 0.9 mmol). After stirring for 2 h at 80 0C the 
reaction was concentrated to dryness under reduced pressure. The residue was purified by column 
chromatography on silica gel eluting with CHCl3/MeOH (18:1) to give desired product 108 (500 
mg, 85%). [α]RTD +34.5 (c 1.0, MeOH). ESIHRMS calculated for C70H81N6O23 [M+H]+, 
1373.5353; found, 1373.5349. 
          4’,6’-O-Benzylidenepenta-N-benzyloxycarbonyl-5”-deoxy-5”-formamido 
paromomycin (109). A stirred solution of 108 (250 mg, 0.18 mmol) in DCM (3 mL) was treated 
with formic acetic anhydride (3 mL) at RT. The reaction mixture was stirred for 2 h and then 
concentrated to dryness under reduced pressure. The residue was dissolved in MeOH (5 mL) and 
to this solution was added aq. NaHCO3 (5 mL) at RT. The mixture was stirred for 1 h at RT and 
concentrated to dryness under reduced pressure. The residue was purified by column 
chromatography on silica gel eluting with CHCl3/MeOH (49:1) to give desired product 109 (175 
mg, 69%). [α]RTD +44.3 (c 0.53, MeOH). ESIHRMS calculated for C71H80N6O24Na [M+Na]+, 
1423.5122; found, 1423.5095.  
          5”-Deoxy-5”-formamido paromomycin acetate salt (110). To a stirred suspension of 
Pd(OH)2/C (160 mg, prewashed with glacial acetic acid) in water (2 mL) was added a solution of 
18 (80 mg, 0.06 mmol) in dioxane (2 mL) at RT. The reaction mixture was stirred under a hydrogen 
atmosphere (45 psi) for 8 h, filtered, concentrated under reduced pressure, and purified by 
Sephadex C-25 column chromatography (0.6% NH4OH). The product containing fractions were 
concentrated under reduced pressure. The residue was dissolved in 10% AcOH and freeze dried to 
give the desired product 110 as the peracetate salt (25 mg, 26%). [α]RTD +44.0 (c 0.8, H2O). 1H 
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NMR (600 MHz, D2O) δ 7.89 (s, 1H), 5.50 (d, J = 2.7 Hz, 1H), 5.07 (d, J = 1.5 Hz, 1H), 5.00 (br 
s, 1H), 4.15 (t, J = 4.9 Hz, 1H), 4.08 – 4.05 (m, 1H), 4.05 – 4.01 (m, 1H), 4.00 – 3.92 (m, 2H), 
3.78 (t, J = 9.0 Hz, 1H), 3.72 – 3.59 (m, 3H), 3.58 – 3.47 (m, 3H), 3.44 (t, J = 9.3 Hz, 1H), 3.40 
(dd, J1 = 14.5 Hz, J2 = 3.5 Hz, 1H), 3.35 – 3.19 (m, 5H), 3.16 (dd, J1 = 13.5 Hz, J2 = 6.1 Hz, 1H), 
3.13 – 3.04 (m, 2H), 2.21 (dt, J1 = 12.5 Hz, J2 = 4.2 Hz, 1H), 1.76 (s, 15H), 1.59 (q, J = 12.5 Hz, 
1H). 13C NMR (150 MHz, D2O) δ 177.4, 164.8, 109.5, 95.3, 95.0, 83.9, 79.7, 77.2, 76.7, 74.1, 
72.9, 71.8, 70.0, 68.9, 68.7, 67.4, 67.2, 60.1, 53.3, 50.6, 49.4, 48.8, 40.3, 39.3, 27.8, 20.8. 
ESIHRMS calculated for C24H47N6O14 [M+H]
+, 643.3150; found, 643.3145.  
          Penta-N-benzyloxycarbonyl-3’,4’,6’-hexa-O-acetyl-5”-deoxy-5”-acetamido 
paromomycin (111). A stirred solution of 108 (80 mg, 0.06 mmol) in DCM (1 mL) was treated 
with an excess of acetic anhydride (1 mL) at RT. The reaction mixture was stirred for 24 h at RT. 
LCMS analysis of the reaction mixture showed incomplete acetamide formation and at the same 
time 4’,6’-O-benzylidene acetal was cleaved completely. Then to the reaction mixture was added 
pyridine (1 mL) and the reaction mixture was stirred for additional 18 hours at RT. Then the 
reaction mixture was concentrated to dryness under reduced pressure. The residue was purified by 
column chromatography on silica gel eluting with CHCl3/MeOH (49:1) to give the desired product 
111 (75 mg, 79%). [α]RTD +33.8 (c 0.94, MeOH). ESIHRMS calculated for C79H92N6O31Na 
[M+Na]+, 1643.5705; found, 1643.5653.  
          5”-Acetamido-5”-deoxy- paromomycin-acetate salt (112). To a stirred solution of 111 
(75 mg, 0.05 mmol) in MeOH (1 mL) was added NaOMe (20 mg, 0.37 mmol) at RT.  After stirring 
for 2 h, the reaction mixture was neutralized with Amberlyst (H-form), filtered, and concentrated 
under reduced pressure. The residue as dissolved in dioxane (1.5 ml) and was added to a stirred 
suspension of Pd/C (75 mg) in 10% AcOH (0.75 mL). The reaction mixture was stirred under a 
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hydrogen atmosphere (45 psi) for 18 h, filtered, concentrated under reduced pressure, and purified 
by Sephadex C-25 column chromatography (0.8% NH4OH). The product-containing fractions 
were concentrated under reduced pressure. The residue was dissolved in 10% AcOH and freeze 
dried to give the desired product 112 as the peracetate salt (26 mg, 49%). [α]RTD +55.7 (c 0.87, 
H2O). 
1H NMR (600 MHz, D2O) δ 5.43 (d, J = 3.7 Hz, 1H), 5.04 (d, J = 3.2 Hz, 1H), 4.97 (br s, 
1H), 4.10 (t, J = 5.4 Hz, 1H), 4.03 – 3.97 (m, 2H), 3.95 – 3.88 (m, 2H), 3.74 (t, J = 9.5 Hz, 1H), 
3.66 – 3.56 (m, 3H), 3.55 – 3.44 (m, 3H), 3.42 (t, J = 9.8 Hz, 1H), 3.32 (dd, J1 = 14.5 Hz, J2 = 3.6 
Hz, 1H), 3.29 – 3.22 (m, 2H), 3.20 (t, J = 9.1 Hz, 1H), 3.16 (dd, J1 = 10.6 Hz, J2 = 4.0 Hz, 1H), 
3.15 – 3.09 (m, 2H), 3.09 – 3.01 (m, 2H), 2.18 (dt, J1 = 12.7 Hz, J2 = 4.1 Hz, 1H), 1.72 (s, 18H), 
1.56 (q, J = 12.7 Hz, 1H). 13C NMR (150 MHz, D2O) δ 177.9, 174.4, 109.4, 95.4, 95.2, 83.8, 79.9, 
77.5, 77.0, 74.1, 73.0, 71.8, 70.0, 68.9, 68.8, 67.4, 67.1, 60.1, 53.4, 50.6, 49.4, 48.8, 41.0, 40.2, 
27.8, 21.9, 21.1. ESIHRMS calculated for C25H49N6O14 [M+H]
+, 657.3307; found, 657.3273. 
          4’,6’-O-Benzylidene-penta-N-benzyloxycarbonyl-5”-deoxy-5”-(3-N-benzylureido) 
paromomycin (113). A stirred solution of 108 (100 mg, 0.07 mmol) in DCM (1 mL) was treated 
with benzyl isocyanate (50 µL) at RT. The reaction mixture was stirred for 2 h, quenched with 
MeOH (5 mL), and concentrated to dryness under reduced pressure. The residue was purified by 
column chromatography on silica gel eluting with CHCl3/MeOH (24:1) to give the desired product 
113 (70 mg, 64%). [α]RTD +16.8 (c 0.9, MeOH). ESIHRMS calculated for C78H87N7O24Na 
[M+Na]+, 1528.5700; found, 1527.5717. 
          5”-Deoxy-5”-ureido-paromomycin acetate salt (114). To a stirred suspension of Pd/C (90 
mg) in 80% AcOH (0.5 mL) was added a solution of 113 (30 mg, 0.02 mmol) in 80% AcOH (1.0 
mL) at RT. The reaction mixture was stirred under a hydrogen atmosphere (45 psi) for 12 h, 
filtered, concentrated under reduced pressure, and purified by Sephadex C-25 column 
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chromatography (0.7% NH4OH). The product-containing fractions were concentrated under 
reduced pressure.  The residue was dissolved in 10% AcOH and freeze dried to give the desired 
product 114 as the peracetate salt (8 mg, 42%). [α]RTD +18.5 (c 0.27, H2O). 1H NMR (600 MHz, 
D2O) δ 5.54 (d, J = 3.4 Hz, 1H), 5.12 (d, J = 3.3 Hz, 1H), 5.05 (br s, 1H), 4.20 (t, J = 5.2 Hz, 1H), 
4.12 – 4.09 (m, 1H), 4.09 – 4.06 (m, 1H), 4.03 – 3.95 (m, 2H), 3.83 (t, J = 9.4 Hz, 1H), 3.74 – 3.64 
(m, 3H), 3.60 (br s, 1H), 3.61 – 3.50 (m, 2H), 3.49 (t, J = 9.8 Hz, 1H), 3.38 – 3.31 (m, 2H), 3.31 – 
3.24 (m, 3H), 3.21 (dd, J1 = 13.8 Hz, J2 = 6.2 Hz, 1H), 3.18 – 3.10 (m, 3H), 2.26 (dt, J1 = 12.7 Hz, 
J2 = 4.2 Hz, 1H), 1.82 (s, 15H), 1.64 (q, J = 12.7 Hz, 1H). 
13C NMR (150 MHz, D2O) δ 177.1, 
161.2, 109.6, 95.5, 95.4, 84.1, 80.4, 77.7, 77.0, 74.1, 73.0, 71.9, 70.0, 69.0, 68.8, 67.5, 67.3, 60.2, 
53.5, 50.7, 49.4, 48.9, 41.4, 40.3, 27.9, 20.6. ESIHRMS calculated for C24H48N7O14 [M+H]
+, 
658.3259; found, 658.3258. 
          2,3-Dimethyl-N-hydroxymaleimide (122). To a mixture of 2,3-dimethylmaleic anhydride 
120 (3.0 g, 23.8 mmol), hydroxylamine hydrochloride (8.3 g, 118.9 mmol), and sodium acetate 
(9.7 g, 118.9 mmol) was added a 1:1 mixture of water and ethanol (100 mL). The reaction mixture 
was heated to reflux for 0.25 h. After cooling to RT the reaction mixture was diluted with water 
(50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed 
with water followed by brine, dried over Na2SO4, and concentrated under reduced pressure. The 
residue was then triturated with hexane to give the desired product 122 (2.5 g, 74%), mp 129-131 
°C, lit 126-127 0C, as an off white solid. 1H NMR (600 MHz, CDCl3) δ 8.19 (br s, 1H), 1.94 (s, 
6H); 13C NMR (150 MHz, CDCl3) δ 168.9, 135.6, 8.8.  
          2,3-Diphenyl-N-hydroxymaleimide (123). To a mixture of 2,3-diphenyl maleic anhydride 
121 (1.0 g, 4.0 mmol), hydroxylamine hydrochloride (1.4 g, 20.0 mmol), and sodium acetate (1.6 
g, 20.0 mmol) was added a 1:1 mixture of water and ethanol (100 mL). The reaction mixture was 
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heated to reflux for 0.25 h. After cooling to RT the reaction mixture was diluted with water (25 
mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic layers were washed with 
water followed by brine, dried over Na2SO4, and concentrated under reduced. The residue was 
purified by column chromatography on silica gel eluting with ethyl acetate/hexane (2:3) to give 
the desired product 123 (0.85 g, 80%), mp 203-204 °C, lit 196-197 0C, as a yellow solid. 1H NMR 
(600 MHz, CD3OD) δ 7.41 (d, J = 7.4 Hz, 4H), 7.39 – 7.34 (m, 2H), 7.32 (t, J = 7.5 Hz, 4H); 13C 
NMR (150 MHz, CD3OD) δ 167.2, 133.8, 129.6, 128.4, 128.1. ESIHRMS calculated for 
C16H11NO3Na [M+Na]+, 288.0637; found, 288.0650. 
          2-Methyl-3-phenyl maleic anhydride (126). To a mixture of sodium pyruvate 124 (5.0 g, 
45.4 mmol) and phenylacetic acid 125 (6.2 g, 45.4 mmol) was added acetic anhydride (80 mL). 
The reaction mixture was refluxed for 3 h then cooled to RT and poured to ice cold water (150 
mL). The water layer was extracted with ethyl acetate (3 x 75 mL). The combined organic layers 
were washed with water followed by brine, dried over Na2SO4, and concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel eluting with ethyl 
acetate/hexane (1:9) to give a yellow solid. This yellow solid was then recrystallized from ethyl 
acetate/hexane (1:8) to give 2-methyl 3-phenyl-maleic anhydride 126 (4.5 g, 53%), mp 99-101 0C, 
lit 98-100 0C as an off white solid. 1H NMR (600 MHz, CDCl3) δ 7.68 – 7.59 (m, 2H), 7.57 – 7.42 
(m, 3H), 2.30 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 166.2, 164.8, 139.9, 138.7, 131.0, 129.4, 
128.9, 127.4, 10.8. 
          2-Methyl-3-phenyl-N-hydroxymaleimide (127). To a mixture of 2-methyl-3-phenyl 
maleic anhydride 126 (3.4 g, 18.1 mmol), hydroxylamine hydrochloride (6.3 g, 90.4 mmol), and 
sodium acetate (7.4 g, 90.4 mmol) was added a 1:1 mixture of water and ethanol (100 mL). After 
stirring for 1 hour at RT the reaction mixture was diluted with water (50 mL) and extracted with 
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ethyl acetate (3 x 50 mL). The combined organic layers were washed with water followed by brine, 
dried over Na2SO4, and concentrated under reduced pressure. The residue was then triturated with 
hexane to give the desired product 3 (3.3 g, 90 %), mp 164-166 °C, as a yellow solid. 1H NMR 
(600 MHz, CDCl3+ CD3OD) δ 7.49 (d, J = 7.0 Hz, 2H), 7.43 – 7.33 (m, 3H), 2.12 (s, 3H); 13C 
NMR (150 MHz, CDCl3+ CD3OD) δ 168.5, 167.6, 134.9, 134.1, 129.7, 129.3, 128.5, 128.4, 9.8. 
ESIHRMS calculated for C11H8NO3 [M-H]
-, 202.0504; found, 202.0524. 
          N-acetoxycyclohexene-1,2-dicarboximide (129). To a mixture of cyclohexene-1,2-
dicarboxylic anhydride 128 (2.0 g, 13.1 mmol), hydroxylamine hydrochloride (4.6 g, 65.7 mmol), 
and sodium acetate (5.4 g, 65.7 mmol) was added a 1:1 mixture of water and ethanol (60 mL). The 
reaction mixture was refluxed for 1 h, then cooled to RT, diluted with water (30 mL), and extracted 
with ethyl acetate (3 x 30 mL). The combined organic layers were washed with water followed by 
brine, dried over Na2SO4, and concentrated under reduced pressure to yield an off-white solid. 
This solid was dissolved in acetic anhydride (20 mL) and heated to reflux for 4 h. Then the reaction 
mixture was cooled to RT and poured to ice cold water (50 mL). The water layer was extracted 
with ethyl acetate (3 x 30 mL). The combined organic layers were washed with water followed by 
brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by 
column chromatography on silica gel eluting with ethyl acetate/hexane (1:9 to 2:8) to give N-
acetoxycyclohexene-1,2-dicarboximide 129 (0.7 g, 25%) as a viscous gel. 1H NMR (600 MHz, 
CDCl3) δ 2.40-2.30 (m, 4H), 2.29 (s, 3H), 1.85-1.70 (m, 4H); 13C NMR (150 MHz, CDCl3+ 
CD3OD) δ 167.3, 165.3, 140.4, 20.9, 20.0. 
          N-Hydroxycyclohexene-1,2-dicarboximide (130). To a stirred solution of N-
acetoxycyclohexene-1,2-dicarboximide 129 (0.7 g, 3.3 mmol) in chloroform (15 mL) was added 
benzylamine (0.44 mL, 4.0 mmol) at RT. After stirring for 12 h at RT, the reaction mixture was 
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vigorously shaken with saturated aq. NaHCO3 (40 mL). The separated aq. NaHCO3 layer was 
acidified with 2N HCl and extracted with ethyl acetate (3 x 25 mL). The combined organic layers 
were washed with water followed by brine, dried over Na2SO4, and concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel eluting with ethyl 
acetate/hexane (2:8 to 3:7) to give the desired product 130 (0.35 g, 62%), mp 136-137 0C, lit 139-
141 0C, as a white solid. 1H NMR (600 MHz, CDCl3) δ 7.84 (br s, 1H), 2.34 – 2.27 (m, 4H), 1.79 
– 1.71 (m, 4H); 13C NMR (150 MHz, CDCl3) δ 167.8, 139.8, 21.0, 19.9. ESIHRMS calculated for 
C8H10NO3 [M+H]+, 168.0661; found, 168.0653.  
          2,3-Dimethyl-N-trifloxymaleimide (131). A stirred solution of compound 122 (0.8 g, 5.7 
mmol) in DCM (20 mL) was treated with pyridine (1.4 mL, 17.0 mmol) at RT and cooled to 0 0C 
before triflic anhydride (1.1 mL, 6.8 mmol) was added dropwise while stirring. After stirring for 
1 additional h at 0 0C the reaction was quenched with water (50 mL). The DCM layer was separated 
and water layer was extracted with DCM (2 x 30 mL). The combined organic layers were washed 
with water followed by brine, dried over Na2SO4, and concentrated under reduced pressure. The 
residue was dissolved in hexane and filtered to remove any insoluble material. The hexane layer 
was concentrated under reduced pressure to obtain the desired product 5 (1.2 g, 77%) as a viscous 
gel. 1H NMR (600 MHz, CDCl3) δ 2.05 (s, 6H); 13C NMR (150 MHz, CDCl3) δ 165.0, 139.2, 
118.4 (q, JCF = 322.6 Hz, CF3), 9.3. ESIHRMS calculated for C7H6NO5F3NaS [M+Na]+, 
295.9816; found, 295.9811. 
          2,3-Diphenyl-N-trifloxymaleimide (115). A stirred solution of compound 123 (0.45 g, 1.7 
mmol) in DCM (10 mL) was treated with pyridine (0.4 mL, 5.1 mmol) at RT and cooled to 0 0C 
before triflic anhydride (0.34 mL, 2.0 mmol) was added dropwise while stirring. After stirring for 
1 additional hour at 0 0C the reaction was quenched with water (20 mL). The DCM layer was 
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separated and the water layer was extracted with DCM (2 x 20 mL). The combined organic layers 
were washed with water followed by brine, dried over Na2SO4, and concentrated under reduced 
pressure. The residue was dissolved in hexane and filtered to remove any insoluble material. The 
filtrate was concentrated under reduced pressure to obtain the desired product 115 (0.6 g, 89%), 
mp 99-100 0C, as a yellow solid. 1H NMR (600 MHz, CDCl3) δ 7.53 – 7.48 (m, 4H), 7.48 – 7.42 
(m, 2H), 7.39 (t, J = 7.6 Hz, 4H); 13C NMR (150 MHz, CDCl3) δ 164.0, 136.1, 131.2, 129.8, 128.9, 
127, 118.6 (q, JCF = 322.7 Hz, CF3). ESIHRMS calculated for C17H10NO5F3NaS [M+Na]+, 
420.0129; found, 420.0121. 
          2-Methyl-3-phenyl-N-trifloxymaleimide (132). A stirred solution of compound 127 (1.0 
g, 4.9 mmol) in DCM (30 mL) was treated with pyridine (1.2 mL, 14.8 mmol) at RT and cooled 
to -25 0C before a solution of triflic anhydride (0.34 mL, 2.0 mmol) in DCM (10 mL) was added 
dropwise over a period of 30 minutes while stirring. After stirring for 1 additional hour at -25 0C 
the reaction mixture was quenched with water (40 mL). The DCM layer was separated and the 
water layer was extracted with DCM (2 x 30 mL). The combined organic layers were washed with 
water followed by brine, dried over Na2SO4, and concentrated under reduced pressure. The residue 
was dissolved in hexane and filtered to discard any insoluble material. The hexane layer was 
concentrated under reduced pressure to obtain the desired product 132 (1.1 g, 67%) as viscous gel 
and used for subsequent reactions without any further purification. 1H NMR (600 MHz, CDCl3) δ 
7.63 – 7.58 (m, 2H), 7.53 – 7.48 (m, 3H), 2.30 (s, 3H); 13C NMR (150 MHz, CDCl3) δ165.0, 164.1, 
138.0, 137.1, 131.1, 129.5, 129.0, 127.3, 118.5 (q, JCF = 322.7 Hz, CF3), 10.8. ESIHRMS 
calculated for C12H8NO5F3NaS [M+Na]+, 357.9973; found, 357.9971. 
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          N-Trifloxycyclohexene-1,2-dicarboxylic acid imide (133). A stirred solution of compound 
130 (0.35 g, 2.1 mmol) in DCM (10 mL) was treated with pyridine (0.5 mL, 6.3 mmol) at RT and 
cooled to 0 0C before triflic anhydride (0.42 mL, 2.5 mmol) was added dropwise while stirring. 
After stirring for 1 additional hour at 0 0C the reaction was quenched with water (20 mL). The 
DCM layer was separated and the water layer was extracted with DCM (2 x 20 mL). The combined 
organic layers were washed with water followed by brine, dried over Na2SO4 and concentrated 
under reduced pressure to obtain the desired product 133 (0.36 g, 57%) as viscous gel. Due to the 
unstable nature of this compound it was used for subsequent reactions without any further 
purification. 1H NMR (600 MHz, CDCl3) δ 2.46 – 2.33 (m, 4H), 1.84 – 1.79 (m, 4H); 13C NMR 
(150 MHz, CDCl3) δ 163.9, 142.9, 118.5 (q, JCF = 322.7 Hz, CF3), 20.6, 20.4. 
          General reaction protocol for the formation of 3-N-alkyl pyrimidin-2,4-diones. To a 
stirred solution of N-trifloxyimide (0.8 mmol) in DMF (2 mL) was added K2CO3 (1.6 mmol) at 
RT. To this mixture was added a solution of amine (0.5 mmol) in DMF (0.5 mL) dropwise at RT. 
After stirring for 4 h at RT the reaction was quenched with water (15 mL). The water layer was 
extracted with ethyl acetate (3 x 15 mL). The combined organic layers were washed with water 
followed by brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was 
subjected to column chromatography on silica gel to give the desired 3-N-alkyl pyrimidin-2,4-
dione. 
          3-N-(2-Hydroxy-2-phenylethyl)-5,6-dimethylpyrimidine-2,4-(1H,3H)-dione (138). This 
compound was prepared according to the general procedure using compound 131 (299 mg, 1.1 
mmol), 2-amino-1-phenylethanol 134 (100 mg, 0.7 mmol), and K2CO3 (302 mg, 2.2 mmol). 
Purification by column chromatography eluting with ethyl acetate/hexane (1:5 to 9:1) afforded the 
desired product 138 (100 mg, 53%), mp 182-183 0C, as a white solid. 1H NMR (600 MHz, 
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CDCl3+CD3OD) δ 7.37 (d, J = 7.5 Hz, 2H), 7.27 (t, J = 7.6 Hz, 2H), 7.19 (t, J = 7.3 Hz, 1H), 4.93 
(dd, J = 9.4, 2.8 Hz, 1H), 4.17 (dd, J = 13.8, 9.4 Hz, 1H), 4.09 – 4.01 (m, 1H), 2.05 (s, 3H), 1.83 
(s, 3H); 13C NMR (150 MHz, CDCl3+CD3OD) δ 165.2, 152.5, 145.8, 141.7, 128.3, 127.6, 152.7, 
106.1, 72.7, 48.4, 16.4, 10.3. ESIHRMS calculated for C14H16N2O3Na [M+Na]+, 283.1059; found, 
283.1070. 
          3-Cyclohexyl-5,6-dimethylpyrimidine-2,4-(1H,3H)-dione (139). This compound was 
prepared according to the general procedure using compound 131 (413 mg, 1.5 mmol), 
cyclohexylamine 135 (100 mg, 1.0 mmol), and K2CO3 (418 mg, 3.0 mmol). Purification by column 
chromatography eluting with ethyl acetate/hexane (1:5 to 2:3) gave the desired product 139 (125 
mg, 56%), mp 215-216.5 0C, as a white solid. 1H NMR (600 MHz, CDCl3) δ 10.47 (s, 1H), 4.75 
(br t, J = 11.4 Hz, 1H), 2.37 (q, J = 12.0 Hz, 2H), 2.11 (s, 3H), 1.87 (s, 3H), 1.79 (d, J = 13.1 Hz, 
2H), 1.61 (dd, J = 26.1, 12.0 Hz, 3H), 1.34 (q, J = 13.1 Hz, 2H), 1.24 – 1.11 (m, 1H); 13C NMR 
(150 MHz, CDCl3) δ 164.4, 152.9, 144.5, 106.6, 53.4, 28.6, 26.3, 25.4, 16.5, 10.6. ESIHRMS 
calculated for C12H18N2O2Na [M+Na]+, 245.1266; found, 245.1283. 
          3-(1-Phenylethyl)-5,6-dimethylpyrimidine-2,4-(1H,3H)-dione (140). This compound 
was prepared according to the general procedure using compound 131 (338 mg, 1.2 mmol), (±)-α-
methyl benzylamine 136 (100 mg, 0.8 mmol), and K2CO3 (342 mg, 2.5 mmol). Purification by 
column chromatography eluting with ethyl acetate/hexane (1:5 to 3:2) afforded the desired product 
140 (80 mg, 40 %), mp 150-152 0C, as a white solid. 1H NMR (600 MHz, CDCl3) δ 10.52 (s, 1H), 
7.38 (d, J = 7.7 Hz, 2H), 7.26 (t, J = 7.7. Hz, 2H), 7.19 (t, J = 7.3 Hz, 1H), 6.27 (q, J = 7.0 Hz, 
1H), 1.93 (s, 3H), 1.88 (s, 3H), 1.83 (d, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 164.1, 
152.5, 145.0, 140.5, 127.9, 127.2, 126.8, 106.4, 49.9, 16.4, 15.7, 10.6. ESIHRMS calculated for 
C14H16N2O2Na [M+Na]+, 267.1109; found, 267.1123. 
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          3-(3,4-Dimethoxyphenethyl)-5,6-diphenylpyrimidine-2,4-(1H,3H)-dione (118). This 
compound was prepared according to the general procedure using compound 115 (329 mg, 0.8 
mmol), 3,4-dimethoxyphenethylamine 116 (100 mg, 0.5 mmol) and K2CO3 (229 mg, 1.6 mmol). 
Purification by column chromatography eluting with ethyl acetate/hexane (1:3 to 7:3) afforded the 
desired product 118 (120 mg, 51%), mp 212-213.5 0C, as an off white solid. 1H NMR (600 MHz, 
CDCl3) δ 10.05 (br s, 1H), 7.35 – 7.30 (m, 1H), 7.29 – 7.18 (m, 7H), 7.11 (dd, J = 7.5, 1.6 Hz, 
2H), 6.82 – 6.75 (m, 3H), 4.15 – 4.10 (vr m, 2H), 3.86 (s, 3H), 3.83 (s, 3H), 2.97 – 2.77 (vr m, 
2H); 13C NMR (150 MHz, CDCl3) δ 163.1, 152.0, 148.9, 147.7, 147.4, 132.5, 132.4, 131.3, 131.1, 
130.1, 128.9, 128.5, 128.0, 127.5, 121.0, 112.7, 112.2, 111.3, 55.93, 55.88, 42.8, 33.3. ESIHRMS 
calculated for C26H24N2O4Na [M+Na]+, 451.1634; found, 451.1649. 
          N-(3,4-dimethoxyphenethyl)-3-[3-(3,4-dimethoxyphenethyl)ureido]-2,3-
diphenylacrylamide (119). This compound was isolated as a byproduct (25 mg, 7%) during the 
synthesis of compound 118, mp 235-237 0C, as an off white solid. 1H NMR (600 MHz, CDCl3) δ 
12.09 (br s, 1H), 7.12 – 6.92 (m, 8H), 6.89 – 6.81 (m, 2H), 6.78 (d, J = 7.4 Hz, 1H), 6.72 – 6.61 
(m, 3H), 6.55 (s, 1H), 6.50 (d, J = 7.3 Hz, 1H), 5.39 (br s, 1H), 3.85 (br s, 1H), 3.85 (s, 6H), 3.83 
(s, 3H), 3.80 (s, 3H), 3.48 – 3.30 (vr m, 4H), 2.73 – 2.58 (vr m, 4H). 13C NMR (150 MHz, CDCl3) 
δ 169.7, 153.9, 151.1, 149.0, 148.9, 147.7, 146.6, 135.8, 135.7, 132.1, 131.4, 131.0, 128.5, 128.3, 
127.6, 127.2, 127.1, 120.6, 120.5, 111.9, 111.7, 111.4, 110.6, 55.9, 55.85, 55.81, 40.8, 35.7, 35.0. 
ESIHRMS calculated for C36H39N3O6Na [M+Na]+, 632.2737; found, 632.2710. 
          3-Benzyl-5,6-diphenylpyrimidine-2,4-(1H,3H)-dione (141). This compound was 
prepared according to the general procedure using compound 115 (556 mg, 1.4 mmol), 
benzylamine 137 (100 mg, 0.9 mmol), and K2CO3 (387 mg, 2.8 mmol). Purification by column 
chromatography eluting with ethyl acetate/hexane (1:9 to 3:7) afforded the desired product 141 
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(180 mg, 54 %), mp 222.5-224 0C, as an off-white solid. 1H NMR (600 MHz, CDCl3) δ 10.50 (br 
s, 1H), 7.45 – 7.40 (m, 2H), 7.35 (t, J = 7.3 Hz, 1H), 7.28 (t, J = 7.7 Hz, 2H), 7.26 – 7.22 (m, 5H), 
7.22 – 7.19 (m, 3H), 7.09 (dd, J = 7.3, 2.0 Hz, 2H), 5.08 (s, 2H); 13C NMR (150 MHz, CDCl3) δ 
163.1, 152.4, 147.7, 136.7, 132.6, 132.4, 131.4, 130.1, 129.7, 129.0, 128.4, 128.3, 128.0, 127.7, 
127.4, 112.7, 44.3. ESIHRMS calculated for C23H18N2O2Na [M+Na]+, 377.1266; found, 
377.1282. 
          3-(1-Phenylethyl)-5,6-diphenylpyrimidine-2,4-(1H,3H)-dione (142). This compound 
was prepared according to the general procedure using compound 115 (491 mg, 1.2 mmol), (±)-α-
methyl benzylamine 136 (100 mg, 0.8 mmol), and K2CO3 (342 mg, 2.5 mmol). Purification by 
column chromatography eluting with ethyl acetate/hexane (3:7 to 4:1) afforded the desired product 
142 (50 mg, 16%), mp 234-235.5 0C, as a white solid. 1H NMR (600 MHz, CDCl3) δ 10.27 (br s, 
1H), 7.39 – 7.32 (m, 3H), 7.29 (t, J = 7.7 Hz, 2H), 7.24 – 7.16 (m, 8H), 7.11 – 7.06 (m, 2H), 6.28 
(q, J = 6.9 Hz, 1H), 1.80 (d, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 161.3, 151.9, 147.7, 
140.0, 132.7, 132.4, 131.4, 130.0, 128.9, 128.4, 127.96, 127.90, 127.87, 127.3, 127.1, 112.6, 50.6, 
15.9. ESIHRMS calculated for C24H20N2O2Na [M+Na]+, 391.1422; found, 391.1434.  
          3-(3,4-Dimethoxyphenethyl)-6-methyl-5-phenylpyrimidine-2,4-(1H,3H)-dione (143) 
and 3-(3,4-Dimethoxyphenethyl)-5-methyl-6-phenylpyrimidine-2,4-(1H,3H)-dione (144). 
These compounds were prepared according to the general procedure using compound 132 (277 
mg, 0.8 mmol), 3,4-dimethoxyphenethylamine 116 (100 mg, 0.5 mmol), and K2CO3 (229 mg, 1.7 
mmol). Purification by column chromatography eluting with ethyl acetate/hexane (1:5 to 7:3) 
afforded desired products 143 (60 mg), mp 222-224 0C, and 144 (50 mg), mp 119.5-193 0C, as off-
white solids with a combined yield of 54%.  
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          3-(3,4-Dimethoxyphenethyl)-6-methyl-5-phenylpyrimidine-2,4-(1H,3H)-dione (143). 
1H NMR (600 MHz, (CD3)2SO) δ 11.19 (br s, 1H), 7.34 (t, J = 7.4 Hz, 2H), 7.28 (t, J = 7.3 Hz, 
1H), 7.17 (d, J = 7.3 Hz, 2H), 6.84 (d, J = 8.1 Hz, 1H), 6.73 (s, 1H), 6.69 (d, J = 8.1 Hz, 1H), 3.98 
– 3.92 (vr m, 2H), 3.70 (s, 3H), 3.68 (s, 3H), 2.76 – 2.69 (vr m, 2H), 1.92 (s, 3H); 13C NMR (150 
MHz, (CD3)2SO) δ 162.6, 151.0, 149.0, 147.9, 147.8, 134.0, 131.5, 131.3, 128.3, 127.6, 120.9, 
112.8, 112.4, 111.3, 55.9, 55.7, 41.7, 33.1, 17.6. ESIHRMS calculated for C21H22N2O4Na 
[M+Na]+, 389.1477; found, 389.1481. 
          3-(3,4-Dimethoxyphenethyl)-5-methyl-6-phenylpyrimidine-2,4-(1H,3H)-dione (144). 
1H NMR (600 MHz, (CD3)2SO) δ 11.07 (br s, 1H), 7.47 (dd, J = 6.5, 3.6 Hz, 3H), 7.43 – 7.37 (m, 
2H), 6.84 (t, J = 9.5 Hz, 1H), 6.77 (d, J = 1.8 Hz, 1H), 6.73 (dd, J = 8.1, 1.8 Hz, 1H), 4.03 – 3.93 
(vr m, 2H), 3.71 (s, 3H), 3.69 (s, 3H), 2.78 – 2.71 (vr m, 2H), 1.70 (s, 3H); 13C NMR (150 MHz, 
(CD3)2SO) δ 164.2, 151.0, 149.0, 147.8, 147.7, 132.8, 131.5, 130.2, 129.0, 128.9, 120.9, 112.7, 
112.4, 105.1, 55.9, 55.8, 41.8, 33.1, 12.2. ESIHRMS calculated for C21H22N2O4Na [M+Na]+, 
389.1477; found, 389.1477. 
          3-Benzyl-6-methyl-5-phenylpyrimidine-2,4(1H,3H)-dione (145) and 3-Benzyl-5-
methyl-6-phenylpyrimidine-2,4-(1H,3H)-dione (146). These compounds were prepared 
according to the general procedure using compound 132 (469 mg, 1.4 mmol), benzylamine 137 
(100 mg, 0.9 mmol), and K2CO3 (387 mg, 2.8 mmol). Purification by column chromatography 
eluting with ethyl acetate/hexane (1:5 to 7:3) afforded the desired products 145 (85 mg), mp 288-
290 0C, and 146 (55 mg), mp 210 -212 0C, as off-white solids with a combined yield of 51%.  
          3-Benzyl-6-methyl-5-phenylpyrimidine-2,4(1H,3H)-dione (145). 1H NMR (600 MHz, 
(CD3)2SO) δ 11.30 (br s, 1H), 7.34 (t, J = 7.4 Hz, 3H), 7.30 – 7.25 (m, 5H), 7.23 – 7.17 (m, 4H), 
4.96 (s, 2H), 1.94 (s, 3H); 13C NMR (150 MHz, (CD3)2SO) δ 162.8, 151.2, 148.4, 137.9, 133.9, 
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131.3, 128.7, 128.3, 128.1, 127.6, 127.5, 111.3, 43.4, 17.7. ESIHRMS calculated for 
C18H16N2O2Na [M+Na]+, 315.1109; found, 315.1124. 
          3-Benzyl-5-methyl-6-phenylpyrimidine-2,4-(1H,3H)-dione (146). 1H NMR (600 MHz, 
(CD3)2SO) δ 11.16 (br s, 1H), 7.49 – 7.42 (m, J = 13.5, 6.5, 3.2 Hz, 5H), 7.33 – 7.26 (m, 4H), 7.25 
– 7.20 (m, 1H), 4.99 (s, 2H), 1.70 (s, 3H); 13C NMR (150 MHz, (CD3)2SO) δ 164.3, 151.1, 148.0, 
137.8, 132.8, 130.2, 129.0, 128.9, 128.7, 128.2, 127.5, 105.1, 43.5, 12.2. ESIHRMS calculated for 
C18H16N2O2Na [M+Na]+, 315.1109; found, 315.1107.  
          3-Cyclohexyl-6-methyl-5-phenylpyrimidine-2,4-(1H,3H)-dione (147) and 3-
Cyclohexyl-5-methyl-6-phenylpyrimidine-2,4-(1H,3H)-dione (148). These compounds were 
prepared according to the general procedure using compound 132 (507 mg, 1.5 mmol), 
cyclohexylamine 135 (100 mg, 1.0 mmol) and K2CO3 (387 mg, 3.0 mmol). Purification by column 
chromatography eluting with ethyl acetate/hexane (1:9 to 2:3) afforded the desired products 147 
(60 mg), mp 292-294 0C, and 148 (40 mg), mp 233 -235 0C, as off-white solids with a combined 
yield of 35%.  
          3-Cyclohexyl-6-methyl-5-phenylpyrimidine-2,4-(1H,3H)-dione (147). 1H NMR (600 
MHz, CDCl3+CD3OD) δ; 7.30 (t, J = 7.5 Hz, 2H), 7.27 – 7.21 (m, 5.0 Hz, 1H), 7.13 (d, J = 7.5 
Hz, 2H), 4.68 (br t, J = 11.8 Hz, 1H), 2.25 (q, J=11.4 Hz, 2H), 1.92 (s, 3H), 1.73 (d, J = 13.1 Hz, 
2H), 1.62 – 1.50 (m, 3H), 1.25 (q, J = 13.0 Hz, 2H), 1.17 – 1.05 (m, 1H). 13C NMR (150 MHz, 
CDCl3+CD3OD) δ 163.8, 151.9, 146.5, 133.0, 130.6, 128.2, 127.5, 113.1, 53.8, 28.5, 26.2, 25.2, 
17.0. ESIHRMS calculated for C17H20N2O2Na [M+Na]+, 307.1422; found, 307.1411. 
          3-Cyclohexyl-5-methyl-6-phenylpyrimidine-2,4-(1H,3H)-dione (148). 1H NMR (600 
MHz, CDCl3+CD3OD) δ 7.44 – 7.36 (m, 3H), 7.36 – 7.29 (m, 2H), 7.25 (s, 1H), 4.68 (br t, J = 
10.7 Hz, 1H), 2.25 (d, J = 11.4 Hz, 2H), 1.79 (s, 3H), 1.73 (d, J = 12.5 Hz, 2H), 1.62 – 1.47 (m, 
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3H), 1.27 (q, J=13.2 Hz, 2H), 1.15 – 1.04 (m, 1H); 13C NMR (150 MHz, CDCl3+CD3OD) δ 165.3, 
151.9, 146.5, 132.5, 130.0, 128.6, 128.1, 106.9, 53.7, 28.4, 26.2, 25.2, 11.8. ESIHRMS calculated 
for C17H20N2O2Na [M+Na]+, 307.1422; found, 307.1414.  
          3-(3,4-Dimethoxyphenethyl)-5,6,7,8-tetrahydroquinazoline-2,4-(1H,3H)-dione (149). 
This compound was prepared according to the general procedure using compound 133 (150 mg, 
0.5 mmol), 3,4-dimethoxyphenethylamine 116 (60 mg, 0.3 mmol), and K2CO3 (138 mg, 1.0 
mmol). Purification by column chromatography eluting with ethyl acetate/hexane (3:7 to 4:1) 
afforded the desired product 149 (70 mg, 63 %), mp 229.5-231 0C, as a white solid. 1H NMR (600 
MHz, CDCl3) δ 10.17 (s, 1H), 6.88 – 6.71 (m, 3H), 4.18 – 4.01 (vr m, 2H), 3.85 (s, 3H), 3.83 (s, 
3H), 2.93 – 2.78 (vr m, 2H), 2.42 – 2.34 (m, 4H), 1.80-1.67 (m, 4H); 13C NMR (150 MHz, CDCl3) 
δ 163.5, 152.6, 148.9, 147.6, 146.4, 131.3, 120.8, 112.1, 111.2, 108.0, 55.88, 55.79, 42.0, 33.4, 
26.2, 21.7, 21.3, 21.1. ESIHRMS calculated for C18H22N2O4Na [M+Na]+, 353.1477; found, 
353.1468. 
          3-Cyclohexyl-5,6,7,8-tetrahydroquinazoline-2,4-(1H,3H)-dione (150). This compound 
was prepared according to the general procedure using compound 133 (165 mg, 0.5 mmol), 
cyclohexylamine 135 (37 mg, 0.4 mmol) and K2CO3 (152 mg, 1.1 mmol). Purification by column 
chromatography eluting with ethyl acetate/hexane (3:7 to 4:1) afforded the desired product 150 
(50 mg, 55 %), mp 296-298 0C as a white solid. 1H NMR (600 MHz, CDCl3+CD3OD) δ 4.61 (br 
t, J = 12.2 Hz, 1H), 2.32 – 2.13 (m, 6H), 1.70 (d, J = 13.5 Hz, 2H) 1.66 – 1.43 (m, 7H), 1.22 (q, J 
= 13.0 Hz, 2H) 1.13–1.01 (m, 1H); 13C NMR (150 MHz, CDCl3+CD3OD) δ 164.4, 152.3, 146.2, 
108.0, 53.3, 28.6, 26.3, 25.9, 25.3, 21.7, 21.3, 21.1. ESIHRMS calculated for C14H20N2O2Na 
[M+Na]+, 271.1422; found, 271.1425. 
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          Bacterial strains. Clinical isolates of E. coli, S. aureus and P. aeruginosa were obtained 
from the Diagnostic Department, Institute of Medical Microbiology, University of Zurich. MIC 
values were determined by broth microdilution assays as described.39 
          Recombinant microorganisms. The construction of these strains derived from single 
rRNA allelic M. smegmatis ∆rrnB, has been described previously.68,77 
          Cell-free translation assays. Rabbit reticulocyte lysate (Promega), S-30 extracts and 
purified ribosomes were used for cell-free translation assays as described previously.39 Firefly 
luciferase mRNA was used as reporter to monitor translation activity.  Luminescence was 
measured using a luminometer Flx800 (Bio-Tek Instruments). 
151 
 
 
 
REFERENCES 
(1) Porter, J. R. Bacteriol. Rev. 1976, 40, 260-269. 
(2) Austrian, R. Bacteriol. Rev. 1960, 24, 261. 
(3) Walsh, C. Antibiotics: actions, origins, resistance; American Society for Microbiology 
(ASM), 2003. 
(4) Global T.B. Report 2016. World Health Organization, Geneva, 2016. 
(5) Williams, K. J. R. Soc. Med. 2009, 102, 343-348. 
(6) Bosch, F.; Rosich, L. Pharmacology 2008, 82, 171-179. 
(7) Limbird, L. E. Mol. Interv. 2004, 4, 326. 
(8) Waksman, S. A. Mycologia 1947, 565-569. 
(9) Lloyd, N. C.; Morgan, H. W.; Nicholson, B. K.; Ronimus, R. S. Angew. Chem., Int. Ed. 
Engl. 2005, 44, 941-944. 
(10) Houbraken, J.; Frisvad, J. C.; Samson, R. A. IMA Fungus: The Global Mycological 
Journal 2011, 2, 87. 
(11) Waksman, S. A. Antimicrob. Agents Chemother. 1965, 5, 9. 
(12) Jackson, J.; Chen, C.; Buising, K. Curr. Opin. Infect. Dis. 2013, 26, 516-525. 
(13) Vakulenko, S. B.; Mobashery, S. Clin. Microbiol. Rev. 2003, 16, 430-450. 
(14) Fosso, M. Y.; Li, Y.; Garneau-Tsodikova, S. MedChemComm 2014, 5, 1075-1091. 
(15) World Health Organization, Geneva, 2007. 
(16) Goodman, L. S. Goodman and Gilman's the pharmacological basis of therapeutics; 
McGraw-Hill New York, 1996; Vol. 1549. 
(17) Hanberger, H.; Edlund, C.; Furebring, M.; G. Giske, C.; Melhus, Å.; Nilsson, L. E.; 
Petersson, J.; Sjölin, J.; Ternhag, A.; Werner, M. Scand. J. Infect. Dis. 2013, 45, 161-175. 
152 
 
 
 
(18) Carter, A. P.; Clemons, W. M.; Brodersen, D. E.; Morgan-Warren, R. J.; Wimberly, B. 
T.; Ramakrishnan, V. Nature 2000, 407, 340-348. 
(19) de Loubresse, N. G.; Prokhorova, I.; Holtkamp, W.; Rodnina, M. V.; Yusupova, G.; 
Yusupov, M. Nature 2014, 513, 517-522. 
(20) François, B.; Russell, R. J.; Murray, J. B.; Aboul-ela, F.; Masquida, B.; Vicens, Q.; 
Westhof, E. Nucleic Acids Res. 2005, 33, 5677-5690. 
(21) Peske, F.; Savelsbergh, A.; Katunin, V. I.; Rodnina, M. V.; Wintermeyer, W. J. Mol. 
Biol. 2004, 343, 1183-1194. 
(22) Feldman, M. B.; Terry, D. S.; Altman, R. B.; Blanchard, S. C. Nat. Chem. Biol. 2010, 6, 
54-62. 
(23) Moazed, D.; Noller, H. F. Nature 1987, 327, 389-394. 
(24) Tsai, A.; Uemura, S.; Johansson, M.; Puglisi, E. V.; Marshall, R. A.; Aitken, C. E.; 
Korlach, J.; Ehrenberg, M.; Puglisi, J. D. Cell Rep. 2013, 3, 497-508. 
(25) Arya, D. P. Aminoglycoside antibiotics: from chemical biology to drug discovery; John 
Wiley & Sons, 2007; Vol. 5. 
(26) Wong, C.-H. Carbohydrate-based drug discovery; John Wiley & Sons, 2003; Vol. 1. 
(27) Magnet, S.; Blanchard, J. S. Chem. Rev. 2005, 105, 477-498. 
(28) Houghton, J. L.; Green, K. D.; Chen, W.; Garneau‐Tsodikova, S. ChemBioChem 2010, 
11, 880-902. 
(29) Ramirez, M. S.; Tolmasky, M. E. Drug Resist. Updates 2010, 13, 151-171. 
(30) Labby, K. J.; Garneau-Tsodikova, S. Future Med. Chem. 2013, 5, 1285-1309. 
(31) Yang, L.; Ye, X.-S. Curr. Top. Med. Chem. 2010, 10, 1898-1926. 
(32) ECDC, E. Stockholm: European Center for Disease Prevention and Control 2009. 
153 
 
 
 
(33) Umezawa, S. Adv. Carbohydr. Chem. Biochem. 1974, 30, 111-182. 
(34) Haddad, J.; Kotra, L.; Mobashery, S.; Marcel Dekker, Inc: 2001. 
(35) Chandrika, N. T.; Garneau-Tsodikova, S. MedChemComm 2016, 7, 50-68. 
(36) Aggen, J. B.; Armstrong, E. S.; Goldblum, A. A.; Dozzo, P.; Linsell, M. S.; Gliedt, M. J.; 
Hildebrandt, D. J.; Feeney, L. A.; Kubo, A.; Matias, R. D. Antimicrob. Agents Chemother. 2010, 
54, 4636-4642. 
(37) Zhanel, G. G.; Lawson, C. D.; Zelenitsky, S.; Findlay, B.; Schweizer, F.; Adam, H.; 
Walkty, A.; Rubinstein, E.; Gin, A. S.; Hoban, D. J. Expert Rev. Anti-Infect. Ther. 2012, 10, 459-
473. 
(38) Ryden, R.; Moore, B. J. Antimicrob. Chemother. 1977, 3, 609-613. 
(39) Matt, T.; Ng, C. L.; Lang, K.; Sha, S.-H.; Akbergenov, R.; Shcherbakov, D.; Meyer, M.; 
Duscha, S.; Xie, J.; Dubbaka, S. R. Proc. Natl. Acad. Sci. USA. 2012, 109, 10984-10989. 
(40) Meyer, M.; Freihofer, P.; Scherman, M.; Teague, J.; Lenaerts, A.; Böttger, E. C. 
Antimicrob. Agents Chemother. 2014, 58, 6938-6941. 
(41) Pittengbr, R.; Wolfe, E.; Hoehn, M.; Marks, P. N.; Daily, W.; McGuire, J. Antibiot. 
Chemother. 1953, 3, 1268-1278. 
(42) Jana, S.; Deb, J. Appl. Biochem. Biotechnol. 2006, 70, 140-150. 
(43) Stromgaard, K.; Krogsgaard-Larsen, P.; Madsen, U. Textbook of drug design and 
discovery; CRC Press, 2009. 
(44) Nelson, D. L.; Lehninger, A. L.; Cox, M. M. Lehninger principles of biochemistry; 
Macmillan, 2008. 
(45) Beringer, M.; Bruell, C.; Xiong, L.; Pfister, P.; Bieling, P.; Katunin, V. I.; Mankin, A. S.; 
Böttger, E. C.; Rodnina, M. V. J. Biol. Chem. 2005, 280, 36065-36072. 
154 
 
 
 
(46) Hobbie, S. N.; Pfister, P.; Brüll, C.; Westhof, E.; Böttger, E. C. Antimicrob. Agents 
Chemother. 2005, 49, 5112-5118. 
(47) Hobbie, S. N.; Pfister, P.; Bruell, C.; Sander, P.; François, B.; Westhof, E.; Böttger, E. C. 
Antimicrob. Agents Chemother. 2006, 50, 1489-1496. 
(48) Hobbie, S.; Bruell, C.; Kalapala, S.; Akshay, S.; Schmidt, S.; Pfister, P.; Böttger, E. 
Biochimie 2006, 88, 1033-1043. 
(49) Tor, Y. ChemBioChem 2003, 4, 998-1007. 
(50) Thomas, J. R.; Hergenrother, P. J. Chem. Rev. 2008, 108, 1171-1224. 
(51) Ogle, J. M.; Ramakrishnan, V. Annu. Rev. Biochem. 2005, 74, 129-177. 
(52) Shandrick, S.; Zhao, Q.; Han, Q.; Ayida, B. K.; Takahashi, M.; Winters, G. C.; 
Simonsen, K. B.; Vourloumis, D.; Hermann, T. Angew. Chem. 2004, 116, 3239-3244. 
(53) Kaul, M.; Barbieri, C. M.; Pilch, D. S. J. Am. Chem. Soc. 2004, 126, 3447-3453. 
(54) Forge, A.; Schacht, J. Audiology and Neurotology 2000, 5, 3-22. 
(55) Böttger, E. C.; Schacht, J. Hear. Res. 2013, 303, 12-19. 
(56) Huth, M.; Ricci, A.; Cheng, A. Int. J. Otolaryngol. 2011, 2011. 
(57) Rybak, M. J.; Abate, B. J.; Kang, S. L.; Ruffing, M. J.; Lerner, S. A.; Drusano, G. L. 
Antimicrob. Agents Chemother. 1999, 43, 1549-1555. 
(58) Mingeot-Leclercq, M.-P.; Tulkens, P. M. Antimicrob. Agents Chemother. 1999, 43, 1003-
1012. 
(59) Kishore, B.; Kallay, Z.; Lambricht, P.; Laurent, G.; Tulkens, P. J. Pharmacol. Exp. Ther, 
1990, 255, 867-874. 
(60) Janknegt, R. Pharm. World. Sci. 1990, 12, 81-90. 
(61) O’Neil, W. G. Toxicology 2008, 249, 91-96. 
155 
 
 
 
(62) Tange, R. Ziekenhuisfarmacie 1987, 3, 15-17. 
(63) Lautermann, J.; McLaren, J.; Schacht, J. Hear. Res. 1995, 86, 15-24. 
(64) Huy, P. T. B.; Bernard, P.; Schacht, J. J. Clin. Invest. 1986, 77, 1492. 
(65) Beidler, L. M. Handbook of sensory physiology; Springer, 1971; Vol. 4. 
(66) Fausti, S. A.; Rappaport, B. Z.; Schechter, M. A.; Frey, R. H.; Ward, T. T.; Brummett, R. 
E. Am. J. Otolaryngol. 1984, 5, 177-182. 
(67) Pfister, P.; Hobbie, S.; Brüll, C.; Corti, N.; Vasella, A.; Westhof, E.; Böttger, E. J. Mol. 
Biol. 2005, 346, 467-475. 
(68) Hobbie, S. N.; Bruell, C. M.; Akshay, S.; Kalapala, S. K.; Shcherbakov, D.; Böttger, E. 
C. Proc. Natl. Acad. Sci. USA. 2008, 105, 3244-3249. 
(69) Matt, T.; Akbergenov, R.; Shcherbakov, D.; Böttger, E. C. Isr. J. Chem. 2010, 50, 60-70. 
(70) Prezant, T. R.; Agapian, J. V.; Bohlman, M. C.; Bu, X.; Öztas, S.; Qiu, W.-Q.; Arnos, K. 
S.; Cortopassi, G. A.; Jaber, L.; Rotter, J. I. Nat. Genet. 1993, 4, 289-294. 
(71) Hershko, C. Mol. Aspects Med. 1992, 13, 113-165. 
(72) Tanswell, A. K.; Freeman, B. A. New Horiz. 1995, 3, 330-341. 
(73) Sha, S.-H.; Schacht, J. Lab. Invest. 1999, 79, 807-814. 
(74) Rodnina, M. V.; Wintermeyer, W.; Green, R. Ribosomes Structure, Function, and 
Dynamics; Springer Science & Business Media, 2011. 
(75) Hobbie, S. N.; Akshay, S.; Kalapala, S. K.; Bruell, C. M.; Shcherbakov, D.; Böttger, E. 
C. Proc. Natl. Acad. Sci. USA. 2008, 105, 20888-20893. 
(76) Pape, T.; Wintermeyer, W.; Rodnina, M. V. Nat. Struct. Mol. Biol. 2000, 7, 104-107. 
(77) Hobbie, S. N.; Kalapala, S. K.; Akshay, S.; Bruell, C.; Schmidt, S.; Dabow, S.; Vasella, 
A.; Sander, P.; Böttger, E. C. Nucleic Acids Res. 2007, 35, 6086-6093. 
156 
 
 
 
(78) Nikaido, H.; Pagès, J.-M. FEMS Microbiol. Rev. 2012, 36, 340-363. 
(79) Li, X.-Z.; Plésiat, P.; Nikaido, H. Clin. Microbiol. Rev. 2015, 28, 337-418. 
(80) Macfarlane, E. L.; Kwasnicka, A.; Hancock, R. E. Microbiology 2000, 146, 2543-2554. 
(81) Fernández, L.; Gooderham, W. J.; Bains, M.; McPhee, J. B.; Wiegand, I.; Hancock, R. E. 
Antimicrob. Agents Chemother. 2010, 54, 3372-3382. 
(82) Kwon, D. H.; Lu, C.-D. Antimicrob. Agents Chemother. 2006, 50, 1615-1622. 
(83) Nowicki, E. M.; O'brien, J. P.; Brodbelt, J. S.; Trent, M. S. Mol. Microbiol. 2015, 97, 
166-178. 
(84) Bansal-Mutalik, R.; Nikaido, H. Proc. Natl. Acad. Sci. USA. 2014, 111, 4958-4963. 
(85) Miller, M. H.; Edberg, S. C.; Mandel, L. J.; Behar, C. F.; Steigbigel, N. H. Antimicrob. 
Agents Chemother. 1980, 18, 722-729. 
(86) Fernández, L.; Hancock, R. E. Clin. Microbiol. Rev. 2012, 25, 661-681. 
(87) Sarathy, J. P.; Dartois, V.; Lee, E. J. D. Pharmaceuticals 2012, 5, 1210-1235. 
(88) Danilchanka, O.; Pavlenok, M.; Niederweis, M. Antimicrob. Agents Chemother. 2008, 
52, 3127-3134. 
(89) Faller, M.; Niederweis, M.; Schulz, G. E. Science 2004, 303, 1189-1192. 
(90) Poole, K. J. Antimicrob. Chemother. 2005, 56, 20-51. 
(91) Li, X.-Z.; Poole, K.; Nikaido, H. Antimicrob. Agents Chemother. 2003, 47, 27-33. 
(92) Poelarends, G. J.; Mazurkiewicz, P.; Konings, W. N. Biochim. Biophys. Acta 2002, 1555, 
1-7. 
(93) Begum, A.; Rahman, M. M.; Ogawa, W.; Mizushima, T.; Kuroda, T.; Tsuchiya, T. 
Microbiol. Immunol. 2005, 49, 949-957. 
(94) De Stasio, E.; Moazed, D.; Noller, H.; Dahlberg, A. EMBO J. 1989, 8, 1213. 
157 
 
 
 
(95) Prammananan, T.; Sander, P.; Brown, B. A.; Frischkorn, K.; Onyi, G. O.; Zhang, Y.; 
Böttger, E. C.; Wallace Jr, R. J. J. Infect. Dis. 1998, 177, 1573-1581. 
(96) Recht, M. I.; Douthwaite, S.; Puglisi, J. D. EMBO J. 1999, 18, 3133-3138. 
(97) Basso, L. A.; Blanchard, J. S. In Resolving the Antibiotic Paradox; Springer: 1998, p 
115-144. 
(98) Springer, B.; Kidan, Y. G.; Prammananan, T.; Ellrott, K.; Böttger, E. C.; Sander, P. 
Antimicrob. Agents Chemother. 2001, 45, 2877-2884. 
(99) Unemo, M.; Golparian, D.; Skogen, V.; Olsen, A. O.; Moi, H.; Syversen, G.; Hjelmevoll, 
S. O. Antimicrob. Agents Chemother. 2013, 57, 1057-1061. 
(100) Wachino, J.-i.; Arakawa, Y. Drug Resist. Updates 2012, 15, 133-148. 
(101) Doi, Y.; Yokoyama, K.; Yamane, K.; Wachino, J.-i.; Shibata, N.; Yagi, T.; Shibayama, 
K.; Kato, H.; Arakawa, Y. Antimicrob. Agents Chemother. 2004, 48, 491-496. 
(102) Chow, J. W. Clin. Infect. Dis. 2000, 31, 586-589. 
(103) Beauclerk, A. A.; Cundliffe, E. J. Mol. Biol. 1987, 193, 661-671. 
(104) Yokoyama, K.; Doi, Y.; Yamane, K.; Kurokawa, H.; Shibata, N.; Shibayama, K.; Yagi, 
T.; Kato, H.; Arakawa, Y. The Lancet 2003, 362, 1888-1893. 
(105) Tada, T.; Miyoshi-Akiyama, T.; Kato, Y.; Ohmagari, N.; Takeshita, N.; Hung, N. V.; 
Phuong, D. M.; Thu, T. A.; Binh, N. G.; Anh, N. Q. BMC Infect. Dis. 2013, 13, 251. 
(106) Shoma, S.; Kamruzzaman, M.; Ginn, A. N.; Iredell, J. R.; Partridge, S. R. Diagn. 
Microbiol. Infect. Dis. 2014, 78, 93-97. 
(107) Galimand, M.; Courvalin, P.; Lambert, T. Antimicrob. Agents Chemother. 2003, 47, 
2565-2571. 
158 
 
 
 
(108) González-Zorn, B.; Teshager, T.; Casas, M.; Porrero, M. C.; Moreno, M. A.; Courvalin, 
P.; Domínguez, L. Emerg. Infect. Dis. 2005, 11, 954. 
(109) Livermore, D.; Mushtaq, S.; Warner, M.; Zhang, J.-C.; Maharjan, S.; Doumith, M.; 
Woodford, N. J. Antimicrob. Chemother. 2010, 66, 48-53. 
(110) Garneau-Tsodikova, S.; Labby, K. J. MedChemComm 2016, 7, 11-27. 
(111) Bacot-Davis, V. R.; Bassenden, A. V.; Berghuis, A. M. MedChemComm 2016, 7, 103-
113. 
(112) Bassenden, A. V.; Rodionov, D.; Shi, K.; Berghuis, A. M. ACS Chem. Biol. 2016, 11, 
1339-1346. 
(113) Wolf, E.; Vassilev, A.; Makino, Y.; Sali, A.; Nakatani, Y.; Burley, S. K. Cell 1998, 94, 
439-449. 
(114) Wybenga-Groot, L. E.; Draker, K.-a.; Wright, G. D.; Berghuis, A. M. Structure 1999, 7, 
497-507. 
(115) Vetting, M. W.; Magnet, S.; Nieves, E.; Roderick, S. L.; Blanchard, J. S. Chemistry & 
Biology 2004, 11, 565-573. 
(116) Vetting, M. W.; Hegde, S. S.; Javid-Majd, F.; Blanchard, J. S.; Roderick, S. L. Nat. 
Struct. Mol. Biol. 2002, 9, 653-658. 
(117) Vetting, M. W.; de Carvalho, L. P. S.; Yu, M.; Hegde, S. S.; Magnet, S.; Roderick, S. L.; 
Blanchard, J. S. Arch. Biochem. Biophys. 2005, 433, 212-226. 
(118) Kotra, L. P.; Haddad, J.; Mobashery, S. Antimicrob. Agents Chemother. 2000, 44, 3249-
3256. 
(119) Resistance in Pseudomonas, I.-M. R. Antimicrob. Agents Chemother. 1999, 43, 727-737. 
(120) Gray, G. S.; Fitch, W. M. Mol. Biol. Evol. 1983, 1, 57-66. 
159 
 
 
 
(121) Fong, D. H.; Berghuis, A. M. EMBO J. 2002, 21, 2323-2331. 
(122) McKay, G.; Thompson, P. R.; Wright, G. Biochemistry 1994, 33, 6936-6944. 
(123) Trieu-Cuot, P.; Courvalin, P. Gene 1983, 23, 331-341. 
(124) Cox, J. R.; McKay, G. A.; Wright, G. D.; Serpersu, E. H. J. Am. Chem. Soc. 1996, 118, 
1295-1301. 
(125) Thompson, P. R.; Hughes, D. W.; Wright, G. D. Biochemistry 1996, 35, 8686-8695. 
(126) Young, P. G.; Walanj, R.; Lakshmi, V.; Byrnes, L. J.; Metcalf, P.; Baker, E. N.; 
Vakulenko, S. B.; Smith, C. A. J. Bacteriol. 2009, 191, 4133-4143. 
(127) Buynak, J. D. Biochem. Pharmacol. 2006, 71, 930-940. 
(128) Allen, N.; Alborn, W.; Hobbs, J.; Kirst, H. Antimicrob. Agents Chemother. 1982, 22, 
824-831. 
(129) Gao, F.; Yan, X.; Baettig, O. M.; Berghuis, A. M.; Auclair, K. Angew. Chem., Int. Ed. 
Engl. 2005, 44, 6859-6862. 
(130) Boehr, D. D.; Draker, K.-a.; Koteva, K.; Bains, M.; Hancock, R. E.; Wright, G. D. 
Chemistry & Biology 2003, 10, 189-196. 
(131) Sucheck, S. J.; Wong, A. L.; Koeller, K. M.; Boehr, D. D.; Draker, K.-a.; Sears, P.; 
Wright, G. D.; Wong, C.-H. J. Am. Chem. Soc. 2000, 122, 5230-5231. 
(132) Chang, C.-W. T.; Hui, Y.; Elchert, B.; Wang, J.; Li, J.; Rai, R. Org. Lett. 2002, 4, 4603-
4606. 
(133) Rai, R.; Chen, H.-N.; Czyryca, P. G.; Li, J.; Chang, C.-W. T. Org. Lett. 2006, 8, 887-889. 
(134) Russell, R. J.; Murray, J. B.; Lentzen, G.; Haddad, J.; Mobashery, S. J. Am. Chem. Soc. 
2003, 125, 3410-3411. 
160 
 
 
 
(135) Bastida, A.; Hidalgo, A.; Chiara, J. L.; Torrado, M.; Corzana, F.; Pérez-Canadillas, J. M.; 
Groves, P.; Garcia-Junceda, E.; Gonzalez, C.; Jimenez-Barbero, J. J. Am. Chem. Soc. 2006, 128, 
100-116. 
(136) Hanessian, S.; Maianti, J. P.; Matias, R. D.; Feeney, L. A.; Armstrong, E. S. Org. Lett. 
2011, 13, 6476-6479. 
(137) Sati, G. C.; Shcherbakov, D.; Hobbie, S. N.; Vasella, A.; Böttger, E. C.; Crich, D. ACS 
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          The ever-growing increase in multidrug resistant infectious diseases is one of the major 
cause of human mortality, and there is an inherent need for the development of new antibiotics. 
Since the discovery of streptomycin, AGAs have been playing a very important role in human 
therapy as highly potent broad-spectrum antibiotics and are listed as one of the critically important 
antimicrobials by WHO. AGAs act by inhibiting the bacterial protein synthesis and by targeting 
the A-site present in the small subunit of bacterial ribosome. The clinical use of AGAs is somewhat 
restricted due to their toxic effects (ototoxicity and nephrotoxicity) and emergence of resistant 
bacterial strains. However, with the increase in resistance to current antibiotics and significant 
hurdles in discovering a new class of antibiotics, researchers started to revisit the AGAs,  leading 
to much interest in development of novel AGAs. The goal of this thesis is to utilize the well 
understood mechanism of action and mechanisms of resistance for the development of novel 
AGAs. This research work is mainly focused on the modification of neomycin B and 
paromomycin. 
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          Chapter one introduces the problem of infectious diseases caused by bacteria, history of 
antibiotics and need for the development of new antibiotics. Then it discusses history of AGAs, 
their classification, mechanism of action, and toxic effects. It also discusses the common 
mechanisms of resistance adopted by bacteria and the recent strategies used to evade those 
resistance mechanisms.  
          Chapter two discusses a series of modifications made to neomycin B and the influence of 
each modification on antibacterial activity and ribosomal selectivity. Fourteen different neomycin 
B derivatives were synthesized and their antiribosomal and antibacterial activities were 
determined. These derivatives include modifications at 2’-, 4’-, 6’-, and 6’’’ positions.  Newly 
synthesized compounds were also screened against ESKAPE pathogens and engineered strains of 
E. Coli carrying specific resistance determinants in order to determine their susceptibility to 
modifications by common AMEs.  
          Chapter three describes the modifications at 2’- and 5’’- positions in paromomycin and their 
influence on antiribosomal activity and selectivity. The 2’-position is susceptible to modification 
by AAC-(2’) and was mainly modified by alkylating the 2’-amino substituent. APH-(3’, 5’’) is 
one of the most important AME and has been known to modify most of the AGAs. There has been 
a lot of effort in the past to circumvent the action of this AME and it still remains a great challenge. 
This chapter also discusses the successful 5’’-formamido and 5’’-ureido modifications to 
paromomycin. These 5’’-modifications provide an effective alternative for 5’’-hydroxy substituent 
and are not susceptible to modification at this position by APH-(3’, 5’’). 
          In Chapter four, an efficient and facile method for the synthesis of highly substituted 
pyrimidine-2,4-dione derivatives was described. Pyrimidine-2,4-diones are important nitrogen-
based heterocycles and present in biologically active natural products and pharmaceuticals. This 
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chapter discuss their synthesis form easily accessible and inexpensive maleic anhydrides and 
primary amines. 
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